SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the Month of February, 2000
AMDOCS LIMITED
Tower Hill House Le Bordage
St. Peter Port, Island of Guernsey, GY1 3QT Channel Islands
Amdocs, Inc.
1390 Timberlake Manor Parkway, Chesterfield, Missouri 63017
(Address of principal executive offices)
(Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F.)
FORM 20 F X FORM 40 F
----- ----
(Indicate by check mark whether the registrant by furnishing the information
contained in this form is also thereby furnishing the information to the
Commission pursuant to rule 12g3-2(b) under the Securities Exchange Act of
1934.)
YES NO X
<PAGE>
AMDOCS LIMITED
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
FOR THE MONTH OF FEBRUARY, 2000
AGREEMENT TO ACQUIRE SOLECT TECHNOLOGY GROUP INC.
On February 28, 2000, the registrant, Amdocs Limited ("Amdocs") and
certain of its subsidiaries entered into a Combination Agreement (the
"Combination Agreement") with Solect Technology Group Inc. ("Solect"), a private
company based in Toronto, Canada. The Combination Agreement provides for a
business combination in which Solect's common shares and options will be
exchanged for Solect exchangeable shares exchangeable at any time for an
aggregate 15.5 million Amdocs ordinary shares.
Closing under the Combination Agreement is conditioned on, among other
things, approval by Solect's shareholders, expiration or termination of any
applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act
of 1976, as amended, the Competition Act (Canada) and the Investment Canada Act,
and approval by the Ontario Securities Commission of the Share Restructuring
Plan by which the transaction will be implemented. Shareholders representing
over 70% of Solect's outstanding share capital have agreed to vote in favor of
the transaction.
The transaction contemplated by the Combination Agreement is intended
to be accounted for under the purchase accounting method under United States
generally accepted accounting principles and to be treated as a reorganization
of capital of Solect under the Income Tax Act (Canada) and as a tax free
reorganization for U.S. federal income tax purposes.
Attached and incorporated herein by reference in their entirety as
Exhibits are copies of the Combination Agreement, a related Principal
Securityholders' Voting Agreement, and a press release announcing the
combination.
<PAGE>
EXHIBITS
EXHIBIT
NO. DESCRIPTION
2.1 Combination Agreement dated as of February 28, 2000, among
Amdocs Limited, Amdocs (Denmark) ApS., Amdocs Holdings ULC
and Solect Technology Group Inc.
2.2 Principal Securityholders' Voting Agreement dated as of
February 28, 2000, among Amdocs Limited, Amdocs (Denmark)
ApS., Amdocs Holdings ULC and each of the Securityholders
named in Schedule I thereto.
99.1 Amdocs Press Release dated February 29, 2000
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
AMDOCS LIMITED
Date: March 3, 2000 /s/ THOMAS G.O'BRIEN
Thomas G. O'Brien
Treasurer and Secretary
Authorized U.S. Representative
<PAGE>
EXHIBIT INDEX
EXHIBIT
NO. DESCRIPTION
2.1 Combination Agreement dated as of February 28, 2000, among
Amdocs Limited, Amdocs (Denmark) ApS., Amdocs Holdings ULC
and Solect Technology Group Inc.
2.2 Principal Securityholders' Voting Agreement dated as of
February 28, 2000, among Amdocs Limited, Amdocs (Denmark)
ApS., Amdocs Holdings ULC and each of the Securityholders
named in Schedule I thereto.
99.1 Amdocs Press Release dated February 29, 2000
COMBINATION AGREEMENT
AMONG
AMDOCS LIMITED,
AMDOCS (DENMARK) APS.,
AMDOCS HOLDINGS ULC
AND
SOLECT TECHNOLOGY GROUP INC.
Dated as of February 28, 2000
<PAGE>
TABLE OF CONTENTS
1. THE SHARE RESTRUCTURING PLAN...........................................1
1.1 The Share Restructuring Plan..................................1
1.2 Exchange Ratio................................................2
1.2a Section 85 Election...........................................3
1.3 Adjustments for Capital Changes...............................4
1.4 Dissenting Shares.............................................4
1.5 Escrow of Shares..............................................4
1.6 Registration of Amdocs Option Shares..........................5
1.7 Other Effects of the Share Restructuring......................5
1.8 Reorganization................................................5
1.9 Material Adverse Effect.......................................5
1.10 Currency......................................................6
2. REPRESENTATIONS AND WARRANTIES.........................................6
2.1 Organization; Good Standing; Qualification and Power..........6
2.2 Capital Structure.............................................6
2.3 Authority.....................................................8
2.4 Financial Statements.........................................10
2.5 Compliance with Applicable Laws..............................10
2.6 Litigation...................................................10
2.7 Employee Benefits and ERISA..................................11
2.8 Absence of Undisclosed Liabilities...........................14
2.9 Absence of Certain Changes or Events.........................15
2.10 Agreements...................................................17
2.11 No Defaults..................................................20
2.12 Certain Agreements...........................................21
2.13 Taxes........................................................21
2.14 Intellectual Property........................................23
2.15 Fees and Expenses............................................26
2.16 Insurance....................................................26
2.17 Ownership and Property.......................................27
2.18 Environmental Matters........................................27
2.19 Interested Party Transactions................................28
2.20 Board Approval...............................................29
2.21 Vote Required................................................29
2.22 Amendment to Solect Option Plans.............................29
2.23 Disclosure...................................................29
2.24 Fairness and Equivalency Opinions............................30
2.25 Restrictions on Business Activities..........................30
i
<PAGE>
2.26 Books and Records............................................30
2.27 Customers....................................................31
2.28 Competition Act..............................................31
2.29 Investment Canada Matters....................................31
2.30 Year 2000 Problem............................................31
2.31 Solect Creditors.............................................32
2.32 Accounts Receivable..........................................32
2.33 Sales of Solect Securities...................................32
2.34 Absence of Questionable Payments.............................32
3. REPRESENTATIONS AND WARRANTIES OF AMDOCS, AMDOCS
PARENTCO AND AMDOCS HOLDCO............................................33
3.1 Organization; Good Standing; Qualification and Power.........34
3.2 Capital Structure............................................33
3.3 Authority....................................................35
3.4 SEC Documents and Financial Statements.......................36
3.4a Information Supplied.........................................37
3.5 Compliance with Applicable Laws..............................37
3.6 Litigation...................................................38
3.7 ERISA and Employee Benefits..................................38
3.8 Absence of Undisclosed Liabilities...........................40
3.9 Absence of Certain Changes or Events.........................40
3.10 No Defaults..................................................41
3.11 Taxes........................................................41
3.12 Intellectual Property........................................42
3.13 Insurance....................................................43
3.14 Ownership of Property........................................43
3.15 Environmental Matters........................................44
3.16 Board Approval...............................................44
3.17 Disclosure...................................................45
3.18 Restrictions on Business Activities..........................45
3.19 Books and Records............................................45
3.20 Year 2000 Problem............................................45
3.21 Solect Customers.............................................46
3.22 Amdocs Ordinary Shares.......................................46
3.23 Competition Act..............................................46
3.24 Investment Canada Act and Competition Act (Canada)...........46
3.25 Specified Financial Institution/PFIC.........................46
4. SOLECT COVENANTS......................................................47
4.1 Advice of Changes............................................47
ii
<PAGE>
4.2 Maintenance of Business..................................47
4.3 Conduct of Business......................................47
4.4 Shareholder Approval.....................................50
4.5 Representation Agreements................................50
4.6 Regulatory Approvals.....................................51
4.7 Necessary Consents.......................................51
4.8 Access to Information....................................51
4.9 Satisfaction of Conditions Precedent.....................51
4.10 No Other Negotiations....................................52
4.11 Cooperation..............................................53
4.12 Canadian Clearance Certificates..........................53
4.13 Insurance Policies.......................................54
4.14 Employee Retention Arrangements..........................55
4.15 Establishment of Escrow..................................55
4.16 BT and Nokia Letters.....................................55
5 AMDOCS COVENANTS..................................................55
5.1 Advice of Changes........................................55
5.2 Regulatory Approvals.....................................56
5.3 Necessary Consents.......................................56
5.4 Satisfaction of Conditions Precedent.....................56
5.5 Employment and Employee Benefits After the Closing.......56
5.6 Employee Retention Arrangements..........................57
5.7 Issuance and Listing of Amdocs Ordinary Shares...........57
5.8 Certain Tax Filings......................................57
5.9 Solect Customers.........................................57
5.10 Indemnification..........................................57
5.11 Covenant to Inform.......................................58
6. CLOSING MATTERS...................................................58
6.1 The Closing..............................................58
6.2 Ancillary Agreements/Reservation of Shares...............59
6.3 Exchange of Options......................................59
7. CONDITIONS OF PRECEDENT TO OBLIGATIONS OF SOLECT..................60
7.1 Accuracy of Representations and Warranties...............60
7.2 Covenants................................................60
7.3 Absence of Material Adverse Change.......................60
7.4 Compliance with Law......................................60
7.5 Government Consents......................................60
7.6 Opinion of Amdocs' Counsel...............................61
iii
<PAGE>
7.7 Consents, Waivers, Etc...................................61
7.8 Shareholder Approval.....................................61
7.9 No Legal Action..........................................61
7.10 Regulatory Authorities, Etc..............................61
7.11 Tax-Free Status..........................................62
8. CONDITIONS PRECEDENT TO OBLIGATIONS OF AMDOCS, AMDOCS
PARENTCO AND AMDOCS HOLDCO........................................63
8.1 Accuracy of Representations and Warranties...............63
8.2 Covenants................................................63
8.3 Absence of Material Adverse Change.......................63
8.4 Compliance with Law......................................63
8.5 Government Consents......................................63
8.6 Opinion of Solect's Counsel..............................64
8.7 Consents, Waivers, Etc...................................64
8.8 Solect Approvals.........................................64
8.9 Share Restructuring Plan.................................64
8.10 Solect Convertible Debentures............................64
8.11 Solect Warrants..........................................65
8.12 Securityholder Agreement.................................65
8.13 No Legal Action..........................................65
8.14 Termination of Certain Agreements........................65
8.15 Regulatory Authorities, Etc..............................65
8.16 Resignation of Directors.................................66
8.17 Certificates.............................................66
8.18 Dissenting Shareholders..................................66
9. TERMINATION OF AGREEMENT..........................................66
9.1 Termination..............................................66
9.2 Notice of Termination....................................67
9.3 Effect of Termination....................................68
10. SURVIVAL OF REPRESENTATIONS, WARRANTIES AND COVENANTS;
INDEMNITY.........................................................68
10.1 Survival.................................................68
10.2 Indemnity................................................68
11. MISCELLANEOUS.....................................................68
11.1 Governing Law............................................68
11.2 Assignment; Binding Upon Successors and Assigns..........69
11.3 Severability.............................................69
iv
<PAGE>
11.4 Counterparts.............................................69
11.5 Other Remedies...........................................69
11.6 Amendment and Waivers....................................69
11.7 Expenses.................................................70
11.8 Attorneys' Fees..........................................70
11.9 Notices..................................................70
11.10 Construction of Agreement................................72
11.11 No Joint Venture.........................................72
11.12 Further Assurances.......................................72
11.13 Public Announcement......................................73
11.14 Entire Agreement.........................................73
v
<PAGE>
EXHIBITS
Exhibit 1.1 Share Restructuring Plan
Exhibit 1.5 Escrow Agreement
Exhibit 2.8 Solect Balance Sheet
Exhibit 3.8 Amdocs Balance Sheet
Exhibit 4.4 Securityholder Agreement
Exhibit 4.5 Representation Agreement
Exhibit 6.2(b)(i) Support Agreement
Exhibit 6.2(b)(ii) Voting and Exchange Trust Agreement
Exhibit 6.2(b)(iii) Registration Rights Agreement
Exhibit 6.2(c) Amdocs Special Voting Share
vi
<PAGE>
COMBINATION AGREEMENT
COMBINATION AGREEMENT, dated as of February 28, 2000, among AMDOCS LIMITED,
a Guernsey corporation ("Amdocs"), AMDOCS (DENMARK) APS., a Danish corporation
("Amdocs Parentco"), AMDOCS HOLDINGS ULC, a Nova Scotia unlimited liability
company ("Amdocs Holdco"), and SOLECT TECHNOLOGY GROUP INC., a New Brunswick
corporation ("Solect").
RECITALS
WHEREAS, the respective boards of directors of Amdocs, Amdocs Parentco,
Amdocs Holdco and Solect deem it advisable and in the best interests of their
respective shareholders to combine their respective businesses by Amdocs
acquiring shares in the capital stock of Solect through Amdocs Holdco pursuant
to this Agreement and the Share Restructuring Plan (as defined below); and
WHEREAS, in furtherance of such combination, the respective boards of
directors of Amdocs and Solect have approved the transactions contemplated by
this Agreement and the board of directors of Solect has agreed to submit the
Share Restructuring Plan and the other transactions contemplated hereby to its
shareholders for their approval; and
WHEREAS, the transactions contemplated by this Agreement and the Share
Restructuring Plan are intended to be treated (i) as a reorganization of capital
of Solect under Section 86 of the Income Tax Act (Canada) (the "ITA") and (ii)
as a plan of reorganization under Section 368(a)(1) of the Internal Revenue Code
of 1986, as amended (the "Code"), in each case to the extent that Exchangeable
Shares (as defined below) are received in exchange for shares of Solect capital
stock; and
WHEREAS, the parties hereto desire to set forth certain representations,
warranties and covenants made by each to the other as an inducement to the
consummation of the Share Restructuring Plan;
NOW, THEREFORE, the parties hereto hereby agree as follows:
1. THE SHARE RESTRUCTURING PLAN
1.1 THE SHARE RESTRUCTURING PLAN.
As soon as practicable after all of the conditions precedent set forth in
Articles 7 and 8 hereof have been satisfied or effectively waived pursuant to
1
<PAGE>
the terms hereof, Solect shall cause articles of amendment giving effect to the
Share Restructuring Plan in the form of Exhibit 1.1 attached hereto (the "Share
Restructuring Plan") to be filed with the Director under the Business
Corporations Act (New Brunswick) (the "NBBCA"). At 12:01 a.m. (the "Effective
Time") on the date (the "Effective Date") shown on the Certificate of Amendment
giving effect to the share restructuring contemplated by the Share Restructuring
Plan (the "Share Restructuring"), the reorganization of capital and the other
transactions set out in clauses (a) through (j), inclusive, of Section 2.1 of
the Share Restructuring Plan shall occur and shall be deemed to occur (without
any further act or formality) in the order set forth therein.
1.2 EXCHANGE RATIO.
Subject to the provisions of Sections 1.4 and 1.5 hereof, at the Effective
Time and in the following sequence:
(a) Each of the outstanding common shares of Solect (the "Solect Common
Shares"), without any further action on the part of any holder
thereof, will be exchanged for a number of Exchangeable Shares (as
defined in the Share Restructuring Plan) equal to the quotient (the
"Exchange Ratio"), taken to five decimal places, derived by dividing
15,500,000 by the Fully-Diluted Share Capital (as defined below). Each
holder of Solect Common Shares (collectively, the "Solect
Shareholders") will be entitled to delivery of that whole number of
Exchangeable Shares resulting from the exchange of such holder's
Solect Common Shares or, if such holder shall have so irrevocably
elected prior to the Effective Time pursuant to Section 2.1(j) of the
Share Restructuring Plan, that whole number of Amdocs Ordinary Shares
(as defined below) resulting from the immediate exchange of such
Exchangeable Shares for Amdocs Ordinary Shares pursuant to a
retraction request by such holder and the exercise of the Retraction
Call Right by Amdocs, Amdocs Parentco or Amdocs Holdco, as the case
may be. In lieu of fractional Exchangeable Shares, each holder of an
Solect Common Share who otherwise would be entitled to receive a
fraction of an Exchangeable Share shall be paid by Solect an amount
determined in accordance with the Share Restructuring Plan.
(b) Immediately following completion of the transactions provided for in
Section 2.1 of the Share Restructuring Plan, each of the outstanding
options held by employees of Solect or any of the Solect Subsidiaries
(as defined in Section 2.1 hereof) and listed in Section 2.2(a) of the
Solect Disclosure Letter (as defined in Article 2 hereof)
(collectively, the "Solect Options") (including all outstanding
options granted under Solect's 1999 Stock Option Plan and the
Predecessor Plans (as defined in and as incorporated into the 1999
Stock Option Plan) (collectively, the "Solect Option Plans")) to
purchase Solect Common Shares will, without any further action on the
part of any holder thereof, be exchanged for an option (collectively,
2
<PAGE>
the "Amdocs Options") to purchase that number of ordinary voting
shares, par value (pound)0.01 per share, of Amdocs (collectively,
"Amdocs Ordinary Shares") determined by multiplying the number of
Solect Common Shares subject to such Solect Option at the Effective
Time by the Exchange Ratio (rounded down to the nearest whole share),
at an exercise price per Amdocs Ordinary Share equal to the exercise
price per Solect Common Share of such Solect Option immediately prior
to the Effective Time (converted from Canadian dollars to U.S. dollars
as provided below) divided by the Exchange Ratio (rounded up to the
nearest whole cent). For purposes of determining the exercise price of
the Amdocs Options, the exercise price of the Solect Options shall be
converted from Canadian to U.S. dollars by multiplying the Canadian
dollar exercise price of the Solect Options by the noon spot exchange
rate on the business day immediately preceding the Effective Time for
Canadian dollars expressed in U.S. dollars as reported by the Bank of
Canada or, in the event such spot exchange rate is not available, such
exchange rate on such date as may be mutually agreed by Amdocs and
Solect for such purpose. Except as provided above, the term,
exercisability, vesting schedule, status as an "incentive stock
option" under Section 422 of the Code, if applicable, and all other
terms and conditions of the Solect Options will otherwise continue
unamended with respect to the Amdocs Options. Continuous employment
with Solect or any of the Solect Subsidiaries (as hereinafter defined)
will be credited to an optionee of Solect for purposes of determining
the number of Amdocs Ordinary Shares subject to exercise under an
exchanged Solect Option after the Effective Time.
For purposes of this Agreement, the Fully-Diluted Share Capital shall be
determined immediately prior to the Effective Time and shall be equal to the sum
of (i) the outstanding Solect Common Shares, (ii) the Solect Common Shares
issuable upon conversion of all of the outstanding convertible debentures of
Solect listed on Schedule 2.2(a) of the Solect Disclosure Letter (the "Solect
Convertible Debentures"), including any additional shares issuable upon a change
of control transaction, (iii) the Solect Common Shares issuable upon exercise of
all of the outstanding warrants of Solect listed on Schedule 2.2(a) of the
Solect Disclosure Letter (the "Solect Warrants" and, together with the Solect
Convertible Debentures, the "Solect Convertible Securities"), (iv) the Solect
Common Shares issuable upon exercise of the outstanding Solect Options and (v)
the 437,500 Solect Common Shares issuable to British Telecommunications PLC
("BT") pursuant to the transaction contemplated by Section 4.16(1) below. The
Chief Executive Officer and Chief Financial Officer of Solect shall deliver a
Certificate to Amdocs, Amdocs Parentco and Amdocs Holdco on the Closing Date
certifying, in their capacity as such officers on behalf of Solect, as to the
true and correct Fully-Diluted Share Capital as of the such date.
3
<PAGE>
1.2a. SECTION 85 ELECTION.
Solect agrees that it will jointly elect under subsection 85(1) of the ITA
with any shareholder that is a trust governed by a registered retirement savings
plan under the ITA and that notifies Solect, prior to the Effective Date, that
it wishes to make a Tax Election, as described below, in respect of the exchange
of all Solect Common Shares held by it for Exchangeable Shares, at an elected
amount equal to the fair market value of the Solect Common Shares so exchanged.
For this purpose, the fair market value shall be determined on a basis
consistent with the manner in which the Exchange Ratio is determined. In order
to make such an election the shareholder shall deliver to the Corporate
Secretary of Solect, within 90 days after the Effective Date, two copies of Form
T2057 duly completed by the shareholder. Subject to the election forms complying
with the above described requirements and the provisions of the ITA, the forms
will be returned to such shareholder within 60 days of receipt thereof by
Solect's Corporate Secretary, signed by Solect, for filing by the shareholder
with the Canada Customs and Revenue Agency. It will be the responsibility of
each shareholder who wishes to make an election to complete and review all
relevant portions of both copies of the form, to sign both copies of the form
where required and to forward the signed forms to Solect's Corporate Secretary.
Solect shall not be responsible for the proper completion or filing of any
election and the shareholder will be solely responsible for the payment of any
late filing penalty.
1.3 ADJUSTMENTS FOR CAPITAL CHANGES.
If, prior to the Effective Time, Amdocs or Solect recapitalizes its
outstanding capital stock through a subdivision of its outstanding shares into a
greater number of shares, or a combination of its outstanding shares into a
lesser number of shares, or reorganizes, reclassifies or otherwise changes its
outstanding shares into the same or a different number of shares of other
classes, or declares a dividend on its outstanding shares payable in shares of
its capital stock or securities convertible into shares of its capital stock or
other property, or completes a rights offering to its existing shareholders at a
price less than market price, then the Exchange Ratio will be adjusted so as to
maintain the relative proportionate interests of the holders of Solect Common
Shares and the holders of Amdocs Ordinary Shares.
1.4 DISSENTING SHARES.
Holders of Solect Common Shares may exercise rights of dissent with respect
to such shares in connection with the Share Restructuring pursuant to and in the
manner set forth in Section 131 of the NBBCA (such holders referred to as
"Dissenting Shareholders"). Solect shall give Amdocs (i) prompt notice of any
written demands of a right of dissent, withdrawals of such demands, and any
other instruments served pursuant to the NBBCA and received by Solect, and (ii)
the opportunity to participate in all negotiations and proceedings (to the
extent permitted by any judicial authority having jurisdiction) with respect to
such rights. Solect shall not, except with the prior written consent of Amdocs,
voluntarily make any payment with respect to any such rights or offer to settle
or settle any such rights. All payments to Dissenting Shareholders shall be
4
<PAGE>
the sole responsibility of Solect, and Amdocs will not directly or indirectly
provide any funds for the purposes of making payments to Dissenting
Shareholders.
1.5 ESCROW OF SHARES.
At the Effective Time, Solect shall deliver to the escrow agent (the
"Escrow Agent") designated under the Escrow Agreement (the "Escrow Agreement"),
substantially in the form of Exhibit 1.5, a certificate or certificates
representing an aggregate 1,170,000 Exchangeable Shares issued to certain
shareholders of Solect pursuant to Section 1.2(a) hereof (such shares are
collectively hereinafter referred to as the "Escrowed Shares") for the purposes
of satisfying any indemnity obligations arising out of a breach by Solect of any
its representations, warranties or covenants contained herein, all as more
particularly described in the Escrow Agreement.
1.6 REGISTRATION OF AMDOCS OPTION SHARES.
To the extent legally required, Amdocs will cause the Amdocs Ordinary
Shares issuable upon exercise of the exchanged Solect Options to be registered
on Form S-8 promulgated by the United States Securities and Exchange Commission
(the "SEC") as soon as reasonably practicable after the Effective Time and will
use its commercially reasonable efforts to maintain the effectiveness of such
registration statement or registration statements for so long as any exchanged
Solect Option shall remain outstanding.
1.7 OTHER EFFECTS OF THE SHARE RESTRUCTURING.
At the Effective Time: (a) the bylaws of Solect immediately prior to the
Effective Time will continue as the bylaws of Solect, subject to any later
amendment; (b) the persons recommended by Amdocs prior to the Effective Time
will be elected as directors of Solect; (c) the persons designated by Amdocs
prior to the Effective Time will be elected as officers of Solect; and (d) the
Share Restructuring will, from and after the Effective Time, have all of the
effects provided by applicable law, including the NBBCA.
1.8 REORGANIZATION.
The parties intend to effect the Share Restructuring as a reorganization of
capital of Solect under Section 86 of the ITA, and as a plan of reorganization
under Section 368(a)(1) of the Code to the extent that the Exchangeable Shares
are received in exchange for Solect Common Shares.
1.9 MATERIAL ADVERSE EFFECT.
In this Agreement, any reference to any event, change or effect being
"material" with respect to any entity or group of entities means any material
5
<PAGE>
event, change or effect related to the financial condition, properties, assets,
liabilities, businesses, operations, results of operations or long-term
prospects of such entity or group of entities. In this Agreement, the term
"Material Adverse Effect" used with respect to any entity or group of entities
means any event, change or effect, that is materially adverse to the financial
condition, properties, assets, liabilities, businesses, operations, results of
operations or long-term prospects of such entity or group, taken as a whole;
provided that a Material Adverse Effect shall not include any adverse event,
change or effect resulting from any change in general economic, financial,
political or general capital market trading conditions or conditions generally
affecting the communications or software industry.
1.10 CURRENCY.
Unless otherwise specified, all references in this Agreement to "dollars"
or "$" shall mean United States dollars.
2. REPRESENTATIONS AND WARRANTIES OF SOLECT
Except as set forth in a letter dated the date of this Agreement and
delivered by Solect to Amdocs concurrently herewith (the "Solect Disclosure
Letter"), Solect hereby represents and warrants to Amdocs, Amdocs Parentco and
Amdocs Holdco that:
2.1 ORGANIZATION; GOOD STANDING; QUALIFICATION AND POWER.
Each of Solect and each corporation, partnership, company, joint venture
and other entity in which Solect beneficially owns or controls, directly or
indirectly, more than 50% of the equity, voting rights, profits interest,
capital or other similar interest thereof (the "Solect Subsidiaries") is duly
organized, validly existing and in good standing under the laws of the
jurisdiction of its formation, or continuance, as applicable, has all requisite
corporate power and authority necessary to own, lease and operate its properties
and to carry on its business as now being conducted, and is duly qualified and
in good standing to do business in each jurisdiction in which the nature of its
business or the ownership or leasing of its properties makes such qualification
necessary, other than in such jurisdictions where the failure so to qualify
would not have a Material Adverse Effect on Solect. Section 2.1 of the Solect
Disclosure Letter sets forth a correct and complete list of the Solect
Subsidiaries, together with the jurisdiction of incorporation, continuance or
organization of each Solect Subsidiary, a list of the shareholders of each
Solect Subsidiary, the number of shares held by each shareholder, the directors
and officers (or local law equivalent) of such Solect Subsidiary and a correct
and complete list of each jurisdiction in which Solect and each Solect
Subsidiary is duly qualified and in good standing to do business. Solect has
delivered to Amdocs' counsel complete and correct copies of the certificates or
articles of incorporation (or similar documents) and bylaws of Solect and each
Solect Subsidiary, in each case as amended to the date of this Agreement and
currently in effect. Neither Solect nor any of the Solect Subsidiaries is in
6
<PAGE>
violation of any of the provisions of its articles of incorporation or
continuance, as applicable, or bylaws or equivalent organizational documents.
Except as set forth in Section 2.1 of the Solect Disclosure Letter, Solect does
not have any subsidiaries or any equity interest, direct or indirect, in any
corporation, partnership, joint venture or other business entity, and except as
disclosed in Section 2.1 of the Solect Disclosure Letter, all such equity
interests are held beneficially by Solect free and clear of any lien, security
interest, charge or encumbrance.
2.2 CAPITAL STRUCTURE.
(a) STOCK AND OPTIONS. The authorized capital stock of Solect consists of
an unlimited number of Solect Common Shares, without par value. At the
close of business on February 25, 2000, 10,499,072 Solect Common
Shares were issued and outstanding. An aggregate of 3,648,528 Solect
Common Shares are authorized for issuance pursuant to the Solect
Option Plans in respect of which Solect Options to purchase a total of
2,891,745 Solect Common Shares were outstanding as of February 25,
2000. An aggregate of 9,880,425 Solect Common Shares are authorized
for issuance upon the conversion of the Solect Convertible Debentures.
An aggregate of 3,350,950 Solect Common Shares are authorized for
issuance upon the exercise of the Solect Warrants. All issued and
outstanding Solect Common Shares and all issued and outstanding shares
of the capital stock of each of the Solect Subsidiaries have been duly
authorized and validly issued and are fully paid and non-assessable,
are not subject to preemptive rights, are not subject to any right of
rescission, and have been offered, issued, sold and delivered by
Solect and each of the Solect Subsidiaries in compliance with all
registration, qualification and prospectus requirements (or applicable
exemptions therefrom) of applicable securities laws. Section 2.2(a) of
the Solect Disclosure Letter sets forth a correct and complete list of
each holder of Solect Common Shares, Solect Options and Solect
Convertible Securities outstanding as of the date hereof, including,
(i) in the case of each Solect Common Share, the name of the holder
thereof, the province or state of residence of such holder and the
number of Solect Common Shares held by such holder, (ii) in the case
of each Solect Option, the name of the holder thereof, the province or
state of residence of such holder, the Solect Option Plan pursuant to
which such Solect Option was issued, the grant date of such Solect
Option, the number of shares issuable upon exercise thereof, the per
share exercise price and the vesting schedule applicable thereto,
(iii) in the case of each Solect Convertible Debenture, the name of
the holder thereof, the issue date and principal amount thereof, the
conversion price thereof and the number of Solect Common Shares
issuable upon conversion thereof and (iv) in the case of each Solect
Warrant, the name of the holder thereof, the exercise price thereof,
the issue date and expiration date thereof and the number of Solect
Common Shares issuable upon exercise thereof.
7
<PAGE>
(b) NO OTHER COMMITMENTS. Except for the Solect Options and Solect
Convertible Securities disclosed in Section 2.2(a) above and as listed
in the Solect Disclosure Letter, the rights of parties pursuant to the
Shareholders Agreement (as defined in Section 8.14 below) and the
obligations of Solect under this Agreement, there are no options,
warrants, calls, rights (including, without limitation, stock
appreciation rights), commitments, conversion rights, understandings,
negotiations or agreements of any character to which Solect or any of
the Solect Subsidiaries is a party or by which Solect or any of the
Solect Subsidiaries is bound obligating Solect or any of the Solect
Subsidiaries to issue, deliver or sell, or cause to be issued,
delivered or sold, any shares of capital stock of Solect or any of the
Solect Subsidiaries or securities convertible into or exchangeable for
shares of capital stock of Solect or any of the Solect Subsidiaries,
or obligating Solect or any of the Solect Subsidiaries to grant,
extend or enter into any such option, warrant, call, right,
commitment, conversion right or agreement. Except for the Shareholders
Agreement, there are no voting trusts or other agreements or
understandings to which Solect is a party or, to the knowledge of
Solect, among any of its shareholders, with respect to the voting of
the capital stock of Solect or any of the Solect Subsidiaries.
(c) REGISTRATION RIGHTS. Except as set forth in Section 2.2(c) of the
Solect Disclosure Letter, the Investor's Rights Agreement (as defined
in Section 8.14 below) or as contemplated herein, neither Solect nor
any of the Solect Subsidiaries is under any obligation to register
under the United States Securities Act of 1933, as amended (the
"Securities Act"), or any similar laws of any jurisdiction any of its
presently outstanding securities or any securities issuable upon
conversion or exercise thereof.
2.3 AUTHORITY.
(a) CORPORATE ACTION. Solect has all requisite corporate power and
authority to enter into this Agreement and the Ancillary Agreements to
which it is a party, to perform its obligations hereunder and
thereunder and to consummate the Share Restructuring (subject to its
approval by the shareholders of Solect) and the other transactions
contemplated by this Agreement and such Ancillary Agreements. The
execution and delivery by Solect of this Agreement and the Ancillary
Agreements to which it is a party and the consummation by Solect of
the Share Restructuring (subject to its approval by the shareholders
of Solect) and the other transactions contemplated hereby and thereby
have been duly authorized by all necessary corporate action on the
part of Solect. Solect has not taken any action or, to its knowledge,
has not failed to take any action, which action or failure would
preclude or prevent Solect from conducting its business after the
8
<PAGE>
Closing in the manner heretofore conducted. This Agreement has been
duly executed and delivered by Solect and is, and the Ancillary
Agreements to which it is a party when executed and delivered in
accordance with the terms hereof shall be, valid and binding
obligations of Solect, enforceable in accordance with their respective
terms, except that such enforceability may be subject to (i)
bankruptcy, insolvency, reorganization or other similar laws affecting
or relating to enforcement of creditors' rights generally and (ii)
general equitable principles.
(b) NO CONFLICT. Neither the execution, delivery and performance by Solect
of this Agreement or of any of the Ancillary Agreements to which it is
a party, nor the consummation by Solect of the transactions
contemplated hereby or thereby nor compliance with the provisions
hereof or thereof by Solect will: (i) conflict with, or result in any
violations of, the articles of incorporation or bylaws of Solect or
the comparable governing instruments of any of the Solect
Subsidiaries, (ii) result in any breach or violation of or cause a
default (with or without notice or lapse of time, or both) under, or
give rise to a right of termination, amendment, cancellation or
acceleration of any obligation contained in, or give rise to any claim
or the loss of any material benefit under, or result in the creation
of any lien, security interest, charge or encumbrance upon any of the
material properties or assets of Solect or any of the Solect
Subsidiaries under, any term, condition or provision of any loan or
credit agreement, note, bond, mortgage, indenture, lease, customer or
supplier contract or other agreement, judgment, order, decree,
statute, law, ordinance, rule, license, permit or regulation
applicable to Solect or any of the Solect Subsidiaries or their
respective properties or assets or by which any of their properties
may be bound (the "Solect Agreements"), other than any such breaches,
violations, claims, defaults, rights, losses, liens, security
interests, charges or encumbrances which, individually or in the
aggregate, would not have a Material Adverse Effect on Solect and the
Solect Subsidiaries, taken as a whole, or (iii) violate or conflict
with any order, writ, injunction, decree, statute, rule or regulation
of any court, administrative agency, regulatory body or commission or
other governmental authority or instrumentality, whether federal,
provincial, state or local and whether domestic or foreign (each a
"Governmental Entity").
(c) GOVERNMENTAL CONSENTS. No consent, approval, order or authorization
of, or registration, declaration or filing with, any Governmental
Entity is required to be obtained by Solect or any of the Solect
Subsidiaries in connection with the execution and delivery of this
Agreement or any of the Ancillary Agreements to which Solect is a
party or the consummation of the transactions contemplated hereby or
thereby, except for: (i) the filing of a request for, and obtaining
the approval of the Ontario Securities Commission for relief from the
prospectus and registration requirements of the Securities Act
9
<PAGE>
(Ontario) and all rules and regulations thereunder in connection with
the Share Restructuring Plan; (ii) such filings and notifications as
may be necessary under the Hart-Scott-Rodino Antitrust Improvements
Act of 1976, as amended (the "HSR Act"); (iii) required notices,
filings and consents under the Investment Canada Act and under the
Competition Act (Canada); and (iv) where the failure to obtain such
consents, approvals, etc., would not prevent or delay the consummation
of the Share Restructuring or otherwise prevent Solect from performing
its obligations under this Agreement or any of the Ancillary
Agreements to which it is a party and would not reasonably be expected
to have a Material Adverse Effect on Solect and the Solect
Subsidiaries, taken as a whole.
2.4 FINANCIAL STATEMENTS.
Solect has provided to Amdocs true and complete copies of (i) the audited
consolidated balance sheets of Solect and its subsidiaries as of July 31, 1999,
1998 and 1997 and the related consolidated statements of loss and deficit and
cash flows for the three years ended July 31, 1999, reported on by Ernst &
Young, Chartered Accountants, and (ii) the unaudited consolidated balance sheet
of Solect and its subsidiaries as of December 31, 1999 and the related
consolidated statements of loss and deficit and cash flows for the five months
ended December 31, 1999, certified by the chief financial officer of Solect
(collectively, the "Solect Financial Statements"). The Solect Financial
Statements present fairly in all material respects the consolidated financial
position and the consolidated results of operations and changes in financial
position of Solect and its consolidated subsidiaries as of the dates or for the
periods presented therein in conformity with Canadian generally accepted
accounting principles ("Canadian GAAP") applied on a consistent basis during the
periods involved, except as otherwise noted therein and subject in the case of
interim financial statements to normal and recurring year-end audit adjustments.
2.5 COMPLIANCE WITH APPLICABLE LAWS.
The businesses of Solect and the Solect Subsidiaries are not being
conducted in violation of any law, ordinance, regulation, rule or order of any
Governmental Entity where such violation would have a Material Adverse Effect on
Solect and the Solect Subsidiaries, taken as a whole. Solect has not been
notified by any Governmental Entity that any investigation or review with
respect to Solect or any of the Solect Subsidiaries is pending or threatened,
nor has any Governmental Entity notified Solect of its intention to conduct the
same. Solect and the Solect Subsidiaries have all material permits, licenses and
franchises from Governmental Entities required to conduct their businesses as
now being conducted, and are in material compliance with all such permits,
licenses and franchises, except for those permits, licenses and franchises whose
absence would not have a Material Adverse Effect on Solect and the Solect
Subsidiaries, taken as a whole.
10
<PAGE>
2.6 LITIGATION.
Except as set forth in Section 2.6 of the Solect Disclosure Letter, there
is no suit, action, arbitration, demand, claim or proceeding pending against
Solect or any of the Solect Subsidiaries or any of their respective officers or
investors (in their capacity as such); except as listed in the Solect Disclosure
Letter, to the knowledge of Solect, there is no suit, action, arbitration,
demand, claim or proceeding threatened against Solect or any of the Solect
Subsidiaries or any of their respective officers in their capacity as such, nor
is there any judgment, decree, injunction, rule or order of any Governmental
Entity or arbitrator outstanding against Solect or any of the Solect
Subsidiaries or any of their respective properties or assets, nor is there any
governmental inquiry or investigation pending or, to the knowledge of Solect,
threatened against Solect or any of the Solect Subsidiaries or the properties,
assets or business of any of them before any Governmental Entity with regard to
Solect, or any of the Solect Subsidiaries nor, to the knowledge of Solect, is
there a basis for such a material, justifiable and valid inquiry, proceeding,
governmental inquiry or investigation. There is no action, suit, proceeding or
investigation by Solect or any of the Solect Subsidiaries that is currently
pending or that Solect or Solect Subsidiaries intends to initiate. Solect has
made available to Amdocs correct and complete copies of all audit response
letters prepared by its counsel for Solect's auditors in connection with the
last two completed audits of Solect's financial statements and any such
correspondence since the date of the last such audit.
2.7 EMPLOYEE BENEFITS AND ERISA.
(a) Section 2.7(a) of the Solect Disclosure Letter contains a schedule
setting forth a list of all employees of Solect and of each Solect
Subsidiary ("Employees") and their salaries (and the date and amount
of their most recent salary increase) and other benefits and
identifies those employees considered key employees by Solect or any
Solect Subsidiary. Section 2.7(a) of the Solect Disclosure Letter
identifies each Canadian plan, arrangement, agreement, program, policy
or practice, whether oral or written, formal or informal, funded or
unfunded, which Solect or any Solect Subsidiary is a party to or bound
by or under which Solect or any Solect Subsidiary has any liability or
contingent liability or which has application to the employees of
Solect or any Solect Subsidiary relating to retirement savings or
pensions (other than the Canada Pension Plan), including any defined
benefit pension plan, defined contribution pension plan, group
registered retirement savings plan, or supplemental pension or
retirement savings plan, or any bonus, profit sharing, deferred
compensation, incentive compensation, hospitalization, health, dental,
disability or other benefit plan with respect to any of their
employees or former employees, individuals working on contract with
them or other individuals providing services to them of a kind
normally provided by employees ("Canadian Pension/Benefit Plan"), and
(iii) all other Solect Benefit Arrangements (as defined below)
(including those sponsored by the federal or any provincial government
of Canada), and all other material written or formal plans or
agreements, if any, which currently provides compensation or benefits
11
<PAGE>
to any Employee or former employee of Solect or any of the Solect
Subsidiaries (including any employment agreements entered into between
Solect or any of the Solect Subsidiaries and any Employee and workers'
compensation, unemployment compensation and other government-mandated
programs) and which is currently or previously was maintained,
contributed to or entered into by Solect or any of the Solect
Subsidiaries under which Solect or any of the Solect Subsidiaries has
any present obligation or liability (collectively, the "Solect
Employee Plans"). Copies of all Solect Employee Plans (and, if
applicable, related trust agreements) and all amendments thereto and
any summary plan descriptions have been delivered to Amdocs. All
contributions due from Solect or any of the Solect Subsidiaries
through the Effective Time with respect to any of the Solect Employee
Plans has been or will be timely made as required under any other
applicable Canadian legislation or have been accrued on Solect's or
any such Solect Subsidiary's financial statements as of the Solect
Balance Sheet Date (as defined in Section 2.8). Except as set forth in
Section 2.7(a) of the Solect Disclosure Letter, each Solect Employee
Plan is in compliance in all material respects with, and has been
maintained in material compliance with its terms and with the
requirements prescribed by, any and all Canadian statutes, orders,
rules and regulations which are applicable to such Solect Employee
Plan. Each Solect Employee Plan that is required to be qualified under
applicable Canadian law or registered or approved by a Canadian
governmental agency or authority has been so qualified, registered or
approved by the appropriate governmental agency or authority, and
nothing has occurred since the date of the last qualification,
registration or approval which would materially adversely affect, or
cause the appropriate governmental agency or authority to revoke, such
qualification, registration or approval.
(b) Solect has fewer than ten employees who are residents of the United
States, is in compliance in all material respects with the Employee
Retirement Income Security Act of 1974, as amended ("ERISA"), as
applicable to such employees and has no contingent liabilities with
respect thereto.
(c) Neither Solect, any Solect Subsidiary nor any administrator, or any
fiduciary of the Canadian Pension/Benefit Plans (or any agent of the
foregoing) has been in breach of any fiduciary obligation with respect
to the administration of the Canadian Pension/Benefit Plans. Neither
Solect, any Solect Subsidiary, nor any administrator or fiduciary of
the Canadian Pension/Benefit Plans (or agent of any of the foregoing)
has engaged in any transaction or acted or failed to act in a manner
which could subject Solect or any Solect Subsidiary to any material
liability for breach of fiduciary duty under applicable laws.
12
<PAGE>
(d) No event has occurred respecting any Canadian Pension/Benefit Plan
which would entitle any persons to wind-up or terminate any Canadian
Pension/Benefit Plan, in whole or in part, or which would materially
adversely affect the tax status thereof.
(e) The Canadian Pension/Benefit Plans are fully funded in accordance with
Canadian pension legislation and the rules of such plans and there are
no going concern unfunded actuarial liabilities, past service unfunded
liabilities or solvency deficiencies respecting any of the Canadian
Pension/Benefit Plans.
(f) None of the Canadian Pension/Benefit Plans require or permit a
retroactive increase in premiums or payments, and the level of
insurance reserves, if any, under any insured Canadian Pension/Benefit
Plan is reasonable and sufficient to provide for all material incurred
but unreported items.
(g) There are no outstanding actions, suits or claims pending or
threatened concerning the assets held in the funding media for the
Canadian Pension/Benefit Plans other than routine claims for the
payment of benefits and there are no outstanding material liabilities
pending or threatened under the Canadian Pension/Benefit Plans for
taxes, penalties or fees under any applicable laws.
(h) Except for those Solect Benefit Arrangements (as defined below)
regarding severance benefits or employment termination that exist
under the employment laws, regulations or judicial decisions relating
to employers in Canada and other jurisdictions in which Solect or any
Solect Subsidiary has employees ("Employer Laws"), the Solect
Disclosure Letter identifies each employment, consulting, severance or
other similar contract, arrangement or policy and each plan or
arrangement (written or oral) providing for insurance coverage
(including any self-insured arrangements), workers' benefits, vacation
benefits, severance benefits, disability benefits, death benefits,
hospitalization benefits, retirement benefits, deferred compensation,
profit-sharing, bonuses, stock options, stock purchase, phantom stock,
stock appreciation or other forms of incentive compensation or
post-retirement insurance, compensation or benefits for employees,
consultants or directors which (A) is not an Solect Employee Plan, (B)
is entered into, maintained or contributed to, as the case may be, by
Solect or any of the Solect Subsidiaries and (C) covers any Employee
or former employee of Solect or any of the Solect Subsidiaries. Such
contracts, plans and arrangements as are described in this Section
2.7(h) are herein referred to collectively as the "Solect Benefit
Arrangements." Each Solect Benefit Arrangement has been maintained in
substantial compliance with its terms and with the requirements
prescribed by any and all statutes, orders, rules and regulations that
are applicable to such Solect Benefit Arrangement. Solect has
13
<PAGE>
delivered to Amdocs or its counsel a complete and correct copy or
description of each Solect Benefit Arrangement. None of the Solect
Benefits Arrangements or Solect Employee Plans promises or provides
retiree medical or retiree insurance benefits to any current or former
employee, other than (i) coverage mandated by applicable law, (ii)
death benefits under any "pension plan" or (iii) benefits the full
cost of which is borne by the current or former employee (or his
beneficiary).
(i) Except as set forth in Section 2.7(i) of the Solect Disclosure Letter,
there has been no amendment to, written interpretation or announcement
by Solect or any of the Solect Subsidiaries relating to, or change in
employee participation or coverage under, any Solect Employee Plan or
Solect Benefit Arrangement that would increase materially the expense
of maintaining such Solect Employee Plan or Solect Benefit Arrangement
above the level of the expense incurred in respect thereof for the
fiscal year ended December 31, 1999.
(j) Except where non-compliance would not have a Material Adverse Effect
to Solect and the Solect Subsidiaries, taken as a whole, Solect and
each Solect Subsidiary are in compliance in all material respects with
all applicable laws (other than ERISA), agreements and contracts
relating to employment, employment practices, wages, hours, and terms
and conditions of employment, including, but not limited to, employee
compensation matters.
(k) Neither Solect nor any Solect Subsidiary is a party to any collective
bargaining or union agreement, and no such agreement is or has been
applicable to any employees of Solect or any Solect Subsidiary and no
union certification process has been proposed or threatened.
(l) There are no material complaints, grievances (other than routine
individual grievances) or arbitrations, employment-related litigation,
administrative proceedings or controversies either pending, or to the
knowledge of Solect, threatened, involving any current or former
employee of Solect or any of the Solect Subsidiaries; and, except as
set forth in Section 2.7 of the Solect Disclosure Letter, neither
Solect nor any Solect Subsidiary has any knowledge that any of the
employees of Solect who have executed new employment letters on the
date hereof intends to leave its employ.
(m) Except as set forth in Section 2.7 of the Solect Disclosure Letter,
neither Solect nor any of the Solect Subsidiaries has an employment
agreement or material consulting agreement currently in effect that is
not terminable at will (other than agreements with the sole purpose of
providing for the confidentiality of proprietary information or
ownership and assignment of inventions), except as such termination
14
<PAGE>
rights are limited under Employer Laws. Except as set forth in Section
2.7 of the Disclosure Letter, no such employment or consulting
agreement has any provision that provides to such employee or
consultant any benefit upon or as a result of the consummation of the
transactions contemplated hereby. All Employees and all officers and
consultants of Solect and the Solect Subsidiaries having access to
proprietary information of Solect have executed and delivered to
Solect an agreement regarding the protection of such proprietary
information and the assignment of inventions to Solect and a
non-competition agreement; copies of the forms of all such agreements
have been delivered or made available to Amdocs' counsel.
2.8 ABSENCE OF UNDISCLOSED LIABILITIES.
At December 31, 1999 (the "Solect Balance Sheet Date"), (i) neither Solect
nor any of the Solect Subsidiaries had any liabilities or obligations of any
nature (matured or unmatured, fixed or contingent) that were material to Solect
and the Solect Subsidiaries, taken as a whole, and were not provided for in the
consolidated balance sheet of Solect at the Solect Balance Sheet Date, a copy of
which is attached hereto as Exhibit 2.8 (the "Solect Balance Sheet"); and (ii)
all reserves established by Solect and set forth in the Solect Balance Sheet
were reasonably adequate.
2.9 ABSENCE OF CERTAIN CHANGES OR EVENTS.
Except as disclosed in Section 2.9 of the Solect Disclosure Letter and as
expressly contemplated in this Agreement and the Ancillary Agreements, since the
Solect Balance Sheet Date, Solect and the Solect Subsidiaries have conducted
their respective businesses only in the ordinary and usual course of such
businesses and there has not occurred:
(a) any change in the financial condition, properties, assets,
liabilities, businesses, operations, results of operations or
long-term prospects of Solect and the Solect Subsidiaries, taken as a
whole, that could reasonably be expected to have a Material Adverse
Effect on Solect and the Solect Subsidiaries, taken as a whole;
(b) any amendments or changes in the articles of continuance or bylaws of
Solect;
(c) any damage, destruction or loss, whether covered by insurance or not,
that would have a Material Adverse Effect on Solect and the Solect
Subsidiaries, taken as a whole;
(d) any redemption, repurchase or other acquisition of Solect Common
Shares by Solect (other than the repurchase of shares at the then
current option pricing pursuant to arrangements with terminated
employees or consultants), or any
15
<PAGE>
declaration, setting aside or payment of any dividend or other
distribution (whether in cash, stock or property) with respect to
Solect Common Shares;
(e) any material increase in or material modification (including
acceleration) of the compensation or benefits payable or to become
payable by Solect to any of its directors or employees;
(f) any material increase in or material modification of any bonus,
pension, insurance or Solect Employee Plan or Solect Benefit
Arrangement (including, but not limited to, the granting of stock
options, restricted stock awards or stock appreciation rights) made
to, for or with any of its employees;
(g) any change by Solect in its accounting methods, principles or
practices;
(h) any writing down or writing off of the value of any assets other than
in the ordinary course of business;
(i) any acquisition or sale of a material amount of property or assets of
Solect, except in the ordinary course of business consistent with past
practice or other nonmaterial amounts;
(j) any alteration in any term of any outstanding security of Solect;
(k) (A) any incurrence, assumption or guarantee by Solect of any debt for
borrowed money; (B) any issuance or sale of any securities convertible
into or exchangeable for debt securities of Solect; (C) any agreement
to act as surety for any obligation of a third party; or (D) any
issuance or sale of options or other rights to acquire from Solect,
directly or indirectly, debt securities of Solect or any securities
convertible into or exchangeable for any such debt securities;
(l) other than in the ordinary course of business consistent with past
practice or, in respect of nonmaterial amounts, any creation or
assumption by Solect of any lien, security interest, charge or
encumbrance on any asset;
(m) any making of any loan, advance or capital contribution to or
investment in any person other than (i) travel loans or advances made
in the ordinary course of business of Solect, (ii) other loans and
advances in an aggregate amount which does not exceed US$100,000
outstanding at any time and (iii) purchases on the open market of
liquid, publicly traded securities;
16
<PAGE>
(n) any entering into, amendment of, relinquishment, failure in any
material respect to perform under, occurrence of any material default
under, or termination or non-renewal by Solect or any Solect
Subsidiary of any material contract (including, without limitation,
any material customer or supplier contract), lease transaction,
commitment or other right or obligation;
(o) any transfer or grant of a material right (including, without
limitation, under the Solect IP Rights (as defined in Section 2.14
below)), other than in the ordinary course of business consistent with
past practice, or any grant of an exclusive right;
(p) any agreement, arrangement or other transaction with any "affiliate"
or "associate" (as those terms are defined in Rule 405 promulgated
under the Securities Act) of Solect or any Solect Subsidiary, other
than the payment and provision of regular salary and benefits in the
ordinary course of such person's employment with Solect or any Solect
Subsidiary;
(q) any material complaint, grievance (other than routine individual
grievances), to the knowledge of Solect any activity or proceeding by
a labor union or representative thereof to organize any employees of
Solect or any Solect Subsidiary or to the knowledge of Solect any
campaign being conducted to solicit authorization from employees to be
represented by such labor union;
(r) any waiver or release of any material right or claim of Solect or any
Solect Subsidiary;
(s) any agreement or arrangement made by Solect or any Solect Subsidiary
to take any action which, if taken prior to the date hereof, would
have made any representation or warranty set forth in this Agreement
materially untrue or incorrect as of the date when made unless
otherwise disclosed;
(t) any (i) failure to maintain in full force and effect substantially the
same level and type of insurance coverage as in effect on the Solect
Balance Sheet Date or (ii) change in any insurance coverage or the
issuance of any insurance policy, except in the ordinary course of
business consistent with past practice;
(u) any sale, assignment, transfer, license or encumbrance of any tangible
or intangible asset, including any Intellectual Property Right (as
hereinafter defined), except for sales, assignments, transfers,
licenses and encumbrances in the ordinary course of business;
17
<PAGE>
(v) the entering into any material lease or contract for the purchase or
sale or license of any property, real or personal, except in the
ordinary course of business consistent with past practice;
(w) any failure to maintain its equipment and other assets in good working
condition and repair according to the standards it has maintained to
the date of this Agreement, subject only to ordinary wear and tear;
(x) any issuance or sale of any shares of its capital stock of any class
or any other of its securities, or issuance or creation of any
warrants, obligations, subscriptions, options, convertible securities
or other commitments to issue shares of capital stock, or acceleration
of the vesting of any outstanding option or other security;
(y) any merger, consolidation or reorganization with, or the acquisition
of, any entity, or the entering into of any agreement to do any of the
foregoing;
(z) any agreement to any audit assessments by any Tax authority in excess
of US$100,000 in the aggregate.
2.10 AGREEMENTS.
Section 2.10 of the Solect Disclosure Letter sets forth a complete list of
all of the following written or oral contracts, agreements and other instruments
which bind Solect or any of the Solect Subsidiaries (collectively, the "Solect
Contracts"), and complete and correct copies of the Solect Contracts have been
made available to Amdocs for review:
(a) contract with or commitment to any labor union;
(b) continuing contract for the future purchase, sale, development or
manufacture of products, material, supplies, equipment, software or
services requiring payment to or from Solect or any Solect Subsidiary
(i) in an amount in excess of US$100,000 per annum which is not
terminable on 120 days or less notice without material cost or other
liability at, or at any time after, the Effective Time or in which
Solect or such Solect Subsidiary has granted or received manufacturing
rights or most favored nations pricing provisions rights relating to
any product, group of products or territory, or (ii)(A) in which
Solect or such Solect Subsidiary has granted or received any
Intellectual Property Rights, (B) which require consent or are
otherwise terminable upon a change of control of Solect or (C) in
which Solect or such Solect Subsidiary has granted exclusive market
rights relating to any product, group of products or territory;
18
<PAGE>
(c) contract providing for the development of software for, or license of
software to, Solect or any Solect Subsidiary, or other Intellectual
Property Rights (as defined in Section 2.14) used or incorporated in
one or more of the products of Solect or any Solect Subsidiary (other
than software licensed to Solect or any Solect Subsidiary from a third
party as to which Solect or such Solect Subsidiary has a fully-paid
perpetual license to use and distribute as Solect or such Solect
Subsidiary is currently doing without any material restrictions or
limitations, or that is generally available to the public from such
third party at a per copy license fee of less than US$5,000, but
including any site or corporate license and each agreement providing
for either the delivery of source code or the escrow of source code
for the benefit of the licensee or any original equipment manufacturer
("OEM"), distribution or other agreement that requires Solect or any
Solect Subsidiary to perform any ongoing development of software
including updates and error corrections);
(d) joint venture, partnership or other agreement that has involved or is
reasonably expected to involve a sharing of profits or losses in
excess of US$100,000 per annum with any other party;
(e) to the extent not identified in Section 2.7 of the Solect Disclosure
Letter, contract or commitment for the employment of any officer,
employee or consultant or any other type of contract or understanding
with any officer, employee or consultant which is not immediately
terminable without cost or other liability (except for normal
severance benefits available to employees generally as set forth in
any Solect Benefit Plan and except for limitations on such termination
rights as exist under applicable Employer Laws) or any contract,
commitment or other instrument providing for, or any understanding
with respect to any deferred compensation, incentive, profit sharing
or pension plans;
(f) indenture, mortgage, promissory note, loan agreement, guarantee or
other agreement or commitment for the borrowing of money, for a line
of credit or for a leasing transaction of a type required to be
capitalized in accordance with Statement of Financial Accounting
Standards No. 13 of the Financial Accounting Standards Board in each
case in excess of, or with respect to any debt in excess of, US
$100,000;
(g) lease or other agreement under which Solect or any Solect Subsidiary
is lessee of or holds or operates any items of tangible personal
property or real property owned by any third party and under which
payments to such third party exceed US$100,000 per annum;
19
<PAGE>
(h) agreement or arrangement for the sale of any assets, properties or
rights having a value in excess of US$100,000, other than in the
ordinary course of business consistent with past practice;
(i) agreement which restricts Solect or any Solect Subsidiary from
engaging in any material aspect of its business or competing in any
line of business in any geographic area or in any functional area or
that requires Solect or any Solect Subsidiary to distribute or use
exclusively a third party technology or product;
(j) agreement between or among Solect or any Solect Subsidiary regarding
intercompany loans, revenue or cost sharing, ownership or license of
Solect IP Rights, intercompany royalties or dividends or similar
matters;
(k) written dealer, distributor, sales representative, OEM, value added
remarketer, subcontractor or other agreement for the ongoing
distribution of the products and services of Solect or any Solect
Subsidiary;
(l) any loan or credit agreement, note, bond, mortgage, indenture, lease
or other material agreement that is not otherwise disclosed elsewhere
in the Solect Disclosure Letter, the breach or termination of which
would have a Material Adverse Effect on Solect and the Solect
Subsidiaries, taken as a whole;
(m) Solect IP Rights Agreement (as defined in Section 2.14 below) or other
material agreements relating to the products and services of Solect or
any Solect Subsidiary other than any Solect IP Rights Agreement or
other such material agreement already identified in response to
Section 2.10(b) or (c) above or elsewhere in the Solect Disclosure
Letter;
(n) any agreement by Solect or any Solect Subsidiary regarding directors
and officers indemnification;
(o) any agreement, contract or commitment by Solect or any Solect
Subsidiary relating to material capital expenditures or involving
future obligations in excess of US$100,000, other than those listed in
its financial statements ending December 31, 1999;
(p) any voting trust or stockholders agreement known to Solect between or
among Solect or any Solect Subsidiary and shareholders of Solect;
(q) any tax sharing or tax indemnification agreement between or among
Solect or any Solect Subsidiary; and
20
<PAGE>
(r) any material agreement pursuant to which either the execution of this
Agreement or any of the Ancillary Agreements by Solect or the
consummation of the transactions contemplated hereby or thereby will
or may result in (i) a breach by Solect or any Solect Subsidiary of
any term, provisions or condition of such agreement, or (ii) the
ability of the other party thereto to terminate such agreement or
materially change any of the terms, provisions or conditions thereof.
2.11 NO DEFAULTS.
All material provisions of the Solect Contracts are valid and enforceable
obligations of Solect or the applicable Solect Subsidiaries and, to Solect's
knowledge, of the other parties thereto, enforceable against each such party in
accordance with its terms but subject to bankruptcy, insolvency, reorganization
or other similar laws affecting or relating to enforcement of creditors' rights
generally and general equitable principles. Solect has not been notified of any
claim that any material provision of any Solect Contract is not valid and
enforceable in accordance with its terms (subject to bankruptcy, insolvency,
reorganization or other similar laws affecting or relating to enforcement of
creditors' rights generally and general equitable principles) for the periods
stated therein. Neither Solect nor any of the Solect Subsidiaries is in default
under, and to the knowledge of Solect there exists no event, condition or
occurrence which, after notice or lapse of time, or both, would constitute such
a default by Solect or any of the Solect Subsidiaries under, any contract or
agreement (other than this Agreement) to which Solect or any of the Solect
Subsidiaries is a party and which would, if terminated due to such default, have
a Material Adverse Effect on Solect and the Solect Subsidiaries, taken as a
whole. To Solect's knowledge, no other party to any such contract or agreement
is in material default thereunder, nor, to Solect's knowledge, does there exist
any event, condition or occurrence which, after notice or lapse of time, or
both, would constitute such a default by any such other party which would, if
terminated due to such default, have a Material Adverse Effect on Solect and the
Solect Subsidiaries, taken as a whole.
2.12 CERTAIN AGREEMENTS.
Except as disclosed in the Solect Disclosure Letter, neither the execution
and delivery of this Agreement or the Ancillary Agreements to which Solect is a
party nor the consummation of the transactions contemplated hereby or thereby
will (i) result in any material payment (including, without limitation,
severance, unemployment compensation, golden parachute, bonus or otherwise)
becoming due to any director or employee of Solect or any of the Solect
Subsidiaries from Solect or any of the Solect Subsidiaries under any Solect
Employee Plan, Solect Benefit Arrangement or otherwise, (ii) materially increase
any benefits otherwise payable under any Solect Employee Plan or Solect Benefit
Arrangement or (iii) result in the acceleration of the time of payment or
vesting of any such benefits, including but not limited to the time of exercise
of stock options.
21
<PAGE>
2.13 TAXES.
Except as set forth in Section 2.13 of the Solect Disclosure Letter, Solect
and each of the Solect Subsidiaries have timely filed, or caused to be filed,
all material Tax Returns (as defined below) required to be filed by them (all of
which returns were correct and complete in all material respects). Except as set
forth in Section 2.13 of the Solect Disclosure Letter and Taxes incurred since
December 31, 1999 in the ordinary course of business, Solect and each of the
Solect Subsidiaries have paid or withheld, or caused to be paid or withheld, all
Taxes (as defined below) that are due and payable, or Solect has provided
adequate accruals in accordance with Canadian GAAP in its financial statements
for the periods ending December 31, 1999 and Taxes incurred subsequent thereto
in the ordinary course of business, for any Taxes for any period up to and
including those periods covered by such statements that have not been paid,
whether or not shown as being due on any returns. Except as set forth in Section
2.13 of the Solect Disclosure Letter, since the Solect Balance Sheet Date, no
material Tax liability has been assessed, proposed to be assessed, incurred or
accrued other than in the ordinary course of business. Except as set forth in
Section 2.13 of the Solect Disclosure Letter and except for any Taxes for which
Solect has provided adequate accruals in accordance with Canadian GAAP in its
financial statements ending December 31, 1999 and Taxes incurred subsequent
thereto in the ordinary course of business, Solect and the Solect Subsidiaries
have withheld from all payments made by them, or otherwise collected, and have
remitted all amounts in respect of Taxes required to be withheld, collected or
remitted by them to the applicable governmental authority within the required
time periods. Except as set forth in Section 2.13 of the Solect Disclosure
Letter and except for any Taxes for which Solect has provided adequate accruals
in accordance with Canadian GAAP in its financial statements ending December 31,
1999 and Taxes incurred subsequent thereto in the ordinary course of business,
neither Solect nor any of the Solect Subsidiaries has any liability for the
Taxes of any other person, corporation, partnership, trust or other taxpayer.
Except as set forth in Section 2.13 of the Solect Disclosure Letter, there
are no audits or investigations in progress, pending or, to the knowledge of
Solect, threatened by Canada Customs and Revenue Agency, the Internal Revenue
Service or any other taxing authority, including, without limitation, any value
added tax or sales tax authority (a "Taxing Authority"), against Solect, any
Solect Subsidiary or any of the assets of Solect or any of the Solect
Subsidiaries, and neither Solect nor any Solect Subsidiary has received any
notification that any material issues have been raised (and are currently
pending) by any Taxing Authority in connection with any of the Tax Returns
referred to above, and no waivers of statutes of limitations have been given or
requested with respect to Solect or any of the Solect Subsidiaries. Except as
set forth in Section 2.13 of the Solect Disclosure Letter and except for any
Taxes for which Solect has provided adequate accruals in accordance with
Canadian GAAP in its financial statements ending December 31, 1999 and Taxes
incurred subsequent thereto in the ordinary course of business, there are no
material proposed (but unassessed) additional Taxes, none have been asserted and
22
<PAGE>
no Tax liens have been filed other than for Taxes not yet due and payable.
Notices of Determination have neither been requested nor issued by Solect or any
of the Solect Subsidiaries.
Except as set forth in Section 2.13 of the Solect Disclosure Letter, no
material amount in respect of any outlay or expense that is deductible for the
purposes of computing the income of Solect or any of the Solect Subsidiaries for
the purposes of the ITA has been owing by Solect or any of the Solect
Subsidiaries, as the case may be, for longer than two years to a person not
dealing at arm's length (for the purposes of the ITA) with Solect or any of the
Solect Subsidiaries at the time the outlay or expense was incurred. Except as
set forth in Section 2.13 of the Solect Disclosure Letter, there are no
circumstances which exist and would result in, or which have existed and
resulted in, Section 80 of the ITA applying to Solect or any of the Solect
Subsidiaries. Except as set forth in Section 2.13 of the Solect Disclosure
Letter, neither Solect nor any of the Solect Subsidiaries have either directly
or indirectly transferred property to or supplied services to or acquired
property or services from a person, corporation, partnership, trust or other
taxpayer with whom it was not dealing at arm's length (for the purposes of the
ITA) for consideration other than consideration equal to the fair market value
of the property or services at the time of the transfer, supply or acquisition
of the property or services. Solect and the Solect Subsidiaries have not entered
into any advance pricing agreement with any Taxing Authority. Neither Solect nor
any corporation to which Solect is related (for the purposes of the ITA) is a
corporation whose principal business is (i) the lending of money to persons with
whom such corporation is dealing at arm's length (for the purposes of the ITA);
(ii) the purchasing of debt obligations issued to such persons; or (iii) a
combination thereof. Except as set forth in Section 2.13 of the Solect
Disclosure Letter, none of Solect or any of the Solect Subsidiaries (i) has made
an election to be treated as a "consenting corporation" under Section 341(f) of
the Code, or (ii) is a party to any Tax sharing or other similar agreement or
arrangement of any nature with any other person pursuant to which Solect or any
of the Solect Subsidiaries has or could have any liabilities in respect of
Taxes.
Except as set forth in Section 2.13 of the Solect Disclosure Letter, the
net operating loss carryforwards and research and development tax credits
reflected in the Solect Financial Statements are valid and reasonably estimated
and will be unaffected by the consummation of the transactions contemplated
hereby.
As used in this Agreement, "Tax" and "Taxes" means, with respect to any
entity, (A) all income taxes (including any tax on or based upon net income,
gross income, income as specially defined, earnings, profits or selected items
of income, earnings or profits) all capital, corporate, gross receipts, sales,
use, goods and services, turnover, ad valorem, transfer, real or personal
property, VAT, gains, franchise, license, withholding, payroll, wage, employer
health, employ ment, excise, severance, utility, compensation, stamp,
occupation, premium and windfall profits taxes, all social security or
unemployment insurance charges, workers' compensation levies and retirement
contributions, all alternative or add-on minimum taxes, all customs or excise
23
<PAGE>
duties and all other taxes, fees, levies, duties, assessments or charges of any
kind whatsoever, together with any interest and any penalties or additional
amounts imposed by any taxing authority (domestic or foreign) on such entity,
and any interest, penalties, additional taxes and additions to tax imposed with
respect to the foregoing, and (B) any liability for the payment of any amount of
the type described in the immediately preceding clause (A) as a result of being
a "transferee" (within the meaning of Section 6901 of the Code or any other
applicable law) of another entity or a member of an affiliated, consolidated,
unitary or combined group. As used in this Agreement, "Tax Returns" means all
returns, declarations, reports, statements, claims for refund, amended returns
and declarations of estimated taxes (including any attached schedules) or other
written information (including elections, declarations, disclosures, estimates
and informational returns) required to be supplied to a Taxing Authority in
connection with or relating to Taxes.
2.14 INTELLECTUAL PROPERTY.
(a) Solect and the Solect Subsidiaries own, or, as applicable, have the
right to use, sell, distribute or license all Intellectual Property
Rights (as defined below) material to the conduct of their respective
businesses as presently conducted (including, without limitation, the
development, manufacture, operation and sale or license, as
applicable, of all products and services sold by Solect or the Solect
Subsidiaries), and, to the knowledge of Solect, without infringing
upon or violating any right, lien, or claim of others, including
without limitation, former employers of the past and present employees
of Solect (such Intellectual Property Rights being hereinafter
collectively referred to as the "Solect IP Rights"); Section 2.14 of
the Solect Disclosure Letter sets forth a complete and correct list of
all material Solect IP Rights and specifies whether each such right is
owned by or licensed (including sublicensed) to Solect or a Solect
Subsidiary and other agreements pursuant to which Solect or any of the
Solect Subsidiaries or any other person is authorized to use, sell,
distribute or license any material Solect IP Rights (excluding object
code end-user licenses granted to end-users which in some cases
include standard third party commercial source code escrows), entered
in the ordinary course of business that permit use of software
products without a right to modify, distribute or sublicense the same
("End-User License"); and, except as set forth in Section 2.14 of the
Solect Disclosure Letter, no such license will terminate by its terms
within 24 months after the date hereof;
(b) except as set forth in Section 2.14 of the Solect Disclosure Letter,
the execution, delivery and performance of this Agreement and the
consummation of the transactions contemplated hereby will not
constitute a material breach of any assignment, conveyance or
agreement governing any material Solect IP Right (the "Solect IP
Rights Agreements"), will not cause the forfeiture or termination or
give rise to a right of forfeiture or termination of any material
24
<PAGE>
Solect IP Right or materially impair the right of Solect and/or the
Solect Subsidiaries to use, sell or license any material Solect IP
Right or portion thereof necessary or required for the conduct of
their respective businesses;
(c) there are no royalties, honoraria, fees or other payments in excess of
$100,000 payable by Solect or any of the Solect Subsidiaries to any
person in respect of any Solect IP Rights by reason of the
publication, use or distribution of products or services or in
connection with the conduct of the business of Solect or any Solect
Subsidiary or otherwise other than as set forth in the Solect IP
Rights Agreements listed in the Solect Disclosure Letter;
(d) neither the manufacture, marketing, license, sale or lawful use of any
product currently licensed or sold by Solect or any of the Solect
Subsidiaries or currently under development by Solect or any of the
Solect Subsidiaries violates any license or agreement between Solect
or any of the Solect Subsidiaries and any third party or infringes any
Intellectual Property Right of any other party; and there is no
pending or, to the knowledge of Solect, threatened, claim or
litigation contesting the validity, ownership or right to use, sell,
license or dispose of any material Solect IP Right nor, to the
knowledge of Solect, is there any basis for any such claim, nor has
Solect received any notice asserting that any material Solect IP Right
or the proposed use, sale, license or disposition thereof conflicts or
will conflict with the rights of any other party, nor, to the
knowledge of Solect, is there any basis for any such assertion;
(e) except as set forth in Section 2.14 of the Solect Disclosure Letter,
Solect has taken reasonable and practicable steps designed to
safeguard and maintain the secrecy and confidentiality of, and its
proprietary rights in, all material Solect IP Rights. Except as set
forth in Section 2.14 of the Solect Disclosure Letter, all officers
and employees involved in the development of products or product
documentation and consultants of Solect or any of the Solect
Subsidiaries have executed and delivered to Solect or the Solect
Subsidiary an agreement regarding the protection of proprietary
information and the assignment to Solect or the Solect Subsidiary of
all Intellectual Property Rights arising from the services performed
for Solect or the Solect Subsidiary by such persons; and copies of the
forms of all such agreements have been delivered to Amdocs' counsel.
No current or prior officers, employees or consultants of Solect claim
an ownership interest in any material Solect IP Rights as a result of
having been involved in the development of such property while
employed by or consulting to Solect, or otherwise;
(f) any and all Intellectual Property Rights currently being developed or
developed in the past by any employee of Solect or any Solect
25
<PAGE>
Subsidiary while in the employ of Solect or any Solect Subsidiary, is
or will be the sole property of Solect or such Solect Subsidiary. It
is not necessary for the conduct of the business of Solect or the
Solect Subsidiaries to utilize any inventions of any employee of
Solect or any Solect Subsidiary made prior to their employment by
Solect, other than those that have been assigned to Solect or such
Solect Subsidiary pursuant to the Proprietary Information Agreement
signed by such employee; and
(g) Solect and the Solect Subsidiaries have not received and do not have
any knowledge regarding any injunctions or claims from administrative
or judicial authorities or from clients or consumers in respect of
material failures affecting the products or any one of them sold by
Solect or any Solect Subsidiary nor in respect of any requirement to
recall said products. In addition, there are no errors in any
documentation, specifications, manuals, user guides, promotional
material, internal notes and memos, technical documentation, drawings,
flow charts, diagrams, source language statements, demo disks,
benchmark test results, and other written materials related to,
associated with or used or produced in the development Solect or any
of Solect Subsidiaries software products (collectively, the "Design
Documentation") which defects or errors would reasonably be expected
to have, individually or in the aggregate, a Material Adverse Effect
on Solect and the Subsidiaries of Solect, taken as a whole. To the
knowledge of Solect, no portion of the material Solect IP Rights
contains any unauthorized disabling mechanism or protection feature
designed to prevent its use, computer virus, worm software lock, drop
dead device, Trojan-horse routine, trap door, time bomb or any other
codes or instructions that may be used to access, modify, delete,
damage or disable any of the Intellectual Property or any computer
system on which any of the software comprising part thereof is
installed or in connection with which they may operate.
Solect has made available to Amdocs for review a list of all applications,
registrations, filings and other formal actions made or taken pursuant to United
States, Canadian, provincial, federal, state and foreign laws by Solect to
perfect or protect its interest in Solect IP Rights, including, without
limitation, all patents, patent applications, trademarks and service marks,
trademark and service mark applications, copyrights and copyright applications
and, to the knowledge of Solect, there is no cancellation, termination or
expiration of any such registration or patent that is reasonably foreseeable and
is not intended to be renewed or extended by Solect, except where the failure to
renew or extend would not have a Material Adverse Effect on Solect and the
Subsidiaries of Solect, taken as a whole. To the knowledge of Solect, it is not
using any confidential information or trade secrets of any former employer of
any past or present employees.
As used herein, the term "Intellectual Property Rights" shall mean all
worldwide industrial and intellectual property rights, including, without
26
<PAGE>
limitation, patents, patent applications, patent rights, software (in both
source code for all software owned by Solect or the Solect Subsidiaries and
object code form), nonproductized software technology, trademarks, trademark
applications, trade names, service marks, service mark applications, copyright,
copyright applications, mask works, franchises, licenses, know-how, trade
secrets, customer lists, proprietary processes and formulae, all source and
object code, algorithms, architecture, structure, display screens, layouts,
inventions, development tools, designs, processes, works of authorship, computer
programs and technical data and information and all documentation and media
constituting, describing or relating to the above, including, without
limitation, manuals, memoranda and records.
2.15 FEES AND EXPENSES.
Except for the fees and expenses set forth in Section 2.15 of the Solect
Disclosure Letter payable to Morgan Stanley Dean Witter ("Morgan Stanley"),
neither Solect nor any of the Solect Subsidiaries has paid or become obligated
to pay any fee or commission to any broker, investment banker, person or firm
acting in a similar capacity on behalf of or under the authority of Solect,
finder or intermediary, directly or indirectly, in connection with the
transactions contemplated by this Agreement. Solect has delivered to Amdocs a
complete and correct copy of Solect's agreement with Morgan Stanley, pursuant to
which Morgan Stanley shall be entitled to be paid the foregoing fees and
expenses in connection with the transactions contemplated by this Agreement.
2.16 INSURANCE.
Solect and the Solect Subsidiaries maintain and at all times since January
1, 1998 have maintained fire and casualty, general liability, business
interruption, product liability, sprinkler and water damage and any other
insurance that Solect believes or believed to be reasonably prudent for its
business. Section 2.16 of the Solect Disclosure Letter contains a list of all
such insurance policies presently in effect, and correct and complete copies of
all such policies along with a history of claims made under such policies have
been provided to Amdocs. Solect and each of the Solect Subsidiaries has fully
paid all payments required under the terms of each of the foregoing insurance
policies and neither Solect nor any Solect Subsidiary has received notice of
intent to cancel any of the foregoing insurance policies.
Except as set forth in Section 2.16 to the Solect Disclosure Letter,
Solect does not have any knowledge of any state of facts or the occurrence of
any event, which reasonably might (i) form the basis for any claim against
Solect or any of the Solect Subsidiaries not reasonably expected to be fully
covered by the insurance policies referred to on Section 2.16 to the Solect
Disclosure Letter, and which exceeds US$100,000 in liability, or (ii) increase
the insurance premiums paid by Solect, in excess of US$100,000 per annum in the
27
<PAGE>
aggregate, or affect the availability of the insurance coverage listed in
Section 2.16 to the Solect Disclosure Letter on substantially the same terms as
now in effect.
2.17 OWNERSHIP OF PROPERTY.
Section 2.17 of the Solect Disclosure Letter sets forth a brief description
of all real property owned by or leased to Solect and the Solect Subsidiaries.
Except (a) as disclosed in Section 2.17 of the Solect Disclosure Letter, (b) for
liens for current Taxes not yet delinquent and (c) for liens imposed by law and
incurred in the ordinary course of business for obligations not yet due to
carriers, warehousemen, laborers, materialmen and the like (other than as may be
contested), Solect and each of the Solect Subsidiaries have good and marketable
title to all of their respective material real and personal property (other than
property as to which it is lessee, in which case it has a valid leasehold
interest) and own all of such property free and clear of all security interests,
mortgages, liens, charges, options and encumbrances. All real and tangible
personal property of Solect and each of the Solect Subsidiaries is generally in
good repair and is operational and usable in the operations of Solect or the
Solect Subsidiaries, subject to ordinary wear and tear and subject to technical
obsolescence. Neither Solect nor any Solect Subsidiary is in violation of any
zoning, building or safety ordinance, regulation or requirement or other law or
regulation applicable to the operation of owned or leased properties, or has
received any notice of violation with which it has not complied, except, in each
case, where such violation would not have a Material Adverse Effect on Solect
and the Solect Subsidiaries, taken as a whole.
Solect's shareholders do not own, hold or possess, in their individual or
any other capacities, any property, whether tangible or intangible, used or
connected to the business of Solect which is material, individually or in the
aggregate, to the financial condition, operations, or business of Solect and the
Solect Subsidiaries, taken as a whole.
2.18 ENVIRONMENTAL MATTERS.
(a) To the knowledge of Solect, during the period that Solect and the
Solect Subsidiaries have leased or owned their respective properties
or owned or operated any facilities, there have been no disposals,
releases, emissions, spills, discharges or threatened releases of
Hazardous Materials (as defined below) on, from or under such
properties or facilities which could result in a material violation of
any applicable law. Solect has no knowledge of any presence,
disposals, releases, emissions, spills, discharges or threatened
releases of Hazardous Materials on, from or under any of such
properties or facilities, which may have occurred prior to Solect or
any of the Solect Subsidiaries having taken possession of any of such
properties and facilities which could result in a material violation
of any applicable law. For the purposes of this Agreement, insofar as
properties and facilities in Canada are concerned, "Hazardous
28
<PAGE>
Materials" shall mean any pollutant, contaminant, chemical,
deleterious substance or industrial, toxic or hazardous waste or
substance and, insofar as properties and facilities in the United
States are concerned, shall mean any hazardous or toxic substance,
material or waste which is or becomes prior to the Closing regulated
under, or defined as a "hazardous substance," "pollutant,"
"contaminant," "toxic chemical," "hazardous chemical" under, (1) the
Comprehensive Environmental Response, Compensation and Liability Act
of 1980, 42 U.S.C. Section 9601 et seq., as amended ("CERCLA"); (2)
any similar federal, state or local law; or (3) regulations
promulgated under any of the above laws or statutes. Insofar as
properties and facilities in the United States are concerned, the
terms "disposal," "release" and "threatened release" shall have the
definitions assigned thereto by CERCLA.
(b) To the knowledge of Solect, none of the properties, facilities and
operations of Solect and the Solect Subsidiaries is in material
violation of any federal, provincial, state, municipal and local laws,
statutes, bylaws, ordinances, regulations and orders ("Environmental
Laws") relating to protection of the environment, occupational health
and safety, industrial hygiene or Hazardous Materials. During the time
that Solect or the Solect Subsidiaries have owned or leased their
respective properties and facilities, neither Solect nor any of the
Solect Subsidiaries nor, to the knowledge of Solect, any third party,
has used, generated, manufactured, processed, treated, disposed of,
handled or stored on, under or about such properties or facilities or
transported to or from such properties or facilities any Hazardous
Materials.
(c) There has been no litigation brought or threatened against Solect or
any of the Solect Subsidiaries by, or any settlement reached by Solect
or any of the Solect Subsidiaries with, any party or parties alleging
the presence, disposal, emission, spill, discharge, release or
threatened release of any Hazardous Materials on, from or under any
properties or facilities.
2.19 INTERESTED PARTY TRANSACTIONS.
Schedule 2.19 of the Solect Disclosure Letter sets forth a current list of
all shareholders, directors, officers and affiliates of Solect and each Solect
Subsidiary. Except as disclosed in Schedule 2.19 of the Solect Disclosure Letter
or expressly contemplated herein or in connection with the transactions
contemplated hereby, no shareholder, officer or director of Solect or any
affiliate or associate of any such person has had, either directly or
indirectly, or proposes to have a material interest in: (i) any person or entity
that purchases from or sells, licenses or furnishes to Solect or any of the
Solect Subsidiaries any goods, property, technology or intellectual or other
property rights or services; or (ii) any current or proposed contract or
agreement to which Solect or any of the Solect Subsidiaries is or proposes to be
a party or by which it may be bound or affected.
29
<PAGE>
2.20 BOARD APPROVAL.
The Board of Directors of Solect has, on or before the date hereof, (i)
approved this Agreement, the Ancillary Agreements to which Solect is a party and
the Share Restructuring Plan, (ii) determined that the Share Restructuring Plan
is in the best interests of the shareholders of Solect and is on terms that are
fair from a financial point of view to such shareholders, (iii) resolved to
recommend that the shareholders of Solect approve the Share Restructuring, (iv)
taken all other action necessary to authorize the calling of a shareholders
meeting and for the adoption and implementation of the Share Restructuring other
than the preparation of the Information Statement (as defined below) and the
filing of the articles of amendment giving effect to the Share Restructuring,
and (v) resolved pursuant to Section 12 of the Solect Option Plans to amend the
Solect Options as contemplated in Section 1.2(b) and further resolved, based on
the unanimous recommendation of the Compensation Committee of Solect's Board of
Directors, that such action, when taken with any related action, would not
materially and adversely affect the holders of Solect Options.
2.21 VOTE REQUIRED.
The affirmative vote of two-thirds of the votes cast by the holders of the
outstanding Solect Common Shares entitled to be cast is the only vote of the
holders of any class or series of Solect's capital stock or of any securities
convertible into or exchangeable for such capital stock (including, without
limitation, the Solect Options and the Solect Convertible Securities) necessary
to approve the Share Restructuring Plan and there are no agreements between
Solect and any of the holders of the outstanding securities of Solect or among
any of such holders that relate in any manner to the procedure for such voting
which have not been waived.
2.22 AMENDMENT TO SOLECT OPTION PLANS.
The Board of Directors of Solect has, on or before the date hereof, adopted
an amendment to the Solect Option Plans, conditional on the Share Restructuring
Plan taking effect, to provide for the exchange of the Solect Options as
contemplated by Section 1.2 hereof, and no other action on the part of Solect
shareholders or the holders of Solect Options is required to effect such
amendment.
2.23 DISCLOSURE.
No representation or warranty made by Solect in this Agreement, nor any
document, written information, financial statement, certificate or Exhibit
30
<PAGE>
prepared and furnished or to beprepared and furnished by Solect or its
representatives pursuant hereto or in connection with the transactions
contemplated hereby, when taken together, contains any untrue statement of a
material fact when made, or omitted to state a material fact necessary to make
the statements or facts contained herein or therein not misleading in light of
the circumstances under which they were made or furnished.
2.24 FAIRNESS AND EQUIVALENCY OPINIONS.
Solect's Board of Directors has received a written opinion from Morgan
Stanley that (i) the Exchange Ratio is fair to Solect's shareholders from a
financial point of view; (ii) an Exchangeable Share represents a participating
security of Solect of equivalent value to a Solect Common Share for the purposes
of the definition of a "going private transaction" in OSC Policy 9.1, (iii) the
ancillary rights granted to a holder of Solect Common Shares in connection with
the Share Restructuring Plan, the Registration Rights Agreement (as defined in
Section 6.2) and the call rights granted by such holders are of nominal value
and (iv) the substitution of Amdocs Ordinary Shares for Solect Common Shares
upon the exercise of options does not materially adversely affect the
optionholders.
2.25 RESTRICTIONS ON BUSINESS ACTIVITIES.
There is no material agreement, judgment, injunction, order or decree
binding upon Solect or any Solect Subsidiary that has or could reasonably be
expected to have the effect of prohibiting or materially impairing any business
practice of Solect or any Solect Subsidiary, any acquisition of property by
Solect or any Solect Subsidiary or the conduct of business by Solect or any
Solect Subsidiary as currently conducted.
2.26 BOOKS AND RECORDS.
(a) The books, records and accounts of Solect and the Solect Subsidiaries
(i) have been maintained in accordance with good business practices on
a basis consistent with prior years, (ii) are stated in reasonable
detail and accurately and fairly reflect the transactions and
dispositions of the assets of Solect and the Solect Subsidiaries and
(iii) accurately and fairly reflect the basis for Solect's financial
statements. Solect has devised and maintains a system of internal
accounting controls sufficient to provide reasonable assurances that
(A) transactions are executed in accordance with management's general
or specific authorization; and (B) transactions are recorded as
necessary (1) to permit preparation of financial statements in
conformity with Canadian GAAP, US GAAP or any other criteria
applicable to such statements and (2) to maintain accountability for
assets.
31
<PAGE>
(b) The minute books of Solect and the Solect Subsidiaries which have been
provided to Amdocs contain accurate and complete copies of the minutes
of every meeting of their respective shareholders and Boards of
Directors and any committee thereof since their incorporation. No
resolutions have been passed, enacted, consented to or adopted by the
Board of Directors or any committee thereof or shareholders of Solect
or the Solect Subsidiaries, except for those contained in such minute
books, which accurately reflect all material transactions referred to
in such minutes. The corporate records of Solect and the Solect
Subsidiaries are up to date and have been maintained in accordance
with all applicable statutory requirements and are complete and
accurate in all material respects.
2.27 CUSTOMERS.
(a) Except as set forth in Section 2.27 of the Solect Disclosure Letter,
since January 1, 1999, neither Solect nor any of the Solect
Subsidiaries has lost its relationship with any of its material
customers. Neither Solect nor any of the Solect Subsidiaries has been
notified that it will lose or might lose, or suffer any diminution in,
its relationship with any such customers. No representative of any
such material customer has notified either Solect or any of the Solect
Subsidiaries that, in the event of a sale or change of control of
Solect, either Solect or any Solect Subsidiary would lose, or suffer
any diminution in, its relationship with any such material customer
nor does Solect expect any such loss or diminution.
(b) Except as set forth in Section 2.27 of the Solect Disclosure Letter,
Solect has received no material customer complaints concerning its
products and/or services, nor has it had any of its products returned
by a purchaser thereof, other than for minor, non-recurring warranty
problems.
2.28 COMPETITION ACT.
Solect and its affiliates do not have assets in Canada that exceed CDN$300
million in aggregate value and did not have gross revenues from sales in, from
or into Canada, that exceed CDN$300 million in aggregate value, determined for
purposes of and in the manner prescribed by the Competition Act (Canada) and the
Notifiable Transactions Regulations promulgated thereunder.
2.29 INVESTMENT CANADA MATTERS.
Neither Solect nor any of the Solect Subsidiaries provides any financial
services or transportation services and does not carry on a "cultural business"
within the meaning of the Investment Canada Act, and the value of the assets of
32
<PAGE>
Solect and of all other entities in Canada the control of which is acquired,
directly or indirectly, for the purposes of the Investment Canada Act is less
than CDN$192 million.
2.30 YEAR 2000 PROBLEM.
Solect has reviewed its operations and has inquired of third parties with
which Solect and the Solect Subsidiaries have a material relationship to
evaluate the extent to which the business or operations of Solect and the Solect
Subsidiaries will be affected by the Year 2000 Problem. As a result of such
review and inquiries, Solect has no reason to believe, and does not believe,
that the Year 2000 Problem will have a Material Adverse Effect on Solect or
result in any material loss or interference with any of the business or
operations of Solect and the Solect Subsidiaries. The "Year 2000 Problem" as
used herein means any significant risk that computer hardware or software used
in the receipt, transmission, processing, manipulation, storage, retrieval,
retransmission or other utilization of data or in the operation of mechanical or
electrical systems of any kind will not, in the case of dates or time periods
occurring after December 31, 1999, function at least as effectively as in the
case of dates or time periods occurring prior to January 1, 2000.
2.31 SOLECT CREDITORS.
Section 2.31 of the Solect Disclosure Letter sets forth the names of all
the material creditors ("Creditors"), whether secured or unsecured, of Solect
and the Solect Subsidiaries, and the amounts owed or reasonably estimated to be
owed to each of the Creditors and the names and business addresses of all the
persons who are known to Solect to have asserted claims against Solect or the
Solect Subsidiaries even though such claims are disputed and the amounts of such
disputed claims.
2.32 ACCOUNTS RECEIVABLE.
All accounts receivable of Solect and the Solect Subsidiaries, whether
reflected in the Solect Financial Statements or otherwise, represents sales
actually made in the ordinary course of business pursuant to Canadian GAAP, and
are current and collectible net of any reserves shown on such balance sheet
(which reserves are adequate and were calculated consistently with past
practices and Canadian GAAP).
2.33 SALES OF SOLECT SECURITIES.
Neither Solect nor anyone acting on its behalf has offered securities of
Solect or any part thereof or any similar securities for issuance or sale to, or
solicited any offer to acquire any of such securities from, anyone so as to
render the issuance and sale of any such securities not exempt from the
registration requirements of all applicable securities laws. None of the Solect
33
<PAGE>
Common Shares, Solect Convertible Securities or Solect Options have been offered
or sold in such a manner as to make the issuance and sale of such shares not
exempt from such registration requirements, and all such securities have been
offered and sold in compliance with all applicable securities laws.
2.34 ABSENCE OF QUESTIONABLE PAYMENTS.
Neither of Solect nor any of the Solect Subsidiaries, nor any director,
officer, agent, employee or other person acting on behalf of Solect or any of
the Solect Subsidiaries has used any corporate or other funds for unlawful
contributions, payments, gifts or entertainment, or made any unlawful
expenditures relating to political activity to government officials or others or
established or maintained any unlawful or unrecorded funds in connection with
Solect's business. Neither Solect, nor any of the Solect Subsidiaries or any
current director, officer, agent, employee or other person acting on behalf of
Solect or any of the Solect Subsidiaries has accepted or received any unlawful
contributions, payments, gifts or expenditures in connection with Solect's
business.
3. REPRESENTATIONS AND WARRANTIES OF AMDOCS, AMDOCS PARENTCO AND AMDOCS HOLDCO
Amdocs acknowledges that it and its representatives have conducted certain
due diligence reviews of Solect and the Solect Subsidiaries based on materials
provided by Solect and the Solect Subsidiaries to Amdocs and its representatives
and interviews with selected employees or customers of Solect and the Solect
Subsidiaries made available to Amdocs and its representatives by Solect and the
Solect Subsidiaries, but such due diligence in no way limits the obligations of
Solect with respect to the foregoing representations and warranties by Solect,
nor does it in any way limit the right of Amdocs, Amdocs Parentco or Amdocs
Holdco to pursue any action with respect to a breach of such representations or
warranties or a material misstatement by Solect in such representations and
warranties or the Solect Disclosure Letter to the extent set forth in the Escrow
Agreement, including without limitation any rights of indemnification
thereunder.
Except as set forth in a letter dated the date of this Agreement and
delivered by Amdocs to Solect concurrently herewith (the "Amdocs Disclosure
Letter"), Amdocs, Amdocs Parentco and Amdocs Holdco jointly and severally
represent and warrant to Solect that:
3.1 ORGANIZATION; GOOD STANDING; QUALIFICATION AND POWER.
Each of Amdocs, Amdocs Management Limited ("Amdocs Management"), Amdocs
Parentco and Amdocs Holdco and each corporation, partnership, company, joint
venture and other entity in which Amdocs beneficially owns or controls, directly
or indirectly, more than 50% of the equity, voting rights, profits interest,
34
<PAGE>
capital or other similar interest thereof and which would be a "significant
subsidiary" for purposes of Rule 1-02(w) of Regulation S-X under the United
States Securities Exchange Act of 1934, as amended (the "Amdocs Subsidiaries")
is duly organized, validly existing and in good standing (where applicable)
under the laws of the jurisdiction of its formation, has all requisite corporate
power and authority and is in possession of all material Approvals necessary to
own, lease and operate its properties and to carry on its business as now being
conducted, and is duly qualified and in good standing to do business in each
jurisdiction in which the nature of its business or the ownership or leasing of
its properties makes such qualification necessary, other than in such
jurisdictions where the failure so to qualify would not have a Material Adverse
Effect on Amdocs. Amdocs has delivered to Solect's counsel complete and correct
copies of the memorandum of association and articles of association (or other
similar organizational documents) of each of Amdocs, Amdocs Parentco and Amdocs
Holdco, as amended to the date of this Agreement. Neither Amdocs, Amdocs
Parentco nor Amdocs Holdco is in violation of its memorandum of association or
articles of association or equivalent organizational documents.
Each of Amdocs Parentco, Amdocs Management and Amdocs Holdco is a wholly
owned direct or indirect subsidiary of Amdocs.
3.2 CAPITAL STRUCTURE.
(a) STOCK AND OPTIONS. The authorized share capital of Amdocs consists of
500,000,000 Amdocs Ordinary Shares, of which 182,092,140 shares were
issued and outstanding as of February 22, 2000 (the "Measurement
Date"), 50,000,000 non-voting Amdocs Ordinary Shares, par
value L0.01, of which 24,210,073 shares were issued and
outstanding as of the Measurement Date, and 25,000,000 Amdocs
Preferred Shares, of which there were no shares outstanding as of the
Measurement Date. As of the Measurement Date, no Amdocs Ordinary
Shares were held by Amdocs in treasury. An aggregate of 13,300,000
Amdocs Ordinary Shares are reserved and authorized for issuance
pursuant to the Amdocs 1998 Stock Option and Incentive Plan, as
amended, in respect of which options to purchase a total of 7,543,404
Amdocs Ordinary Shares were outstanding as of the Measurement Date. An
aggregate of 1,102,955 Amdocs Ordinary Shares are reserved and
authorized for issuance pursuant to options assumed in connection with
the acquisition of International Telecommunication Data Systems, Inc.,
in respect of which options to purchase a total of 871,964 Amdocs
Ordinary Shares were outstanding as of the Measurement Date. All
issued and outstanding Amdocs Ordinary Shares and all issued and
outstanding shares of the capital stock of each of the Amdocs
Subsidiaries have been duly authorized and validly issued, and are
fully paid and nonassessable, are not subject to any preemptive rights
or right of rescission, and have been offered, issued, sold and
delivered by Amdocs in compliance with all registration, qualification
35
<PAGE>
and prospectus requirements (or applicable exemptions therefrom) of
applicable securities laws. Except as set forth in Section 3.2 of the
Amdocs Disclosure Letter, Amdocs does not have any material
subsidiaries or any material equity interest, direct or indirect, in
any corporation, partnership, joint venture or other business entity.
Except as set forth in Section 3.2 of the Amdocs Disclosure Letter or
as disclosed in the Amdocs SEC Documents (as defined below) filed
prior to the date of this Agreement, all of the shares of capital
stock of the Amdocs Subsidiaries are owned by Amdocs or an Amdocs
Subsidiary free and clear of all security interests, liens, claims,
pledges, agreements, limitations in Amdocs' voting rights, charges or
other encumbrances of any nature whatsoever.
(b) NO OTHER COMMITMENTS. Except as disclosed in the Amdocs SEC Documents
filed prior to the date of this Agreement, and except for the
obligations of Amdocs under this Agreement, there are no options,
warrants, calls, rights (including, without limitation, stock
appreciation rights), commitments, conversion rights or agreements of
any character to which Amdocs or any of the Amdocs Subsidiaries is a
party or by which Amdocs or any of the Amdocs Subsidiaries is bound
obligating Amdocs or any of the Amdocs Subsidiaries to issue, deliver
or sell, or cause to be issued, delivered or sold, any shares of
capital stock of Amdocs or any of the Amdocs Subsidiaries or
securities convertible into or exchangeable for shares of capital
stock of Amdocs or any of the Amdocs Subsidiaries, or obligating
Amdocs or any of the Amdocs Subsidiaries to grant, extend or enter
into any such option, warrant, call, right, commitment, conversion
right or agreement. There are no voting trusts or other agreements or
understandings to which Amdocs is a party with respect to the voting
of the capital stock of Amdocs or any of the Amdocs Subsidiaries.
(c) REGISTRATION RIGHTS. Except as disclosed in the Amdocs SEC Documents
filed prior to the date of this Agreement, Amdocs is not under any
obligation to register under the Securities Act any of its presently
outstanding securities or any securities that it may subsequently
issue.
3.3 AUTHORITY.
(a) CORPORATE ACTION. Each of Amdocs, Amdocs Parentco and Amdocs Holdco
has all requisite corporate power and authority to enter into this
Agreement and the Ancillary Agreements to which it is a party and to
perform its obligations hereunder and thereunder and to consummate the
transactions contemplated hereby and thereby. The execution and
delivery by each of Amdocs, Amdocs Parentco and Amdocs Holdco of this
Agreement and the Ancillary Agreements to which it is a party and the
36
<PAGE>
consummation by each such party of the transactions contemplated
hereby and thereby have been duly authorized by all necessary
corporate action on the part of each such party. This Agreement has
been duly executed and delivered by each of Amdocs, Amdocs Parentco
and Amdocs Holdco and is, and the Ancillary Agreements to which it is
a party when executed and delivered in accordance with the terms
hereof shall be, valid and binding obligations of each such party
enforceable in accordance with their respective terms, except that
such enforceability may be subject to (i) bankruptcy, insolvency,
reorganization or other similar laws affecting or relating to
enforcement of creditors' rights generally and (ii) general equitable
principles.
(b) NO CONFLICT. Neither the execution, delivery and performance of this
Agreement by each of Amdocs, Amdocs Parentco or Amdocs Holdco, nor the
consummation of the transactions contemplated hereby or thereby by
each such party nor compliance with the provisions hereof or thereof
by each such party will: (i) conflict with, or result in any violation
of the memorandum of association or articles of association or similar
organizational documents of Amdocs or any of the Amdocs Subsidiaries;
or (ii) result in any breach or violation of or cause a default (with
or without notice or lapse of time, or both) under, or give rise to a
right of termination, amendment, cancellation or acceleration of any
obligation contained in, or the loss of any material benefit under, or
result in the creation of any lien, security interest, charge or
encumbrance upon any of the material properties or assets of Amdocs or
any of the Amdocs Subsidiaries under, any term, condition or provision
of any loan or credit agreement, note, bond, mortgage, indenture,
lease or other material agreement, judgment, order, decree, statute,
law, ordinance, rule, license, permit or regulation applicable to
Amdocs or any of the Amdocs Subsidiaries or their respective
properties or assets, other than any such breaches, defaults, losses,
liens, security interests, charges or encumbrances which, individually
or in the aggregate, would not have a Material Adverse Effect on
Amdocs.
(c) GOVERNMENTAL CONSENTS. No consent, approval, order or authorization
of, or registration, declaration or filing with, any Governmental
Entity is required to be obtained by Amdocs or any of the Amdocs
Subsidiaries in connection with the execution and delivery of this
Agreement or the Share Restructuring Plan or the consummation of the
transactions contemplated hereby or thereby, except for: (i) filing
with the SEC of such reports and information under the United States
Securities Exchange Act of 1934, as amended (the "Exchange Act") and
the rules and regulations promulgated by the SEC thereunder, as may be
required in connection with this Agreement and the transactions
contemplated hereby; (ii) required filings with Industry Canada and
appropriate documents with the relevant authorities of other states in
37
<PAGE>
which Amdocs is qualified to do business; (iii) such filings,
authorizations, orders and approvals as may be required under state
"control share acquisition," "anti-takeover" or other similar statutes
and regulations (collectively, "State Takeover Laws"); (iv) such
filings, authorizations, orders and approvals as may be required under
foreign laws, state securities laws and the New York Stock Exchange
(the "NYSE") and the National Association of Security Dealers (the
"NASD"); (v) such filings and notifications as may be necessary under
the HSR Act; (vi) as contemplated by the Registration Rights Agreement
(as defined in Section 6.2(b) hereof); and (vi) where the failure to
obtain such consents, approvals, etc., would not prevent or delay the
consummation of the Arrangement or otherwise prevent Amdocs from
performing its obligations under this Agreement and would not
reasonably be expected to have a Material Adverse Effect on Amdocs.
3.4 SEC DOCUMENTS AND FINANCIAL STATEMENTS.
(a) SEC DOCUMENTS. Amdocs has delivered or made available to Solect's
counsel complete and correct copies of each report, schedule,
effective registration statement and definitive proxy statement (other
than preliminary material) filed by Amdocs with the SEC or the NYSE on
or after January 1, 1998 (the "Amdocs SEC Documents"), which are all
the documents that Amdocs was required to file with the SEC on or
after such date. As of their respective dates or, in the case of
registration statements, their effective dates (or if amended or
superseded by a filing prior to the date of this Agreement, then on
the date of such filing), none of the Amdocs SEC Documents (including
all exhibits and schedules thereto and documents incorporated by
reference therein) contained any untrue statement of a material fact
or omitted to state a material fact required to be stated therein or
necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading, and the
Amdocs SEC Documents complied when filed in all material respects with
the then applicable requirements of the Securities Act or the Exchange
Act, as the case may be, and the rules and regulations promulgated by
the SEC thereunder. Amdocs has filed all documents and agreements that
were required to be filed as exhibits to the Amdocs SEC Documents.
(b) FINANCIAL STATEMENTS. The financial statements of Amdocs included in
the Amdocs SEC Documents complied as to form in all material respects
with the then applicable accounting requirements and the published
rules and regulations of the SEC with respect thereto, were prepared
in accordance with US GAAP applied on a consistent basis during the
periods involved (except as may have been indicated in the notes
thereto or, in the case of the unaudited statements, as permitted by
US GAAP) and fairly present in all material respects (subject, in the
38
<PAGE>
case of the unaudited statements, to normal, year-end audit
adjustments) the consolidated financial position of Amdocs and its
consolidated Amdocs Subsidiaries as at the respective dates thereof
and the consolidated results of their operations and cash flows for
the respective periods then ended.
3.4a INFORMATION SUPPLIED.
None of the information supplied or to be supplied by Amdocs to Solect for
inclusion or incorporation by reference in the Information Statement will, at
the date the Information Statement is mailed to the stockholders of Solect and
at the time of the Solect Shareholders Meeting, contain any untrue statement of
a material fact or omit to state any material fact required to be stated therein
or necessary to make the statements therein, in the light of the circumstances
under which they are made, not misleading. If at any time prior to the Effective
Time any event relating to Amdocs or any of its affiliates, officers or
directors should be discovered by Amdocs that should be set forth in an
amendment to the Information Statement, Amdocs shall promptly inform Solect and
shall coordinate with Solect in effecting the delivery of such amendment or
supplement as promptly as practicable.
3.5 COMPLIANCE WITH APPLICABLE LAWS.
The businesses of Amdocs and the Amdocs Subsidiaries are not being
conducted in violation of any law, ordinance, regulation, rule or order of any
Governmental Entity where such violation would have a Material Adverse Effect on
Amdocs. Except as disclosed in the Amdocs Disclosure Letter, Amdocs has not been
notified by any Governmental Entity that any investigation or review with
respect to Amdocs or any of the Amdocs Subsidiaries is pending or threatened,
nor has any Governmental Entity notified Amdocs of its intention to conduct the
same. Amdocs and the Amdocs Subsidiaries have all material permits, licenses and
franchises from Governmental Entities required to conduct their businesses as
now being conducted, and are in material compliance with all such permits,
licenses and franchises, except for those whose absence would not have a
Material Adverse Effect on Amdocs.
3.6 LITIGATION.
Except as disclosed in the Amdocs SEC Documents filed prior to the date of
this Agreement, there is no suit, action, arbitration, demand, claim or
proceeding pending or, to the knowledge of Amdocs, threatened against Amdocs or
any of the Amdocs Subsidiaries that, individually or in the aggregate, could
reasonably be expected to have a Material Adverse Effect on Amdocs; nor is there
any judgment, decree, injunction, rule or order of any Governmental Entity or
arbitrator outstanding against Amdocs or any of the Amdocs Subsidiaries that,
individually or in the aggregate, could reasonably be expected to have a
Material Adverse Effect on Amdocs. Amdocs has made available to Solect correct
39
<PAGE>
and complete copies of all auditors response letters prepared by its counsel for
Amdocs' auditors in connection with the last two completed audits of Amdocs'
financial statements and any such correspondence since the date of the last such
audit.
3.7 ERISA AND EMPLOYEE BENEFITS.
(a) The Amdocs Disclosure Letter identifies each "employee benefit plan,"
as defined in Section 3(3) of ERISA (collectively, the "Amdocs
Employee Plans"). All Amdocs Employee Plans which individually or
collectively would constitute an "employee pension benefit plan," as
defined in Section 3(2) of ERISA (collectively, the "Amdocs Pension
Plans"), are identified as such in the Amdocs Disclosure Letter. All
contributions due from Amdocs or any of the Amdocs Subsidiaries
through the Effective Time with respect to any of the Amdocs Employee
Plans has been or will be timely made as required under ERISA or any
other applicable legislation or have been accrued on Amdocs' or any
such Amdocs Subsidiary's financial statements as of December 31, 1999.
Each Amdocs Employee Plan has been maintained in material compliance
with its terms and with the requirements prescribed by any and all
statutes, orders, rules and regulations, including, without
limitation, ERISA and the Code, which are applicable to such Amdocs
Employee Plans.
(b) No Amdocs Pension Plan constitutes, or has since the enactment of
ERISA constituted, a "multiemployer plan," as defined in Section 3(37)
of ERISA. No Amdocs Pension Plans are subject to Title IV of ERISA. No
"prohibited transaction," as defined in Section 406 of ERISA or
Section 4975 of the Code, has occurred with respect to any Amdocs
Employee Plan which is covered by Title I of ERISA which would result
in a material liability to Amdocs and the Amdocs Subsidiaries taken as
a whole, excluding transactions effected pursuant to a statutory or
administrative exemption. Nothing done or omitted to be done and no
transaction or holding of any asset under or in connection with any
Amdocs Employee Plan has or will make Amdocs or any officer or
director of Amdocs subject to any material liability under Title I of
ERISA or liable for any material Tax or penalty pursuant to sections
4972, 4975, 4976 or 4979 of the Code or Section 502 of ERISA.
(c) Any Amdocs Pension Plan which is intended to be qualified under
Section 401(a) of the Code (an "Amdocs 401(a) Plan") is so qualified
and has been so qualified during the period from its adoption to date,
and the trust forming a part thereof is exempt from tax pursuant to
Section 501(a) of the Code. Amdocs has delivered to Solect or its
counsel a complete and correct copy of the most recent Internal
Revenue Service determination letter with respect to each Amdocs
401(a) Plan.
40
<PAGE>
(d) Each Amdocs plan or arrangement (written or oral) providing for
insurance coverage (including any self-insured arrangements), workers'
benefits, vacation benefits, severance benefits, disability benefits,
death benefits, hospitalization benefits, retirement benefits,
deferred compensation, profit-sharing, bonuses, stock options, stock
purchase, phantom stock, stock appreciation or other forms of
incentive compensation or post-retirement insurance, compensation or
benefits for employees, consultants or directors (collectively "Amdocs
Benefit Arrangements") has been maintained in substantial compliance
with its terms and with the requirements prescribed by any and all
statutes, orders, rules and regulations which are applicable to such
Amdocs Benefit Arrangement.
(e) There has been no amendment to, written interpretation or announcement
(whether or not written) by Amdocs or any of the Amdocs Subsidiaries
relating to, or change in employee participation or coverage under,
any Amdocs Employee Plan or Amdocs Benefit Arrangement that would
increase materially the expense of maintaining such Amdocs Employee
Plan or Amdocs Benefit Arrangement above the level of the expense
incurred in respect thereof for the fiscal year ended September 30,
1999.
(f) Amdocs has provided, or will have provided prior to the Closing, to
individuals entitled thereto all required notices and coverage
pursuant to Section 4980B of COBRA, with respect to any "qualifying
event" (as defined in Section 4980B(f)(3) of the Code) occurring prior
to and including the Closing Date, and no material Tax payable on
account of Section 4980B of the Code has been incurred with respect to
any current or former employees (or their beneficiaries) of Amdocs or
any of the Amdocs Subsidiaries.
(g) No benefit payable or which may become payable by Amdocs or any of the
Amdocs Subsidiaries pursuant to any Amdocs Employee Plan or any Amdocs
Benefit Arrangement or as a result of or arising under this Agreement
shall constitute an "excess parachute payment" (as defined in Section
280G(b)(1) of the Code) which is subject to the imposition of an
excise Tax under Section 4999 of the Code or which would not be
deductible by reason of Section 280G of the Code.
(h) Amdocs and each Amdocs Subsidiary is in compliance in all material
respects with all applicable laws, agreements and contracts relating
to employment, employment practices, wages, hours, and terms and
conditions of employment, including, but not limited to, employee
compensation matters.
41
<PAGE>
(i) Amdocs and each Amdocs Subsidiary believes it has good labor
relations; nothing has come to Amdocs' attention as a result of the
negotiation or entering into this Agreement that would lead Amdocs to
believe that the consummation of the transactions contemplated hereby
will have a material adverse effect on labor relations; and neither
Amdocs nor any Amdocs Subsidiary has any knowledge that any of its or
their key employees intends to leave its or their employ.
3.8 ABSENCE OF UNDISCLOSED LIABILITIES.
At December 31, 1999 (the "Amdocs Balance Sheet Date"), (i) neither Amdocs
nor any of the Amdocs Subsidiaries had any liabilities or obligations of any
nature (matured or unmatured, fixed or contingent) which were material to Amdocs
and the Amdocs Subsidiaries, taken as a whole, and were not provided for in the
consolidated balance sheet of Amdocs at the Amdocs Balance Sheet Date, a copy of
which is attached hereto as Exhibit 3.8 (the "Amdocs Balance Sheet"); and (ii)
all reserves established by Amdocs and set forth in the Amdocs Balance Sheet
were reasonably adequate. The consolidated balance sheet of Amdocs and the
Amdocs Subsidiaries, as of the Amdocs Balance Sheet Date, and the consolidated
statement of operations, changes in shareholders' equity and cash flows for the
twelve months ended on the Amdocs Balance Sheet Date were prepared on
substantially the same basis as the balance sheet as of September 30, 1999 and
the related statements of operations, changes in Shareholders' equity and cash
flows as of the twelve months ended September 30, 1999.
3.9 ABSENCE OF CERTAIN CHANGES OR EVENTS.
Except as disclosed in the Amdocs SEC Documents filed prior to the date of
this Agreement, since the Amdocs Balance Sheet Date, Amdocs and the Amdocs
Subsidiaries have conducted their respective businesses only in the ordinary and
usual course of such businesses and there has not occurred:
(a) any change in the financial condition, properties, assets,
liabilities, businesses, operations, results of operations or
prospects of Amdocs and the Amdocs Subsidiaries, taken as a whole that
could reasonably be expected to have a Material Adverse Effect on
Amdocs;
(b) any amendments or changes in the memorandum or articles of association
of Amdocs;
(c) any damage, destruction or loss, whether covered by insurance or not,
that could reasonably be expected to have a Material Adverse Effect on
Amdocs;
42
<PAGE>
(d) any redemption, repurchase or other acquisition of Amdocs Ordinary
Shares by Amdocs (other than the repurchase of unvested shares at cost
pursuant to arrangements with terminated employees or consultants), or
any declaration, setting aside or payment of any dividend or other
distribution (whether in cash, stock or property) with respect to
Amdocs Ordinary Shares;
(e) any material alteration in any term of any outstanding security of
Amdocs;
(f) any change by Amdocs in its accounting methods, principles or
practices; or
(g) any agreement or arrangement made by Amdocs to take any action which,
if taken prior to the date hereof, would have made any representation
or warranty set forth in this Agreement materially untrue or incorrect
as of the date when made unless otherwise disclosed.
3.10 NO DEFAULTS.
Neither Amdocs nor any of the Amdocs Subsidiaries is in default under, and
there exists no event, condition or occurrence which, after notice or lapse of
time, or both, would constitute such a default by Amdocs or any of the Amdocs
Subsidiaries under, any contract or agreement to which Amdocs or any of the
Amdocs Subsidiaries is a party and which would, if terminated or modified, be
reasonably likely to have a Material Adverse Effect on Amdocs.
3.11 TAXES.
Amdocs and each of the Amdocs Subsidiaries have timely filed, or caused to
be filed, all Tax Returns required to be filed by them (all of which returns
were correct and complete in all material respects) and have paid or withheld,
or caused to be paid or withheld, all Taxes that are due and payable, and Amdocs
has provided adequate accruals in accordance with US GAAP in its financial
statements for any Taxes that have not been paid, whether or not shown as being
due on any returns. Since the Amdocs Balance Sheet Date, no material Tax
liability has been assessed, proposed to be assessed, incurred or accrued other
than in the ordinary course of business. Amdocs and the Amdocs Subsidiaries have
withheld from all payments made by them, or otherwise collected, and have
remitted all amounts in respect of Taxes required to be withheld, collected or
remitted by them to the applicable governmental authority within the required
time periods. Neither Amdocs nor any of the Amdocs Subsidiaries has any
liability for the Taxes of any other person, corporation, partnership, trust or
other taxpayer. Except as set forth in Section 3.11 of the Amdocs Disclosure
Letter, there are no audits or investigations in progress, pending or threatened
by any Taxing Authority, against Amdocs, any Amdocs Subsidiary or any of the
assets of Amdocs or any Amdocs Subsidiary, and neither Amdocs nor any Amdocs
Subsidiary has received any notification that any material issues have been
43
<PAGE>
raised (and are currently pending) by any Taxing Authority in connection with
any of the Tax Returns referred to above, and no waivers of statutes of
limitations have been given or requested with respect to Amdocs or any of the
Amdocs Subsidiaries. All liability of Amdocs and the Amdocs Subsidiaries for
Taxes has been assessed, or the applicable statute of limitations period has
expired, for all fiscal years up to and including the fiscal year ending
September 30, 1996. There are no material proposed (but unassessed) additional
Taxes, none have been asserted and no Tax liens have been filed other than for
Taxes not yet due and payable. None of Amdocs or any of the Amdocs Subsidiaries
(i) has made an election to be treated as a "consenting corporation" under
Section 341(f) of the Code or (ii) is a "personal holding company" within the
meaning of Section 542 of the Code.
3.12 INTELLECTUAL PROPERTY.
Except in each case as disclosed in the Amdocs SEC Documents filed prior to
the date of this Agreement:
(a) Amdocs and the Amdocs Subsidiaries own, or have the right to use, sell
or license all material Intellectual Property Rights necessary or
required for the conduct of their respective businesses as presently
conducted (such Intellectual Property Rights being hereinafter
collectively referred to as the "Amdocs IP Rights") and such rights to
use, sell or license are reasonably sufficient for such conduct of
their respective businesses;
(b) the execution, delivery and performance of this Agreement and the
consummation of the transactions contemplated hereby will not
constitute a material breach of any assignment, conveyance or
agreement governing any Amdocs IP Right (the "Amdocs IP Rights
Agreements"), will not cause the forfeiture or termination or give
rise to a right of forfeiture or termination of any Amdocs IP Right or
materially impair the right of Amdocs and/or the Amdocs Subsidiaries
to use, sell or license any Amdocs IP Right or portion thereof (except
where such breach, forfeiture or termination would not have a Material
Adverse Effect on Amdocs);
(c) neither the manufacture, marketing, license, sale or lawful use of any
product currently licensed or sold by Amdocs or any of the Amdocs
Subsidiaries or currently under development by Amdocs or any of the
Amdocs Subsidiaries violates any license or agreement between Amdocs
or any of the Amdocs Subsidiaries and any third party or infringes any
Intellectual Property Right of any other party; and there is no
pending or, to the knowledge of Amdocs, threatened claim or litigation
contesting the validity, ownership or right to use, sell, license or
dispose of any Amdocs IP Right nor, to the knowledge of Amdocs, is
there any basis for any such claim, nor has Amdocs received any notice
asserting that any Amdocs IP Right or the proposed use, sale, license
44
<PAGE>
or disposition thereof conflicts or will conflict with the rights of
any other party, nor, to the knowledge of Amdocs, is there any basis
for any such assertion, except to the extent that such violation(s),
or notice or basis therefor, have not had and could not reasonably be
expected to have, a Material Adverse Effect on Amdocs; and
(d) Amdocs has taken reasonable and practicable steps designed to
safeguard and maintain the secrecy and confidentiality of, and its
proprietary rights in, all material Amdocs IP Rights. All officers,
employees and consultants of Amdocs or any of the Amdocs Subsidiaries
have executed and delivered to Amdocs or the Amdocs Subsidiary an
agreement regarding the protection of proprietary information. No
current or prior officers, employees or consultants of Amdocs have
claimed an ownership interest in any Amdocs IP Rights as a result of
having been involved in the development of such property while
employed by or consulting to Amdocs, or otherwise.
3.13 INSURANCE.
Amdocs and the Amdocs Subsidiaries maintain and at all times since January
1, 1996 have maintained fire and casualty, general liability, business
interruption, product liability and sprinkler and water damage insurance that
Amdocs believes to be reasonably prudent for its business.
3.14 OWNERSHIP OF PROPERTY.
Except (a) as disclosed in the Amdocs SEC Documents filed prior to the date
of this Agreement, (b) for liens for current Taxes not yet delinquent or (c) for
liens imposed by law and incurred in the ordinary course of business for
obligations not yet due to carriers, warehousemen, laborers, materialmen and the
like, Amdocs and each of the Amdocs Subsidiaries have good and marketable title
to all of their respective real and personal property (other than property as to
which it is lessee, in which case it has a valid leasehold interest) and own all
of such property free and clear of all security interests, mortgages, liens,
charges, claims, options and encumbrances. All real and tangible personal
property of Amdocs and each of the Amdocs Subsidiaries is generally in good
repair and is operational and usable in the operations of Amdocs or the Amdocs
Subsidiaries, subject to ordinary wear and tear and subject to technical
obsolescence. Neither Amdocs nor any Amdocs Subsidiary is in violation of any
zoning, building or safety ordinance, regulation or requirement or other law or
regulation applicable to the operation of owned or leased properties or has
received any notice of violation with which it has not complied, except, in such
case, where such violation would not have a Material Adverse Effect on Amdocs.
45
<PAGE>
3.15 ENVIRONMENTAL MATTERS.
(a) To Amdocs' knowledge, during the period that Amdocs and the Amdocs
Subsidiaries have leased or owned their respective properties or owned
or operated any facilities, there have been no disposals, releases or
threatened releases of Hazardous Materials on, from or under such
properties or facilities which could result in a material violation of
applicable law. Amdocs has no actual knowledge of any presence,
disposals, releases or threatened releases of Hazardous Materials on,
from or under any of such properties or facilities, which may have
occurred prior to Amdocs or any of the Amdocs Subsidiaries having
taken possession of any of such properties or facilities which could
result in a material violation of applicable law.
(b) To Amdocs' knowledge, none of the properties or facilities of Amdocs
or the Amdocs Subsidiaries is in violation of any federal, state or
local law, ordinance, regulation or order relating to industrial
hygiene or to the environmental conditions on, under or about such
properties or facilities, including, but not limited to, soil and
ground water condition. During the time that Amdocs or the Amdocs
Subsidiaries have owned or leased their respective properties and
facilities, neither Amdocs nor any of the Amdocs Subsidiaries nor, to
Amdocs' knowledge, any third party, has used, generated, manufactured
or stored on, under or about such properties or facilities or
transported to or from such properties or facilities any Hazardous
Materials.
(c) During the time that Amdocs or the Amdocs Subsidiaries have owned or
leased their respective properties and facilities, there has been no
litigation brought or threatened against Amdocs or any of the Amdocs
Subsidiaries by, or any settlement reached by Amdocs or any of the
Amdocs Subsidiaries with, any party or parties alleging the presence,
disposal, release or threatened release of any Hazardous Materials on,
from or under any of such properties or facilities.
3.16 BOARD APPROVAL.
The Board of Directors of Amdocs has, as of the date hereof, (i) approved
this Agreement, the Ancillary Agreements to which it is a party and the Share
Restructuring; (ii) determined that the Share Restructuring is in the best
interests of the stockholders of Amdocs and is on terms that are fair to such
stockholders; (iii) authorized the issuance of the Amdocs Ordinary Shares to
holders of Exchangeable Shares; and (iv) taken all other actions necessary for
it to implement the Share Restructuring in accordance with the terms of this
Agreement and each of the Ancillary Agreements.
46
<PAGE>
3.17 DISCLOSURE.
No representation or warranty made by Amdocs in this Agreement, nor any
document, written information, financial statement, certificate or exhibit
prepared and furnished or to be prepared and furnished by Amdocs or its
representatives pursuant hereto or in connection with the transactions
contemplated hereby, when taken together and read with the Amdocs SEC Documents,
contained any untrue statement of a material fact when made, or omitted to state
a material fact necessary to make the statements or facts contained herein or
therein not misleading in the light of the circumstances under which they were
furnished.
3.18 RESTRICTIONS ON BUSINESS ACTIVITIES.
Except as set forth in the Amdocs SEC Documents filed prior to the date of
this Agreement, there is no material agreement, judgment, injunction, order or
decree binding upon Amdocs or any Amdocs Subsidiary that has or could reasonably
be expected to have the effect of prohibiting or materially impairing any
business practice of Amdocs and the Amdocs Subsidiaries (taken as a whole), any
acquisition of property by Amdocs or any Amdocs Subsidiary or the conduct of
business by Amdocs or any Amdocs Subsidiary as currently conducted.
3.19 BOOKS AND RECORDS.
The books, records and accounts of Amdocs and its Subsidiaries (a) have
been maintained in accordance with good business practices on a basis consistent
with prior years, (b) are stated in reasonable detail and accurately and fairly
reflect the transactions and dispositions of the assets of Amdocs and (c)
accurately and fairly reflect the basis for the Amdocs Financial Statements.
Amdocs has devised and maintains a system of internal accounting controls
sufficient to provide reasonable assurances that (i) transactions are executed
in accordance with management's general or specific authorization; and (ii)
transactions are recorded as necessary (A) to permit preparation of financial
statements in conformity with US GAAP or any other criteria applicable to such
statements and (B) to maintain accountability for assets.
3.20 YEAR 2000 PROBLEM.
Amdocs has reviewed its operations and that of any third parties with which
Amdocs and the Amdocs Subsidiaries have a material relationship to evaluate the
extent to which the business or operations of Amdocs and the Amdocs Subsidiaries
will be affected by the Year 2000 Problem. As a result of such review, Amdocs
has no reason to believe, and does not believe, that the Year 2000 Problem will
have a Material Adverse Effect on Amdocs or result in any material loss or
interference with any of the business or operations of Amdocs and the Amdocs
Subsidiaries.
47
<PAGE>
3.21 SOLECT CUSTOMERS.
Amdocs has not been notified that Solect or any Solect Subsidiariy will
lose or might lose, or suffer any diminution in, its relationship with any of
its material customers. No representative of any such material customer has
notified Amdocs that, in the event of a sale or change of control of Solect,
either Solect or any Solect Subsidiary would lose, or suffer any diminution in,
its relationship with any such material customer, nor does Amdocs have any
knowledge that would reasonably lead it to expect any such loss or diminution.
3.22 AMDOCS ORDINARY SHARES.
The Amdocs Ordinary Shares, when issued upon exchange of the Exchangeable
Shares or upon exercise of any Amdocs Option or Solect Options in accordance
with the terms of this Agreement or the Share Restructuring Plan, will be
validly issued, fully paid and nonassessable and will be free and clear of all
liens, charges, restrictions, claims and encumbrances.
3.23 COMPETITION ACT.
Amdocs and its affiliates do not have assets in Canada that exceed CDN$99
million in aggregate value and did not have gross revenues from sales in, from
or into Canada, that exceed CDN$99 million in aggregate value, determined for
purposes of and in the manner prescribed by the Competition Act (Canada) and the
Notifiable Transactions Regulations promulgated thereunder.
3.24 INVESTMENT CANADA ACT AND COMPETITION ACT (CANADA).
Assuming that the representations and warranties of Solect in Sections 2.28
and 2.29 are true and correct, as of the date hereof the transaction
contemplated by this Agreement is not pre-notifiable under the Investment Canada
Act and the Competition Act (Canada). As of the date hereof, Amdocs is a "WTO
Investor" within the meaning of the Investment Canada Act.
3.25 SPECIFIED FINANCIAL INSTITUTION/PFIC.
None of Amdocs, Amdocs Parentco and Amdocs Holdco is a "specified financial
institution" or a specified person in relation to such an institution for
purposes of subsection 112(2.2) of the ITA or a "passive foreign investment
company" for purposes of Section 1297 of the Code.
48
<PAGE>
4. SOLECT COVENANTS
4.1 ADVICE OF CHANGES.
During the period from the date of this Agreement until the earlier of the
Effective Time and the termination of this Agreement in accordance with its
terms, Solect will promptly advise Amdocs in writing (a) of any event occurring
subsequent to the date of this Agreement which becomes known to Solect that
would render any representation or warranty of Solect contained in this
Agreement, if made on or as of the date of such event or the Effective Time,
untrue, inaccurate or incomplete in any material respect, (b) of any Material
Adverse Effect on Solect and the Subsidiaries of Solect, taken as a whole, which
becomes known to Solect, and (c) of any material breach by Solect of any
covenant or agreement contained in this Agreement. After the end of each monthly
and quarterly accounting period ending after the date of this Agreement and
before the earlier of the Effective Time and the termination of this Agreement
in accordance with its terms, Solect shall deliver to Amdocs (i) within
thirty-five days after the end of each monthly accounting period, an unaudited
consolidated statement of income for Solect and the Solect Subsidiaries and an
unaudited unconsolidated balance sheet, statement of operations and statement of
changes in financial position for Solect and each of the Solect Subsidiaries and
(ii) within forty-five days after the end of each quarterly accounting period,
an unaudited consolidated balance sheet, statement of operations and statement
of changes in financial position for Solect, all of which financial statements
shall be prepared in the ordinary course of business, in Canadian dollars and in
accordance with Solect's books and records and Canadian GAAP, and shall fairly
present the consolidated financial position of Solect and the Solect
Subsidiaries as of their respective dates and the results of Solect's and the
Solect Subsidiaries' operations for the periods then ended.
4.2 MAINTENANCE OF BUSINESS.
During the period from the date of this Agreement until the earlier of the
Effective Time and the termination of this Agreement in accordance with its
terms, Solect will use, and will cause each of the Solect Subsidiaries to use,
all commercially reasonable efforts to carry on and preserve its business and
its relationships with customers, suppliers, employees, consultants and others
in substantially the same manner as it has prior to the date hereof. If Solect
or any of the Solect Subsidiaries becomes aware of any material deterioration,
or an event that may cause future material deterioration in the relationship
with any material customer, supplier or key employee or consultant, Solect will
promptly bring such information to the attention of Amdocs in writing and, if
requested by Amdocs, Solect will use commercially reasonable efforts to restore
the relationship.
49
<PAGE>
4.3 CONDUCT OF BUSINESS.
During the period from the date of this Agreement until the earlier of the
Effective Time and the termination of this Agreement in accordance with its
terms, Solect will continue to conduct its business and use reasonable
commercial efforts to maintain its business relationships in the ordinary and
usual course and, except as expressly contemplated herein, will not, without the
prior consent of Amdocs, which will not be unreasonably withheld:
(a) borrow any money;
(b) enter into any transaction not in the ordinary course of its business;
(c) encumber or permit to be encumbered any of its assets except in the
ordinary course of its business consistent with past practice;
(d) dispose of any portion of its assets except in the ordinary course of
business consistent with past practice;
(e) enter into any material lease or contract for the purchase or sale or
license of any property, real or personal, except in the ordinary
course of business consistent with past practice;
(f) fail to maintain its equipment and other assets in good working
condition and repair according to the standards it has maintained to
the date of this Agreement, subject only to ordinary wear and tear;
(g) pay (or make any oral or written commitments or representations to
pay) any bonus, increased salary or special remuneration to any
director, officer, employee or consultant (except for normal salary
increases and bonuses to employees and consultants consistent with
past practices and except pursuant to existing arrangements previously
disclosed to Amdocs) or enter into or vary the terms of any
employment, consulting or severance agreement with any officers,
directors or consultants, pay any severance or termination pay (other
than payments made in accordance with plans or agreements existing on
the date hereof and disclosed in the Solect Disclosure Letter or as
required by applicable law), grant any stock option or issue any
restricted stock or other securities, or enter into or modify any
agreement or plan or increase benefits of the type described in
Section 2.7;
(h) enter into any agreement, arrangement or other transaction with any
affiliate or associate of Solect or any Solect Subsidiary other than
intercompany agreements, arrangements or other transactions in the
ordinary course of business consistent with past practice;
50
<PAGE>
(i) change accounting methods;
(j) revalue any of its assets or properties other than the writing off of
accounts receivable in the ordinary course of business;
(k) declare, set aside or pay any cash or stock dividend or other
distribution in respect of capital stock, or redeem or otherwise
acquire any of its capital stock;
(l) amend or terminate any material contract, agreement or license to
which it is a party except for those amendments or terminations in the
ordinary course of its business, consistent with past practice, which
are not material in amount or effect;
(m) lend any amount to any person or entity, other than (i) advances for
travel and expenses which are incurred in the ordinary course of
business consistent with past practice and documented by receipts for
the claimed amounts or (ii) any loans pursuant to any Solect Employee
Plan which is intended to be qualified under Section 401(a) of the
Code;
(n) guarantee or act as a surety for any obligation except for obligations
in amounts that are not material in the aggregate;
(o) waive or release any right or claim except for the waiver or release
of non-material rights or claims in the ordinary course of business,
consistent with past practice or the waiver or release of rights or
claims set forth in the Solect Disclosure Letter;
(p) issue or sell any shares of its capital stock of any class (except for
the issuance of Solect Common Shares upon the exercise of Solect
Options or the conversion or exercise of Solect Convertible Securities
currently outstanding), or any other of its securities, or issue or
create any warrants, obligations, subscriptions, options, convertible
securities or other commitments to issue shares of capital stock, or
accelerate the vesting of any outstanding option or other security
except as otherwise contemplated herein or in the Ancillary Agreements
or the Share Restructuring Plan;
(q) split or combine the outstanding shares of its capital stock of any
class or enter into any recapitalization or agreement affecting the
number or rights of outstanding shares of its capital stock of any
class or affecting any other of its securities;
(r) merge, consolidate or reorganize with, or acquire any entity or any
interest in any entity, or enter into any agreement to do any of the
foregoing;
51
<PAGE>
(s) amend its articles of incorporation or bylaws except as contemplated
by this Agreement;
(t) license any Solect IP Rights except in the ordinary course of business
consistent with past practice;
(u) grant any exclusive distribution rights;
(v) agree to any audit assessments by any Tax authority in excess of
$100,000 in the aggregate;
(w) change any insurance coverage or issue any certificates of insurance
except in the ordinary course of business consistent with past
practice;
(x) implement any change in its accounting principles, practices or
methods, other than as may be required by Canadian GAAP and/or US
GAAP; or
(y) agree to do, or permit any Solect Subsidiary to do or agree to do, or
enter into negotiations with respect to, any of the things described
in the preceding clauses in this Section 4.3.
4.4 SHAREHOLDER APPROVAL.
Within 31 days after the date hereof, Solect shall take all action
necessary, subject to and in accordance with applicable law, its articles of
continuance and bylaws and any outstanding shareholder agreements, to obtain the
approval and adoption of this Agreement, the Share Restructuring Plan (including
the articles of amendment giving effect thereto) and related matters by Solect's
shareholders. Solect shall provide to Amdocs reasonable opportunity to review
and comment on any material (collectively, the "Information Statement") proposed
to be mailed to Solect's shareholders and/or other security holders in
connection with the foregoing approval. Such approval has been recommended by
Solect's Board of Directors and management. Concurrently with the execution of
this Agreement, Southwest Sun, Inc., KL Group, Inc., Kevin Kimsa, TCV Solect (A)
SRL, TCV Solect (B) SRL, TCV Solect (C) SRL, Science Applications International
Corporation, BCS Investment SRL, WPG Networking-Software SRL and Morgan Stanley
Dean Witter Equity Funding, Inc. (collectively, the "Solect Principal
Securityholders") have executed a Principal Securityholders' Agreement in the
form of Exhibit 4.4 (the "Securityholder Agreement"), agreeing, among other
things, (i) if such security holder holds Solect Convertible Securities, to
exercise or convert such securities into Solect Common Shares prior to the
Effective Time, (ii) to vote in favor of the Share Restructuring Plan and the
trans actions contemplated by this Agreement, (iii) to take all action necessary
to waive any notice or other time periods contemplated by any agreement that
52
<PAGE>
could result in a delay of the date of the shareholders meeting required to
approve the transactions contemplated hereby or that could otherwise result in a
delay of the consummation of the transactions contemplated hereby, and (iv) to
terminate the Shareholders Agreement, the Investor's Rights Agreement and the
Management Rights Agreement (as such terms are defined in Article 8) upon the
Effective Date.
4.5 REPRESENTATION AGREEMENTS
Solect shall use commercially reasonable efforts to obtain from each of its
securityholders an agreement in the forms (with respect to holders of Solect
Common Shares and options in the capital of Solect, as applicable) of Exhibit
4.5 (each, a "Representation Agreement"), whereby each securityholder makes
certain investment representations and acknowledges certain restrictions under
applicable securities laws on the resale of the securities issuable pursuant to
the Share Restructuring Plan.
4.6 REGULATORY APPROVALS.
Solect will promptly execute and file, or join in the execution and filing
of any application or other document that may be necessary in order to obtain
the authorization, approval or consent of any Governmental Entity, which may be
reasonably required, or which Amdocs may reasonably request, in connection with
the consummation of the transactions contemplated by this Agreement. Solect will
use its commercially reasonable efforts to promptly obtain all such
authorizations, approvals and consents. Without limiting the generality of the
foregoing, as promptly as practicable after the execution of this Agreement,
Solect shall file with the Federal Trade Commission (the "FTC") and the
Antitrust Division of the Department of Justice (the "DOJ"), a pre-merger
notification report under the HSR Act and shall make such filings, if any, as
are necessary under the Investment Canada Act and the Competition Act (Canada).
4.7 NECESSARY CONSENTS.
During the term of this Agreement, Solect will use commercially reasonable
efforts to obtain such written consents and take such other actions as may be
necessary or appropriate in addition to those set forth in Section 4.6
(including, without limitation, those consents and actions set forth in Section
8) to allow the consummation of the transactions contemplated hereby and to
allow Solect to carry on its business after the Effective Time.
4.8 ACCESS TO INFORMATION.
Solect will allow Amdocs and its agents reasonable access to the files,
books, records and offices of Solect and each Solect Subsidiary, including,
without limitation, any and all information relating to Solect's and each Solect
Subsidiary's Taxes, commitments, contracts, leases, licenses, products, Solect
IP Rights, and real, personal and intangible property and financial condition.
53
<PAGE>
Solect will cause its accountants and personnel to cooperate with Amdocs and its
agents in making available to Amdocs all financial and other information
reasonably requested, including, without limitation, the right to examine all
working papers pertaining to all Tax Returns and financial statements prepared
or audited by such accountants.
4.9 SATISFACTION OF CONDITIONS PRECEDENT.
During the term of this Agreement, Solect will use its commercially
reasonable efforts to satisfy or cause to be satisfied all the conditions
precedent that are set forth in Article 8 and Solect will use its commercially
reasonable efforts to cause the Share Restructuring Plan and the other
transactions contemplated by this Agreement to be consummated and shall take
such commercially reasonable steps as are appropriate so that the
representations and warranties of Solect in this Agreement remain complete and
correct on and as of the Closing Date.
4.10 NO OTHER NEGOTIATIONS.
(a) From and after the date of this Agreement until the earlier of the
Effective Time and the termination of this Agreement in accordance
with its terms, Solect and the Solect Subsidiaries shall not, and
shall not permit their respective officers, employees,
representatives, investment bankers, agents and affiliates to,
directly or indirectly, (i) solicit, initiate, continue or engage in
discussions or negotiations with any person, encourage submission of
any inquiries, proposals or offers by, or take any other action
intended or designed to facilitate the efforts of any person, other
than Amdocs, relating to the possible acquisition of Solect or any of
the Solect Subsidiaries (whether by way of arrangement, amalgamation,
take-over bid, tender offer, purchase of capital stock, purchase of
assets or otherwise) or any material portion of its or their capital
stock or assets (with any such efforts by any such person, including a
firm proposal to make such an acquisition, to be referred to as an
"Acquisition Proposal"), (ii) provide information with respect to
Solect or any of the Solect Subsidiaries, or afford any access to the
properties, books or records of Solect or the Solect Subsidiaries, to
any person, other than Amdocs, relating to a possible Acquisition
Proposal by any person other than Amdocs, (iii) make or authorize any
statement, recommendation or solicitation in support of any possible
Acquisition Proposal by any person, other than by Amdocs, or (iv)
enter into an agreement with any person, other than Amdocs, providing
for a possible Acquisition Proposal.
(b) If Solect or any of its Subsidiaries receives any unsolicited offer or
proposal to enter negotiations relating to an Acquisition Proposal, or
any request for non-public information relating to Solect or any
Solect Subsidiary in connection with any Acquisition Proposal, Solect
54
<PAGE>
shall immediately notify Amdocs thereof, in writing, including
information as to the identity of the party making any such offer
proposal or request and the specific terms of such offer proposal or
request, as the case may be. Immediately upon receipt by Solect,
Solect shall immediately provide Amdocs with a true and complete copy
of any Acquisition Proposal or other written communication concerning
a possible Acquisition Proposal received from such third party.
(c) Solect shall immediately cease and cause to be terminated any existing
discussions or negotiations with any parties (other than Amdocs)
conducted heretofore with respect to any of the foregoing, including,
without limitation, any discussions or negotiations with third parties
regarding the issuance of securities of Solect or other investment(s)
in Solect by such third parties whether or not such investments would
result in a change of control of Solect. Solect agrees not to release
any third party from any confidentiality or standstill agreement with
respect to any of the foregoing to which Solect is a party.
(d) Solect shall use commercially reasonable efforts to ensure that the
officers, directors, employees, agents and affiliates of Solect and
the Solect Subsidiaries and any bankers, investment bankers or other
agents, advisors or representatives retained by Solect are aware of
the restrictions described in this Section 4.10, and shall be
responsible for any breach of this Section 4.10 by such bankers,
investment bankers, officers, directors, employees, agents, advisors,
representatives or affiliates.
4.11 COOPERATION.
Solect and Amdocs have discussed a strategy for approaching existing and
prospective customers in an effort to ensure that the business objectives of the
transactions contemplated hereby will be achieved and the business of Solect is
not harmed during the pendency of such transactions. To the extent permitted by
applicable law and the contractual and other legal obligations of Solect and
Amdocs to their respective customers, Solect will cooperate with Amdocs and vice
versa in developing this strategy and the parties agree to approach customers on
a joint basis consistent with the agreed strategy.
4.12 CANADIAN CLEARANCE CERTIFICATES.
Solect will use commercially reasonable efforts to cause each person who
holds, or will hold, a Solect Common Share or a Solect Option immediately prior
to the Effective Time to deliver to Solect, at or before such time:
55
<PAGE>
(i) a certificate confirming that such shareholder or option holder is a
resident of Canada for the purposes of the ITA; or
(ii) in the case of a shareholder or option holder who is a non-resident of
Canada for the purposes of the ITA: (a) a certificate satisfactory to
Solect and Amdocs acting reasonably, issued pursuant to subsection
116(2) or 116(4) of the ITA, with respect to the Solect Common Shares
and/or Solect Options exchanged or disposed of, and, in the case of a
certificate under subsection 116(2) of the ITA, having as the
"certificate limit", as defined in subsection 116(2) of the ITA, an
amount no less than the cost (which may be equal to the fair market
value of the Exchangeable Shares and cash (if any) received by such
holder) to the purchaser of the Solect Common Shares or the Solect
Options, as the case may be; and (b) if applicable, a certificate
satisfactory to Solect and Amdocs acting reasonably issued pursuant to
Section 1098 of the Taxation Act (Quebec) or any other analagous
certificate required by any other provincial taxing authority. Solect
has advised that neither the Solect Common Shares nor the Solect
Options constitute Taxable Quebec Property.
In the case of a holder of Solect Common Shares who is a partnership,
Solect will use commercially reasonable efforts to cause the shareholder to also
provide a certificate confirming the name and address of each member thereof and
the percentage of partnership interest held by each member (which partners and
percentages are clearly contemplated in the applicable certificate).
On any subsequent exchange of Exchangeable Shares for Amdocs Ordinary
Shares, Solect acknowledges that the requirements set forth above shall also be
applicable.
In the event that a holder fails to deliver the requisite certificates
described above at or before the exchange or disposition of such shares or
options, the purchaser of the Solect Common Shares, Solect Options or
Exchangeable Shares, as applicable, shall be entitled to deduct and withhold
from any consideration otherwise payable to any such holder such amounts as the
purchaser is required or permitted to deduct and withhold with respect to such
payment under the ITA or any provision of provincial or governmental tax law, in
each case, as amended or succeeded; provided that such withheld amount shall not
be remitted prior to the date such amount is required by law to be remitted (the
"Remittance Date") and where such certificate is delivered prior to the
Remittance Date, such withheld amount shall be released to the holder. To the
extent that amounts are so withheld, such withheld amounts shall be treated for
all purposes hereof as having been paid to the holder of the shares or options
in respect of which such deduction and withholding was made, provided that such
withheld amounts are actually remitted to the appropriate taxing authority and a
receipt evidencing such remittance is delivered to the holder. To the extent
that the amount so required or permitted to be deducted or withheld from
56
<PAGE>
any payment to a holder exceeds the cash portion of the consideration otherwise
payable to the holder, the purchaser, as agent for the holder, is hereby
authorized to sell or otherwise dispose of such portion of the consideration as
is necessary to provide sufficient funds to the purchaser to enable it to comply
with such deduction or withholding requirement and the purchaser shall notify
the holder thereof and remit to such holder any unapplied balance of the net
proceeds of such sale. If the proceeds of such sale are insufficient to fund the
required withholding, such holder shall forthwith pay to the purchaser or remit
to the applicable taxing authority the deficiency. The holder shall bear all
reasonable costs and expenses associated with any sale by the purchaser pursuant
to the two immediately preceding sentences.
4.13 INSURANCE POLICIES.
Neither Solect nor any Solect Subsidiary shall take, or omit to take, any
action which would cause any of the insurance policies disclosed in Section 2.16
above to cease to be in full force and effect immediately following the Closing.
4.14 EMPLOYEE RETENTION ARRANGEMENTS.
Solect agrees that it will implement the employee retention arrangements
outlined in the letter dated as of February 28, 2000 (the "Employee Retention
Letter") from Amdocs to Solect.
4.15 ESTABLISHMENT OF ESCROW.
Simultaneously with the execution and delivery of the Escrow Agreement,
Solect shall deposit with the Escrow Agent, to be held by the Escrow Agent in
the Escrow Fund (as defined in the Escrow Agreement), certificates representing
the number of Exchangeable Shares set forth opposite the name of each
Stockholder (as defined in the Escrow Agreement) on Schedule I to the Escrow
Agreement under the heading "Number of Escrowed Shares", in the name of each
such Stockholder and representing in the aggregate 1,170,000 Exchangeable
Shares. Each such certificate shall either be duly endorsed in blank by the
Stockholder in whose name such certificate is held or accompanied by stock
transfer powers duly executed in blank by such Stockholder. Solect agrees to pay
the Escrow Agent's fees, expenses and disbursements as provided in Section 9.02
of the Escrow Agreement, and to pay, perform and discharge its indemnity
obligations in accordance with Section 4.01(b) of the Escrow Agreement.
4.16 BT AND NOKIA LETTERS.
Prior to the Effective Date, Solect will enter into (1) an agreement with
BT under the terms of which Solect will issue and sell to BT, prior to the
Effective Date, 437,500 Solect Common Shares at a price per share of US$10.65
(the "BT Letter") and (2) an agreement among Solect, Nokia, Southwest Sun Inc.,
57
<PAGE>
Kevin Kimsa and KL Group Inc. under the terms of which (i) Southwest Sun Inc.,
Kevin Kimsa and KL Group Inc. will sell to Nokia, prior to the Effective Date,
437,500 Solect Common Shares at a price per share of US$10.65, and (ii) Nokia
will provide its consent pursuant to the Internet Administration Framework
System VAR Agreement, dated April 13, 1999, between Solect and Nokia, to the
change of control of Solect and waive any and all rights which Nokia may have
upon a change of control of Solect.
5. AMDOCS COVENANTS
5.1 ADVICE OF CHANGES.
During the period from the date of this Agreement until the earlier of the
Effective Time and the termination of this Agreement in accordance with its
terms, Amdocs will promptly advise Solect in writing (a) of any event occurring
subsequent to the date of this Agreement which becomes known to Amdocs that
would render any representation or warranty of Amdocs, Amdocs Parentco or Amdocs
Holdco contained in this Agreement, if made on or as of the date of such event
or the Closing Date, untrue or inaccurate in any material respect, (b) of any
Material Adverse Effect on Amdocs which becomes known to Amdocs, and (c) of any
material breach by Amdocs of any covenant or agreement contained in this
Agreement. Amdocs will provide Solect a copy of all publicly available materials
filed by Amdocs with the SEC or the NYSE promptly after each such filing is
made.
5.2 REGULATORY APPROVALS.
Amdocs will promptly execute and file, or join in the execution and filing,
of any application or other document that may be necessary in order to obtain
the authorization, approval or consent of any governmental body, federal, state,
local or foreign that may be reasonably required, or that Solect may reasonably
request, in connection with the consummation of the transactions contemplated by
this Agreement. Amdocs will use its commercially reasonable efforts to promptly
obtain all such authorizations, approvals and consents. Without limiting the
generality of the foregoing, as promptly as practicable after the execution of
this Agreement, Amdocs shall file with the FTC and the DOJ a pre-merger
notification report under the HSR Act and shall make such filings, if any, as
are necessary or, in the opinion of Amdocs, desirable to be made prior to
Closing, under the Investment Canada Act and the Competition Act (Canada).
5.3 NECESSARY CONSENTS.
During the term of this Agreement, Amdocs, Amdocs Parentco and Amdocs
Holdco will use their commercially reasonable efforts to obtain such written
consents and take such other actions as may be necessary or appropriate in
addition to those set forth in Section 5.2 to allow the consummation of the
transactions contemplated hereby.
58
<PAGE>
5.4 SATISFACTION OF CONDITIONS PRECEDENT.
During the term of this Agreement, Amdocs will use its commercially
reasonable efforts to satisfy or cause to be satisfied all the conditions
precedent that are set forth in Article 7, and Amdocs will use its commercially
reasonable efforts to cause the Share Restructuring Plan and the other
transactions contemplated by this Agreement to be consummated and shall take
such commercially reasonable steps as are appropriate so that the
representations and warranties of Amdocs in this Agreement remain complete and
correct on and as of the Closing Date.
5.5 EMPLOYMENT AND EMPLOYEE BENEFITS AFTER THE CLOSING.
Amdocs hereby agrees that from and after the Closing, and for a period of
at least 12 months thereafter, Amdocs will provide to the employees who
immediately prior to the Closing were in the employ of Solect or any of the
Solect Subsidiaries and who after the Closing remain Solect employees during
such 12 month period (the "Employees"), benefits either (i) under Amdocs'
employee benefit plans on substantially similar terms as Amdocs employees
generally, or (ii) under the Solect Employee Plans substantially similar in the
aggregate to those currently provided to the Employees under the Solect Employee
Plans. Except as expressly contemplated by this Agreement, Amdocs will, with
respect to Solect Options outstanding at the Effective Time, maintain the Solect
Option Plans, as heretofore modified by any Solect Board of Directors'
resolutions, as in effect on the date hereof.
5.6 EMPLOYEE RETENTION ARRANGEMENTS.
Amdocs agrees that it will implement the employee retention arrangements
outlined in the Employee Retention Letter.
5.7 ISSUANCE AND LISTING OF AMDOCS ORDINARY SHARES
Amdocs hereby covenants that all Amdocs Ordinary Shares issued (i) upon
exchange of the Exchangeable Shares in accordance with their terms and (ii) upon
exercise of Amdocs Options in accordance with their terms after the Effective
Date, will, when issued, be validly issued, fully paid and non-assessable.
Amdocs will cause the Amdocs Ordinary Shares to be issued from time to time upon
exchange of the Exchangeable Shares and the exercise of the Amdocs Options to be
listed on the NYSE, subject only to official notice of issuance, concurrently
with the issuance of the Exchangeable Shares, and will use its best efforts to
maintain such listing. As soon as practicable after the Effective Date, Amdocs
will file a registration statement covering the issuance of the Amdocs Ordinary
Shares issuable upon exercise of the Solect Options and Amdocs Options, and will
use its best efforts to have such registration statement declared effective as
soon as possible thereafter.
59
<PAGE>
5.8 CERTAIN TAX FILINGS.
Amdocs Parentco has filed Form 8832 with the U.S. Internal Revenue Service
to be disregarded as an entity for U.S. federal income tax purposes, and such
election is effective. Amdocs Holdco shall file Form 8832 with the U.S. Internal
Revenue Service to be disregarded as an entity for U.S. federal income tax
purposes prior to the Effective Time, and such election shall become effective
prior to the Effective Time.
5.9 SOLECT CUSTOMERS.
If Amdocs becomes aware of any material deterioration, or an event that may
cause future material deterioration in the relationship with any material
customer, supplier or key employee or consultant of Solect, Amdocs will promptly
bring such information to the attention of Solect in writing and, if requested
by Solect, Amdocs will use commercially reasonable efforts in cooperation with
Solect in an effort to restore such relationship.
5.10 INDEMNIFICATION.
Without derogating from any liability of any such director or officer under
the Escrow Agreement, from and after the Effective Time, Amdocs and Solect will
jointly and severally indemnify and hold harmless each current and former
director and officer of Solect (in their capacity as such and not as a
shareholder of Solect) and each of the Solect Subsidiaries against any costs or
expenses (including reasonable attorneys' fees), judgements, fines, losses,
claims, damages or liabilities incurred in connection with any claim, action,
suit, proceeding or investigation, whether civil, criminal, administrative or
investigative, arising out of matters existing or occurring at or prior to the
Effective Time, whether asserted or claimed prior to, at or after the Effective
Time, to the fullest extent that Solect or such Solect Subsidiary, as the case
may be, would have been permitted under its articles or bylaws as in effect on
the date hereof, or otherwise in accordance with the agreements set forth in
Section 2.9(k) of the Solect Disclosure Letter, to indemnify such person (and
Amdocs shall cause Solect to advance expenses as incurred to the fullest extent
permitted under the Certificate of Incorporation and Bylaws of Solect or such
Solect Subsidiary, as the case may be, as in effect on the date hereof, provided
the person to whom expenses are advanced provides an undertaking to repay such
advances if it is ultimately determined that such person is not entitled to
indemnification) and provided further that Amdocs determines in good faith that,
with respect to any civil action or proceeding, such person acted in good faith
and in a manner he reasonably believed to be in or not opposed to the best
interests of Solect or such Solect Subsidiary, as the case may be, and, with
respect to any criminal action or proceeding, such person had no reasonable
cause to believe this conduct was unlawful.
60
<PAGE>
5.11 COVENANT TO INFORM.
During the period from the date of this Agreement until the earlier of the
Effective Time and the termination of this Agreement in accordance with its
terms, Amdocs will promptly notify Solect if at any time Amdocs has actual
knowledge that any representation or warranty of Solect contained in Section 2
hereof is untrue, inaccurate or incomplete in any material respect.
6. CLOSING MATTERS
6.1 THE CLOSING.
Subject to the termination of this Agreement as provided in Article 9
below, the closing of the transactions contemplated by this Agreement (the
"Closing") will take place at the offices of Goodman Phillips & Vineberg, Suite
2400, 250 Yonge Street, Toronto, Ontario on a date (the "Closing Date") and at a
time to be mutually agreed upon by the parties, which date shall be no later
than the fifth business day after all conditions to Closing set forth herein
shall have been satisfied or waived, unless another place, time and date is
mutually selected by Solect and Amdocs. Concurrently with the Closing, the
Certificate of Amendment giving effect to the Share Restructuring Plan will be
filed with the Director under the NBBCA.
6.2 ANCILLARY AGREEMENTS/RESERVATION OF SHARES.
(a) Provided that the conditions set forth in Articles 7 and 8 of this
Agreement have been satisfied or waived, Solect shall, on the Closing
Date, file the articles of amendment giving effect to the Share
Restructuring Plan pursuant to the NBBCA.
(b) Provided that the conditions set forth in Articles 7 and 8 of this
Agreement have been satisfied or waived, on the Closing Date the
following agreements (collectively, the "Ancillary Agreements") shall
be executed and delivered by the parties thereto:
(i) Amdocs, Amdocs Parentco, Amdocs Holdco and Solect shall execute
and deliver the Support Agreement substantially in the form of
Exhibit 6.2(b)(i) hereto (the "Support Agreement");
(ii) Amdocs, Amdocs Parentco, Amdocs Holdco and Solect and a Canadian
trust company to be selected by Amdocs (the "Trustee") shall
execute and deliver the Voting and Exchange Trust Agreement
substantially in the form of Exhibit 6.2(b)(ii) hereto (the
"Voting and Exchange Trust Agreement");
61
<PAGE>
(iii) Amdocs, Solect, the Solect Principal Securityholders and the
other parties named on the signature pages thereto shall execute
and deliver the Registration Rights Agreement substantially in
the form of Exhibit 6.2(b)(iii) hereto (the "Registration Rights
Agreement"); and
(iv) Amdocs, Amdocs Parentco, Amdocs Holdco, Solect, the shareholders
specified therein and the Escrow Agent shall execute and deliver
the Escrow Agreement (and concurrently therewith, Solect, on
behalf of such shareholders, shall deliver to the Escrow Agent a
certificate or certificates evidencing the Escrowed Shares).
(c) On or before the Closing Date, (i) the Board of Directors of Amdocs
shall have adopted a resolution designating the Amdocs Special Voting
Share (the terms of which are described in Exhibit 6.2(c) hereto), and
such resolution shall be in full force and effect, and (ii) Amdocs
shall have reserved for issuance such number of Amdocs Ordinary Shares
as shall be necessary to give effect to the exchanges and assumptions
of options contemplated hereby and by the Share Restructuring Plan.
6.3 EXCHANGE OF OPTIONS.
Promptly after the Closing Date, Amdocs will notify in writing each holder
of a Solect Option of the amendment to the terms of the Solect Options in
accordance with Section 11 of the Solect Option Plans whereby each such option
became exercisable for Amdocs Ordinary Shares, the number of Amdocs Ordinary
Shares that are then subject to such option, and the exercise price thereof, as
determined pursuant to Section 1.2.
7. CONDITIONS PRECEDENT TO OBLIGATIONS OF SOLECT
The obligations of Solect hereunder are subject to the fulfillment or
satisfaction on or before the Closing of each of the following conditions (any
one or more of which may be waived by Solect, but only in a writing signed by
Solect):
7.1 ACCURACY OF REPRESENTATIONS AND WARRANTIES.
The representations and warranties of Amdocs, Amdocs Parentco and Amdocs
Holdco set forth in Article 3 (as qualified by the Amdocs Disclosure Letter)
shall be true and accurate in all material respects on and as of the Closing
Date with the same force and effect as if they had been made at the Closing
except for changes contemplated by this Agreement (including, without
limitation, Section 5.1) and Solect shall receive a certificate to such effect
executed by the Chief Financial Officer of Amdocs Management Limited.
62
<PAGE>
7.2 COVENANTS.
Amdocs, Amdocs Parentco and Amdocs Holdco shall have performed and complied
in all material respects with all of their covenants required to be performed by
them under this Agreement or the Share Restructuring Plan on or before the
Closing, and Solect shall receive a certificate to such effect signed by the
Chief Financial Officer of Amdocs Management Ltd.
7.3 ABSENCE OF MATERIAL ADVERSE CHANGE.
There shall not have occurred any event or change since the date hereof
that has a Material Adverse Effect on Amdocs.
7.4 COMPLIANCE WITH LAW.
There shall be no order, decree or ruling by any governmental agency or
threat thereof, or any statute, rule, regulation or order enacted, entered,
enforced or deemed applicable to the Share Restructuring Plan, that would
prohibit or render illegal the transactions contemplated by this Agreement.
7.5 GOVERNMENT CONSENTS.
There shall have been obtained on or before the Closing such material
permits or authorizations, and there shall have been taken such other action, as
may be required to consummate the Share Restructuring Plan by any regulatory
authority having jurisdiction over the parties and the actions herein proposed
to be taken, including but not limited to requirements under applicable federal,
provincial and state securities laws and the compliance with, and expiration or
termination of any applicable waiting period under, the HSR Act, the Competition
Act (Canada) or the Investment Canada Act.
7.6 OPINION OF AMDOCS' COUNSEL.
Solect shall have received from Reboul, MacMurray, Hewitt, Maynard &
Kristol, Goodman Phillips & Vineberg and Carey Langlois, United States, Canadian
and Guernsey counsel to Amdocs, respectively, opinions in customary form in
connection with transactions contemplated by this Agreement that are
satisfactory to Solect and its counsel, each acting reasonably.
7.7 CONSENTS, WAIVERS, ETC.
Amdocs, Amdocs Parentco and Amdocs Holdco shall have received all written
consents, assignments, waivers, authorizations or other certificates necessary
63
<PAGE>
to provide for the continuation in full force and effect of any and all material
contracts and leases of Amdocs, Amdocs Parentco and Amdocs Holdco and for
Amdocs, Amdocs Parentco and Amdocs Holdco to consummate the transactions
contemplated hereby, except when the failure to receive such consents or other
certificates would not have a Material Adverse Effect on Amdocs.
7.8 SHAREHOLDER APPROVAL.
The Share Restructuring Plan shall have been approved and adopted by
Solect's shareholders in accordance with applicable law and Solect's articles of
continuance and bylaws, and, provided that Solect shall have filed the articles
of amendment giving effect to the Share Restructuring in accordance with Section
6.2(a) hereof, such articles of amendment shall have become legally effective to
give effect to the Share Restructuring Plan as of the Effective Time.
7.9 NO LEGAL ACTION.
No temporary restraining order, preliminary injunction or permanent
injunction or other order preventing the consummation of the Share Restructuring
or any other transaction contemplated hereby shall have been issued by any
Canadian or United States federal, provincial or state court and remain in
effect, nor shall any proceeding seeking any of the foregoing be pending.
7.10 REGULATORY AUTHORITIES, ETC.
All necessary orders shall have been obtained from the Ontario Securities
Commission in connection with the Share Restructuring. If the transaction is
pre-notifiable under Part IX of the Competition Act (Canada) Amdocs and Solect
shall each have: (i) filed all notices and information required under Part IX of
the Competition Act (Canada) and the applicable waiting periods and any
extensions thereof shall have expired; or (ii) the parties shall have received
an Advance Ruling Certificate pursuant to Section 102 of the Competition Act
(Canada) setting out that the Commissioner under such Act is satisfied he would
not have sufficient grounds on which to apply for an order in respect of the
Share Restructuring. The Share Restructuring shall have received the allowance
or approval or deemed allowance or approval by the responsible Minister under
the Investment Canada Act in respect of the Share Restructuring, to the extent
such allowance or approval is required, on terms and conditions satisfactory to
Amdocs.
7.11 TAX-FREE STATUS.
(a) There shall not have occurred any change in the ITA or the regulations
thereunder enacting into law a change first proposed from and after the date
hereof (for avoidance of doubt, excluding any change proposed as part of the
Canadian budget announced on February 28, 2000), or any proposal made from and
64
<PAGE>
after the date hereof (for avoidance of doubt, excluding any proposal made as
part of the Canadian budget announced on February 28, 2000) by the Minister of
Finance of Canada to amend the ITA or the regulations thereunder which, if
enacted, would, in either case, result in (i) the transactions contemplated by
this Agreement and the Share Restructuring Plan not being treated as a
reorganization of capital of Solect for the purpose of Section 86 of the ITA, to
the extent that Exchangeable Shares are received in exchange for shares of
Solect capital stock; or (ii) holders of Solect Options not receiving tax-free
exchange treatment under the ITA on the exchange of such options for Amdocs
Options; and there shall not, as a result of any official or administrative
pronouncement or action announced or adopted after the date hereof or judicial
decision rendered after the date hereof interpreting or applying the ITA or the
regulations thereunder, that would result in or could reasonably be expected to
result in any of the foregoing.
(b) There shall not have occurred any amendment to, or change in, the laws
(or any proposed, final or temporary regulations thereunder) of the United
States or any political subdivision or taxing authority thereof or therein
(including any proposed change in such regulations announced by an
administrative agency), or as a result of any official or administrative
pronouncement or action or judicial decision interpreting or applying such laws
or regulations, that would result in, or could reasonably be expected to result
in, the transactions contemplated by this Agreement and the Share Restructuring
Plan not being treated as a plan of reorganization under Section 368(a) of the
Code to the extent that Exchangeable Shares are received in exchange for Solect
Common Shares, or that would cause, or could reasonably be expected to cause,
any holder of Solect Common Shares who receives Exchangeable Shares in exchange
for shares of Solect Common Shares pursuant to such plan to be taxable upon the
receipt of such Exchangeable Shares for United States federal income tax
purposes.
8. CONDITIONS PRECEDENT TO OBLIGATIONS OF AMDOCS, AMDOCS PARENTCO AND AMDOCS
HOLDCO
The obligations of Amdocs, Amdocs Parentco and Amdocs Holdco hereunder are
subject to the fulfillment or satisfaction on or before the Closing of each of
the following conditions (any one or more of which may be waived by Amdocs, but
only in a writing signed by Amdocs):
8.1 ACCURACY OF REPRESENTATIONS AND WARRANTIES.
The representations and warranties of Solect set forth in Section 2 (as
qualified by the Solect Disclosure Letter) shall be true and accurate in all
material respects on and as of the Closing Date with the same force and effect
as if they had been made at the Closing except for changes contemplated by this
Agreement (including, without limitation, Section 4.1), the Ancillary Agreements
and the Share Restructuring Plan and Amdocs shall receive a certificate to such
effect executed by Solect's Chief Executive Officer or Chief Financial Officer.
65
<PAGE>
8.2 COVENANTS.
Solect shall have performed and complied in all material respects with all
of its covenants required to be performed by it under this Agreement or the
Share Restructuring Plan on or before the Closing, and Amdocs, Amdocs Parentco
and Amdocs Holdco shall receive a certificate to such effect signed by Solect's
Chief Executive Officer or Chief Financial Officer.
8.3 ABSENCE OF MATERIAL ADVERSE CHANGE.
There shall not have occurred any event or change since the date hereof
that has a Material Adverse Effect on Solect and the Solect Subsidiaries, taken
as a whole.
8.4 COMPLIANCE WITH LAW.
There shall be no order, decree or ruling by any governmental agency or
threat thereof, or any statute, rule, regulation or order enacted, entered,
enforced or deemed applicable to the Share Restructuring Plan, that would
prohibit or render illegal the transactions contemplated by this Agreement.
8.5 GOVERNMENT CONSENTS.
There shall have been obtained on or before the Closing such material
permits or authorizations, and there shall have been taken such other action, as
may be required to consummate the Share Restructuring by any regulatory
authority having jurisdiction over the parties and the actions herein proposed
to be taken, including but not limited to requirements under applicable federal
and state securities laws and the compliance with, and expiration or termination
of any applicable waiting period under, the HSR Act, the Competition Act
(Canada) or the Investment Canada Act.
8.6 OPINION OF SOLECT'S COUNSEL.
Amdocs shall have received from Skadden, Arps, Slate, Meagher & Flom LLP,
Fasken Martineau DuMoulin LLP and Stewart McKelvey Stirling Scales, United
States, Canadian and New Brunswick counsel to Solect, respectively, opinions in
customary form in connection with the transactions contemplated by this
Agreement that are satisfactory to Amdocs and its counsel, each acting
reasonably.
66
<PAGE>
8.7 CONSENTS, WAIVERS, ETC.
Solect shall have received all written consents, assignments, waivers,
authorizations or other certificates necessary to provide for the continuation
in full force and effect of any and all material contracts and leases of Solect
and for Solect to consummate the transactions contemplated hereby, except when
the failure to receive such consents, or other certificates would not have a
Material Adverse Effect on Solect, including, without limitation, the consents
set forth on Section 8.7 of the Solect Disclosure Schedule.
8.8 SOLECT APPROVALS.
This Agreement, the Ancillary Agreements and the Share Restructuring Plan
shall have been approved and adopted by the Solect shareholders in accordance
with applicable law, Solect's certificate of incorporation and bylaws and any
shareholders agreements between Straus and any of its shareholders or among any
of such shareholders.
8.9 SHARE RESTRUCTURING PLAN.
The articles of amendment giving effect to the Share Restructuring shall
have been filed with the Director under the NBBCA and become legally effective
to give effect to the Share Restructuring Plan as of the Effective Time.
8.10 SOLECT CONVERTIBLE DEBENTURES.
All of the holders of the Solect Convertible Debentures shall have taken
all action necessary to convert such securities into Solect Common Shares in
accordance with the terms thereof, the Solect Common Shares issuable upon such
conversion shall have been so issued and all of the Solect Convertible
Debentures shall have been canceled.
8.11 SOLECT WARRANTS.
All of the holders of the Solect Warrants shall have taken all action
necessary to exercise such warrants in accordance with the terms thereof, the
Solect Common Shares issuable upon such exercise shall have been so issued and
all of the Solect Warrants shall have been canceled.
8.12 SECURITYHOLDER AGREEMENT.
The Securityholder Agreement with the Solect Principal Securityholders
shall be in full force and effect.
67
<PAGE>
8.13 NO LEGAL ACTION.
No temporary restraining order, preliminary injunction or permanent
injunction or other order preventing the consummation of the Share Restructuring
or any other transaction contemplated hereby shall have been issued by any U.S.
or Canadian federal, provincial or state court and remain in effect, nor shall
any proceeding seeking any of the foregoing be pending.
8.14 TERMINATION OF CERTAIN AGREEMENTS.
Solect and each of the parties thereto shall have taken all action
necessary to terminate, as of the Effective Time, (i) the Second Amended and
Restated Shareholders Agreement dated as of December 17, 1999, as amended to the
Effective Time (the "Shareholders Agreement"), between Solect and the Major
Shareholders and the Purchasers (and such terms are defined therein), (ii) the
Second Amended and Restated Investor's Rights Agreement dated as of December 17,
1999, as amended to the Effective Time (the "Investor's Rights Agreement"),
between Solect and the investors listed on Schedule A thereto, (iii) the
Management Rights Agreement dated July 27, 1998 between Solect and TCV II
Strategic Partners, L.P., as amended to the Effective Time (the "Management
Rights Agreements"), (iv) the Convertible Debenture Purchase Agreement dated as
of December 17, 1999, as amended to the Effective Time, between Solect and the
Investors listed on Schedule A thereto, (v) the Convertible Debenture and
Warrant Purchase Agreement dated as of January 11, 1999, as amended to the
Effective Time, between Solect and the Investors listed on Schedule A thereto
and (vi) the Convertible Debenture and Warrant Purchase Agreement dated as of
July 27, 1998, as amended to the Effective Time, between Solect and the
Investors listed on Schedule A thereto, and each such agreement shall have been
so terminated as of the Effective Time.
8.15 REGULATORY AUTHORITIES, ETC.
All necessary orders shall have been obtained from the Ontario Securities
Commission in connection with the Share Restructuring. If the transaction is
pre-notifiable under Part IX of the Competition Act (Canada) Amdocs and Solect
shall each have: (i) filed all notices and information required under Part IX of
the Competition Act (Canada) and the applicable waiting periods and any
extensions thereof shall have expired; or (ii) the parties shall have received
an Advance Ruling Certificate pursuant to Section 102 of the Competition Act
(Canada) setting out that the Commissioner under such Act is satisfied he would
not have sufficient grounds on which to apply for an order in respect of the
Share Restructuring. The Share Restructuring shall have received the allowance
or approval or deemed allowance or approval by the responsible Minister under
the Investment Canada Act, to the extent such allowance or approval is required,
on terms and conditions satisfactory to the parties (including that no material
conditions or costs are imposed).
68
<PAGE>
8.16 RESIGNATION OF DIRECTORS.
Each member of the Board of Directors of Solect and of each Solect
Subsidiary shall have delivered to Amdocs an instrument resigning such person's
position as of the Effective Time.
8.17 CERTIFICATES.
The Certificate of the Chief Executive Officer and Chief Financial Officer
of Solect referred to in Section 1.2 hereof shall have been delivered to Amdocs,
Amdocs Parentco and Amdocs Holdco.
8.18 DISSENTING SHAREHOLDERS.
Solect shall not have received on or prior to the Effective Time notice
from the holders of more than 5% of the Solect Common Shares of their intention
to exercise rights of dissent under Section 131 of the NBBCA.
8.19 BT AND NOKIA LETTERS.
Prior to the Effective Date, Solect shall have entered into the BT Letter
and the Nokia Letter and pursuant to the terms thereof, (1) Solect shall have
issued and sold 437,500 Solect Common Shares to BT at a price per share of
US$10.65, (2) Southwest Sun Inc., Kevin Kimsa and KL Group Inc. shall have sold
an aggregate 437,500 Solect Common Shares to Nokia at a price per share of
US$10.65, and (3) Nokia shall have consented to the change of control of Solect
and waived all rights with respect thereto.
9. TERMINATION OF AGREEMENT
9.1 TERMINATION.
This Agreement may be terminated at any time prior to the Effective Time,
whether before or after approval of the Share Restructuring Plan by the
shareholders of Solect:
(a) by mutual agreement of Solect, Amdocs, Amdocs Parentco and Amdocs
Holdco;
(b) by Solect, if there has been a breach by Amdocs of any representation,
warranty, covenant or agreement set forth in this Agreement on the
part of Amdocs, or if any representation of Amdocs shall have become
untrue, in either case which has or can reasonably be expected to have
a Material Adverse Effect on Amdocs and which Amdocs fails to cure
within 15 business days after written notice thereof from Solect
(except that no cure period shall be provided for a breach by Amdocs
which by its nature cannot be cured);
69
<PAGE>
(c) by Amdocs, if there has been a breach by Solect of any representation,
warranty, covenant or agreement set forth in this Agreement on the
part of Solect, or if any representation of Solect shall have become
untrue, in either case which has or can reasonably be expected to have
a Material Adverse Effect on Solect and the Subsidiaries of Solect,
considered as a whole, and which Solect fails to cure within 15
business days after written notice thereof from Amdocs (except that no
cure period shall be provided for a breach by Solect which by its
nature cannot be cured);
(d) by Solect or Amdocs, if all the conditions for Closing the Share
Restructuring shall not have been satisfied or waived on or before
5:00 p.m., Toronto time on June 1, 2000 or such later date as may be
agreed upon in writing by Solect and Amdocs, other than as a result of
a breach of this Agreement by the terminating party, or, in the case
of termination by Solect, a breach by any of the Solect Principal
Securityholders of Solect of any of the provisions of the Option
Agreements referred to in Section 4.4; or
(e) by Solect or Amdocs, if a permanent injunction or other order by any
Guernsey, United States or Canadian federal, provincial or state court
shall have been issued and shall have become final and nonappealable
that would (i) make illegal or otherwise restrain or prohibit the
consummation of the Share Restructuring or any other transaction
contemplated hereby, (ii) prohibit Amdocs' ownership or operation of
all or any material portion of the business or assets of Solect or
(iii) compel Amdocs to dispose of or hold separate all or any material
portion of the business or assets of Solect.
9.2 NOTICE OF TERMINATION.
Any termination of this Agreement under Section 9.1 above will be effective
by the delivery of written notice by the terminating party to the other party
hereto.
9.3 EFFECT OF TERMINATION.
In the case of any termination of this Agreement as provided in this
Article 9, this Agreement shall be of no further force and effect (except as
provided in Article 11) and nothing herein shall relieve any party from
liability for any breach of this Agreement. No termination of this Agreement
shall affect the obligations of the parties contained in the Non-Disclosure and
70
<PAGE>
Confidentiality Agreement, made as of January 16, 2000, as amended as of
February 13, 2000 (the "Confidentiality Agreement"), between Amdocs Management
Limited and Solect.
10. SURVIVAL OF REPRESENTATIONS, WARRANTIES AND COVENANTS; INDEMNITY
10.1 SURVIVAL.
All representations, warranties and covenants of Solect and each of Amdocs,
Amdocs Parentco and Amdocs Holdco, respectively, contained in this Agreement
will remain operative and in full force and effect, regardless of any
investigation made by or on behalf of the parties to this Agreement, until the
one year anniversary of the Effective Time, as provided in the Escrow Agreement.
10.2 INDEMNITY.
Amdocs shall be entitled to exercise the rights set forth in the Escrow
Agreement in the event of any loss, claim, damage, liability or expense suffered
by Amdocs or any of its affiliates resulting from the inaccuracy or breach of
any representation or warranty of Solect or any of the Solect Principal
Securityholders, any breach of or failure to perform any covenant or agreement
of Solect or any of the Solect Principal Securityholders or any other matter set
forth herein to the extent and on the terms set forth in the Escrow Agreement.
11. MISCELLANEOUS
11.1 GOVERNING LAW.
The internal laws of the State of New York (irrespective of its choice of
law principles) will govern the validity of this Agreement, the construction of
its terms and the interpretation and enforcement of the rights and duties of the
parties hereto, except to the extent mandatorily governed by the laws of New
Brunswick, Denmark, Nova Scotia or Guernsey.
11.2 ASSIGNMENT; BINDING UPON SUCCESSORS AND ASSIGNS.
None of the parties hereto may assign any of its rights or obligations
hereunder or under the Ancillary Agreements without the prior written consent of
the other parties hereto or thereto. This Agreement will be binding upon and
inure to the benefit of the parties hereto and their respective successors and
permitted assigns.
71
<PAGE>
11.3 SEVERABILITY.
If any provision of this Agreement, or the application thereof, will for
any reason and to any extent be invalid or unenforceable, the remainder of this
Agreement and application of such provision to other persons or circumstances
will be interpreted so as reasonably to effect the intent of the parties hereto.
The parties further agree to replace such void or unenforceable provision of
this Agreement with a valid and enforceable provision that will achieve, to the
greatest extent possible, the economic, business and other purposes of the void
or unenforceable provision.
11.4 COUNTERPARTS.
This Agreement may be executed in any number of counterparts, each of which
will be an original as regards any party whose signature appears thereon and all
of which together will constitute one and the same instrument. This Agreement
will become binding when one or more counterparts hereof, individually or taken
together, will bear the signatures of all the parties reflected hereon as
signatories.
11.5 OTHER REMEDIES.
Except as otherwise provided herein, any and all remedies herein expressly
conferred upon a party will be deemed cumulative with and not exclusive of any
other remedy conferred hereby or by law on such party, and the exercise of any
one remedy will not preclude the exercise of any other. Notwithstanding the
foregoing, the rights of Amdocs, Amdocs Parentco and Amdocs Holdco to pursue any
claim arising hereunder against any Stockholder (as defined in the Escrow
Agreement) shall be limited to the extent set forth in the Escrow Agreement.
11.6 AMENDMENT AND WAIVERS.
Any term or provision of this Agreement may be amended, and the observance
of any term of this Agreement may be waived (either generally or in a particular
instance and either retroactively or prospectively) only by a writing signed by
the party to be bound thereby. The waiver by a party of any breach hereof or
default in the performance hereof will not be deemed to constitute a waiver of
any other default or any succeeding breach or default. The Agreement may be
amended by the parties hereto at any time before or after approval of Solect's
shareholders, but, after such approval, no amendment will be made which by
applicable law requires the further approval of the Solect's shareholders
without obtaining such further approval.
72
<PAGE>
11.7 EXPENSES.
Each party will bear its respective fees and expenses (including the fees
and expenses of legal counsel, accountants and investment bankers) incurred with
respect to this Agreement, and the transactions contemplated hereby; provided,
that the total of all such fees and expenses incurred by Solect (including the
fees and expenses described in Section 2.15 hereof) shall not exceed $12,000,000
(the "Budgeted Amount"). Solect has provided Amdocs with a budget of all such
fees and expenses required in connection with the completion of the transactions
contemplated by this Agreement and shall use its best efforts to consummate such
transactions without exceeding the Budgeted Amount and shall not enter into any
agreement or take any action inconsistent with the foregoing.
11.8 ATTORNEYS' FEES.
Should suit be brought to enforce or interpret any part of this Agreement,
the prevailing party will be entitled to recover, as an element of the costs of
suit and not as damages, reasonable attorneys' fees to be fixed by the court
(including, without limitation, costs, expenses and fees on any appeal). The
prevailing party will be entitled to recover its costs of suit, regardless of
whether such suit proceeds to final judgment.
11.9 NOTICES.
All notices and other communications pursuant to this Agreement shall be in
writing and deemed to be sufficient if contained in a written instrument and
shall be deemed given if delivered personally, by facsimile, sent by
nationally-recognized overnight courier or mailed by registered or certified
mail (return receipt requested), postage prepaid, to the parties at the
following address (or at such other address for a party as shall be specified by
like notice):
If to Solect to:
Solect Technology Group, Inc.
55 University Avenue
Toronto, Ontario
M5J 2H7
Attention: Chief Executive Officer
Facsimile: (416) 216-6351
73
<PAGE>
with a copy to:
Fasken Martineau DuMoulin LLP
4200 Toronto Dominion Bank Tower
Box 20, Toronto Dominion Centre
Toronto, Ontario
M5K 1N6
Attention: Constance L. Sugiyama
Facsimile: (416) 364-7813
and to:
Skadden, Arps, Slate, Meagher & Flom LLP
Suite 1820 North Tower
Royal Bank Plaza
Toronto, Ontario
M5J 2J4
Attention: Christopher W. Morgan
Facsimile: (416) 777-4747
If to Amdocs, Amdocs Parentco or Amdocs Holdco to:
c/o Amdocs Management Limited
Grand Buildings
1-3 Strand
London WCZN 5EJ
United Kingdom
Facsimile: 44-171-930-2321
with a copy to:
Reboul, MacMurray, Hewitt, Maynard & Kristol
45 Rockefeller Plaza
New York, New York 10111
U.S.A.
Attention: Robert A. Schwed
Facsimile: (212) 841-5725
74
<PAGE>
and to:
Goodman Phillips & Vineberg
250 Yonge Street
Toronto, Ontario
M5B 2M6
Attention: David J. Matlow
Facsimile: (416) 979-1234
All such notices and other communications shall be deemed to have been
received (a) in the case of personal delivery, on the date of such delivery, (b)
in the case of a facsimile, when the party receiving such copy shall have
confirmed receipt of the communication, (c) in the case of delivery by
nationally-recognized overnight courier, on the business day following dispatch,
and (d) in the case of mailing, on the tenth business day following such
mailing.
11.10 CONSTRUCTION OF AGREEMENT.
This Agreement has been negotiated by the respective parties hereto and
their attorneys and the language hereof will not be construed for or against any
party. A reference to a Section or an exhibit will mean a Section in, or exhibit
to, this Agreement unless otherwise explicitly set forth. The titles and
headings herein are for reference purposes only and will not in any manner limit
the construction of this Agreement which will be considered as a whole.
11.11 NO JOINT VENTURE.
Nothing contained in this Agreement will be deemed or construed as creating
a joint venture or partnership between any of the parties. No party is by virtue
of this Agreement authorized as an agent, employee or legal representative of
any other party. No party will have the power to control the activities and
operations of any other and their status is, and at all times, will continue to
be, that of independent contractors with respect to each other. No party will
have any power or authority to bind or commit any other. No party will hold
itself out as having any authority or relationship in contravention of this
Section.
11.12 FURTHER ASSURANCES.
Each party agrees to cooperate fully with the other parties and to execute
such further instruments, documents and agreements and to give such further
written assurances as may be reasonably requested by any other party to evidence
and reflect the transactions described herein and contemplated hereby and to
carry into effect the intents and purposes of this Agreement.
75
<PAGE>
11.13 PUBLIC ANNOUNCEMENT.
Upon execution of this Agreement, Amdocs and Solect promptly will issue a
joint press release approved by both parties announcing the Share Restructuring
Plan. Thereafter, Amdocs may issue such press releases, and make such other
disclosures regarding the Share Restructuring Plan, as it determines (after
consultation with legal counsel) are required under applicable securities laws
or by the NYSE, subject to the prior review of Solect, provided that to the
extent reasonably practicable Amdocs will provide advance notice to the other of
the form and content of any such disclosure and opportunity to comment promptly
thereon, and shall in any case promptly deliver to Solect a copy of such
disclosure in the form released. Notwithstanding the foregoing, before the
earlier of the Effective Time and the termination of this Agreement in
accordance with its terms, Solect shall, prior to the issuance of any disclosure
regarding its financial results for any period, provide to Amdocs a copy of such
disclosure substantially in the form to be released.
11.14 ENTIRE AGREEMENT.
This Agreement and the exhibits hereto and the Ancillary Agreements
constitute the entire understanding and agreement of the parties hereto with
respect to the subject matter hereof and supersede all prior agreements or
understandings, inducements or conditions, express or implied, written or oral,
between the parties with respect hereto other than the Confidentiality
Agreement, which shall remain in full force and effect. The express terms hereof
control and supersede any course of performance or usage of the trade
inconsistent with any of the terms hereof.
76
<PAGE>
IN WITNESS WHEREOF, the parties hereto have executed this Combination
Agreement as of the date first above written.
SOLECT TECHNOLOGY GROUP INC.
By: /s/ PAUL ATKINSON
Name: Mr. Paul Atkinson
Title: Chief Executive Officer
AMDOCS LIMITED
By: /s/ THOMAS G. O'BRIEN
Name: Mr. Thomas G. O'Brien
Title: Treasurer and Secretary
AMDOCS(DENMARK) APS.
By: /s/ THOMAS G. O'BRIEN
Name: Mr. Thomas G. O'Brien
Title: Director
AMDOCS HOLDINGS ULC
By: /s/ THOMAS G. O'BRIEN
Name: Mr. Thomas G. O'Brien
Title: Director
77
EXHIBIT 2.2
PRINCIPAL SECURITYHOLDERS' VOTING AGREEMENT
PRINCIPAL SECURITYHOLDERS' VOTING AGREEMENT, dated as of February 28,
2000, among Amdocs Limited, a Guernsey corporation ("Amdocs"), Amdocs (Denmark)
ApS., a Danish corporation ("Amdocs Parentco"), Amdocs Holdings ULC, a Nova
Scotia unlimited liability company ("Amdocs Holdco"), and each of the
Securityholders (individually, a "Securityholder" and collectively, the
"Securityholders") of the Company named in Schedule I hereto.
WHEREAS, Amdocs, Amdocs Parentco, Amdocs Holdco and Solect Technology
Group Inc., a New Brunswick corporation (the "Company") have entered into a
Combination Agreement of even date herewith (such agreement, as it may be
amended from time to time, the "Combination Agreement"; capitalized terms used
and not defined herein having the respective meanings given such terms in the
Combination Agreement), pursuant to which the parties thereto have agreed, upon
the terms and subject to the conditions set forth therein, to a share
restructuring plan (the "Share Restructuring Plan") described more fully in
Exhibit 1.1 to the Combination Agreement, whereby (i) each issued and
outstanding common share, without par value, of the Company (collectively, the
"Company Common Shares") will be exchanged for a number of Exchangeable Shares
at the Exchange Ratio (which Exchangeable Shares will be subject to the terms of
such Plan) and (ii) options to purchase Company Common Shares will be exchanged
for options to purchase ordinary shares of Amdocs based on the Exchange Ratio;
WHEREAS, as of the date hereof, each Securityholder is the record and
beneficial owner of, and has the sole right to vote (where applicable) and
dispose of, (i) the number of Company Common Shares set forth in the first
column opposite the name of such Securityholder on Schedule I hereto and (ii)
the number of securities (including warrants, convertible debentures and
options) set forth in the second column opposite the name of such Securityholder
on said Schedule (the "Convertible Securities" and, together with the Company
Common Shares, the "Securities") that are convertible or exchangeable into or
exercisable for the number of Company Common Shares set forth in the third
column opposite the name of such Securityholder for the aggregate consideration
set forth in the fourth column opposite the name of such Securityholder; and
WHEREAS, as a condition to their willingness to enter into the
Combination Agreement and to consummate the transactions contemplated thereby,
Amdocs, Amdocs Parentco and Amdocs Holdco have required that each Securityholder
agree, and each of the Securityholders is willing to agree, to the matters set
forth herein; and
1
<PAGE>
WHEREAS, in order to induce the Securityholders to enter into this
Agreement, Amdocs has agreed to consummate the Share Restructuring Plan in
accordance with its terms;
NOW, THEREFORE, in consideration of the foregoing and the agreements set
forth below, the parties hereto agree as follows:
1. REPRESENTATIONS AND WARRANTIES OF SECURITYHOLDERS. Each Securityholder
represents and warrants to each of Amdocs, Amdocs Parentco and Amdocs
Holdco as follows:
1.1 BINDING AGREEMENT. To the extent such Securityholder is a natural
person, such Securityholder has the capacity to execute and deliver
this Agreement and to consummate the transactions contemplated hereby.
Such Securityholder has duly and validly executed and delivered this
Agreement and this Agreement constitutes a legal, valid and binding
obligation of such Securityholder, enforceable against such
Securityholder in accordance with its terms, except as such
enforceability may be limited by applicable bankruptcy, insolvency,
reorganization or other similar laws affecting creditors' rights
generally and by general equitable principles (regardless of whether
enforceability is considered in a proceeding in equity or at law).
1.2 NO CONFLICT. Neither the execution and delivery of this Agreement, the
consummation of the transactions contemplated hereby, nor the
compliance with any of the provisions hereof, in the case of such
Securityholder, (a) require any consent, approval, authorization or
permit of, registration, declaration or filing (except for filings
under the Securities Exchange Act of 1934, as amended (the "1934
Act"), and the Securities Act (Ontario) or the securities acts of any
other Canadian province, if applicable) by such Securityholder with,
or notification by such Securityholder to, any governmental entity,
(b) result in a default by such Securityholder (or an event which,
with notice or lapse of time or both, would become a default) or give
rise to any right of termination by any third party, cancellation,
amendment or acceleration under any contract, agreement, instrument,
commitment, arrangement or understanding binding on such
Securityholder, or result in the creation of a security interest,
lien, charge, encumbrance, equity or claim with respect to any of the
Securities owned by such Securityholder or with respect to any shares
of Company Common Stock issuable upon the exchange, conversion or
exercise thereof, (c) require any consent, authorization or approval
of any person other than a governmental entity, or (d) violate or
conflict with any order, writ, injunction, decree or law applicable to
such Securityholder or the Securities set forth opposite the name of
such Securityholder on Schedule I hereto.
2
<PAGE>
1.3 OWNERSHIP OF SECURITIES. Such Securityholder is the record and
beneficial owner of the Securities set forth opposite such
Securityholder's name on Schedule I hereto, free and clear of any
security interests, liens, charges, encumbrances, equities, claims,
options or limitations of whatever nature and free of any other
limitation or restriction (including any restriction on the right to
vote, sell or otherwise dispose of such Securities) and does not own,
beneficially or of record, any additional equity or debt securities of
the Company. There are no outstanding options or other rights to
acquire from such Securityholder or obligations of such Securityholder
to sell or to acquire (other than the Securities listed on Schedule I
hereto) any Company Common Shares, including without limitation any
Company Common Shares issuable upon conversion, exchange or exercise
of any of the Securities set forth opposite the name of such
Securityholder on Schedule I hereto (except for the proposed sale by
Southwest Sun, Inc., KL Group, Inc. and Kevin Kimsa of an aggregate
437,500 Company Ordinary Shares to Nokia). All of the Convertible
Securities owned by such Securityholder can be converted into the
number of Company Common Shares in the third column opposite such
Securityholder's name on Schedule I hereto for the aggregate
consideration set forth in the fourth column opposite such
Securityholder's name on said Schedule.
1.4 BROKERS. No broker or finder has acted for such Securityholder in
connection with this Agreement or the transactions contemplated hereby
and no broker or finder is entitled to any brokerage or finder's fee
or to any commission in respect thereof based in any way on
agreements, arrangements or understandings made by or on behalf of
such Securityholder, except as referred to in Section 2.15 of the
Combination Agreement.
1.5 NO AFFILIATE OBLIGATIONS. Except for obligations or liabilities
arising between the Company and Telcordia Technologies Inc. (a
subsidiary of Science Applications International Corporation) relating
to the business and operations of the Company and previously disclosed
to Amdocs and under the Combination Agreement and any agreements
executed pursuant thereto, the Company and its affiliates do not have
any obligations or liabilities to such Securityholder or any affiliate
of such Securityholder, except for obligations and liabilities that
will be released in full at no cost to the Company and its affiliates
on or prior to the Closing Date. Immediately subsequent to the
Effective Time, (i) neither the Company nor any of its affiliates will
have any indebtedness outstanding that is payable to such
Securityholder or any of its affiliates and (ii) there will be no
agreements, contracts, leases, arrangements or other understandings
(either written or oral) between such Securityholder and the Company
or any of its affiliates, except for obligations or liabilities
arising between the Company and Telcordia Technologies Inc. (a
subsidiary of Science Applications International Corporation) relating
to the
3
<PAGE>
business and operations of the Company and previously disclosed to
Amdocs and under the Combination Agreement and any agreements executed
pursuant thereto.
1.6 INVESTMENT PURPOSE; ACCREDITED INVESTOR. Such Securityholder, if a
citizen or resident of the United States, (i) is an accredited
investor as that term is defined in Regulation D promulgated under the
Securities Act of 1933, as amended (the "Securities Act"), or, if such
Securityholder is not such an accredited investor, such Securityholder
has sufficient knowledge and experience in investing in companies
similar to Amdocs so as to be able to evaluate the risks and merits of
its investment in the Exchangeable Shares, is able financially to bear
the risks thereof and has had an opportunity to discuss Amdocs'
business, management and financial affairs with Amdocs' management;
and (ii) is acquiring the Exchangeable Shares (and will acquire the
Amdocs ordinary shares issuable upon exchange thereof) for its own
account, for investment purposes and not with a view to, or for resale
in connection with, any distribution or public offering thereof with
the meaning of the Securities Act, except pursuant to a valid
registration statement under the Securities Act or pursuant to a valid
exemption therefrom. Such Securityholder, if a citizen or resident of
Canada, (i) is a "sophisticated purchaser" as that term is understood
under Ontario securities law or similar provisions of the securities
acts of the other provinces of Canada, and (ii) is acquiring the
Exchangeable Shares (and will acquire the Amdocs ordinary shares
issuable upon exchange thereof) as principal for its own account and
pursuant to prospectus and registration exemptions under the Ontario
securities law or similar provisions of the securities acts of the
other provinces of Canada or pursuant to exemption orders or rulings
from the securities regulatory authority in each of the provinces of
Canada.
1.7 RESIDENCE. Such Securityholder represents and warrants that such
Securityholder has read and acknowledges the provisions of Section
4.12 of the Combination Agreement and that such Securityholder shall
make the deliveries described in Sections 4.12(i) and 4.12(ii).
1.8 CAPITAL PROPERTY. If such Securityholder is Canadian, such
Securityholder holds the Securities owned by such Securityholder as
"capital property", within the meaning of the ITA.
1.9 NO UNTRUE STATEMENTS. The representations and warranties of such
Securityholder set forth in Sections 1.1 through 1.8 of this Agreement
do not include any untrue statement of a material fact or omit to
state any material fact necessary to make the representations and
warranties set forth in Section 1.1 through 1.8 not misleading.
4
<PAGE>
2. REPRESENTATION AND WARRANTIES OF AMDOCS, AMDOCS PARENTCO AND AMDOCS HOLDCO.
Amdocs, Amdocs Parentco and Amdocs Holdco jointly and severally represent
and warrant to each of the Securityholders as follows:
2.1 BINDING AGREEMENT. Each of Amdocs, Amdocs Parentco and Amdocs Holdco
is a corporation duly incorporated, validly existing and in good
standing under the laws of the jurisdiction of its formation and each
has full corporate power and authority to execute and deliver this
Agreement and to consummate the transactions contemplated hereby and
in the Share Restructuring Plan. The execution and delivery of this
Agreement by Amdocs, Amdocs Parentco and Amdocs Holdco and the
consummation of the transactions contemplated hereby have been duly
and validly authorized by the Board of Directors of each such company.
Amdocs, Amdocs Parentco and Amdocs Holdco have duly and validly
executed this Agreement and this Agreement constitutes a legal, valid
and binding obligation of each of them enforceable against each in
accordance with its terms, except as such enforceability may be
limited by applicable bankruptcy, insolvency, reorganization or other
similar laws affecting creditors' rights generally and by general
equitable principles (regardless of whether enforceability is
considered in a proceeding in equity or at law).
2.2 NO CONFLICT. Neither the execution and delivery of this Agreement by
Amdocs, Amdocs Parentco or Amdocs Holdco, the consummation by them of
the transactions contemplated hereby, nor compliance by any of them
with any of the provisions hereof will (a) conflict with or result in
a breach of any provision of their respective Memorandum of
Association, Articles of Association or By-laws, (b) require any
consent, approval, authorization or permit of, registration,
declaration or filing (except for filings under the 1934 Act and with
the Ontario Securities Commission under early warning requirements and
insider reporting requirements, if applicable) with, or notification
to, any governmental entity, or (c) result in a default (or an event
which, with notice or lapse of time or both, would become a default)
or give rise to any right of termination by any third party,
cancellation, amendment or acceleration under any contract, agreement,
instrument, commitment, arrangement or understanding applicable to any
of them.
3. CERTAIN PROHIBITED TRANSFERS.
Prior to the earlier of the Termination Date and the Effective Time, each
Securityholder agrees not to:
3.1 sell, transfer, pledge, encumber, assign or otherwise dispose of, or
enter into any contract, option or other arrangement or understanding
5
<PAGE>
with respect to the sale, transfer, pledge, encumbrance, assignment or
other disposition of any Securities or Company Common Shares, or any other
securities into which any Company Shares, Securities or additional shares
of the Company's share capital shall have been converted or changed whether
by amendment to the Articles of Incorporation of the Company, amalgamation,
consolidation or otherwise (collectively, the "Additional Shares") other
than such matters as are expressly contemplated by this Agreement and the
Combination Agreement; or
3.2 grant any proxies or enter into a voting agreement or other
arrangement with respect to any Securities or Company Common Shares
(other than the power of attorney and proxy set forth in Article 5
hereof); or
3.3 deposit any Securities or Company Common Shares into a voting trust.
4. VOTING AGREEMENT AND RELATED MATTERS.
4.1 VOTING AGREEMENT. Until the earlier of the Termination Date and the
Effective Time, each Securityholder agrees to attend all meetings of
the shareholders of the Company and at any meeting of the shareholders
of the Company, however called, or in connection with any action by
written consent by the shareholders of the Company, to vote all of the
shares of Company Common Shares and Additional Shares owned by such
Securityholder (or any shares such Securityholder is entitled to vote,
or direct the voting in respect thereof, as a holder of any Security
other than Company Common Shares) or consents in any action by written
consent:
i) in favor of the transactions contemplated by the Combination
Agreement;
ii) against any action or agreement that could result in a breach in
any material respect of any covenant, representation or warranty
or any other obligation of the Company under the Combination
Agreement; and
iii) against any Acquisition Proposal other than the transactions
contemplated by the Combination Agreement.
4.2 NO DISSENT. Each Securityholder agrees that it will not exercise any
rights of dissent provided under Section 131 of the NBBCA or otherwise
in connection with the Share Restructuring Plan.
4.3 SUPPORT. Each Securityholder agrees that it will do all such things
and take all such steps as Amdocs, Amdocs Parentco or Amdocs Holdco
may reasonably require to be done or taken by such Securityholder to
6
<PAGE>
support and implement the Share Restructuring Plan and complete the
transactions contemplated by the Combination Agreement; provided,
however, that nothing herein shall require any Securityholder to
convert, exercise or otherwise exchange any Convertible Securities
prior to the time of conversion, exercise or exchange required by the
Combination Agreement and the Share Restructuring Plan. Each
Securityholder agrees not to take any step that is inconsistent with,
or that may delay or prevent, the successful completion of the Share
Restructuring Plan and, in any event, shall have taken all steps
required on its part to be taken to facilitate the completion of the
Share Restructuring Plan within five business days of the approval of
the Share Restructuring Plan by the shareholders of the Company, other
than such steps as are expressly provided for in this Agreement and
the Combination Agreement.
4.4 NOKIA AGREEMENT. Each of Southwest Sun Inc., Kevin Kimsa and K.L.
Group Inc. hereby agrees to sell to Nokia prior to the Effective Time
an aggregate 437,000 Solect Common Shares at US $10.65 per share, in
accordance with the term sheet of January 2000 among Nokia and such
Securityholders.
5. POWER OF ATTORNEY AND PROXY.
5.1 GRANT OF POWER OF ATTORNEY AND PROXY. Each Securityholder hereby
irrevocably appoints Avinoam Naor, or failing him Dov Baharav, or
failing him Thomas G. O'Brien, and each of them, (the "Attorneys") or
any other designee of Amdocs, the attorneys-in-fact and proxies of
such Securityholder, each with full power of substitution:
i) to attend any meeting of the shareholders of the Company,
including any adjournment or postponement thereof, on behalf of
such Securityholder, and at such meeting, with respect to all
shares of Company Common Stock or other securities owned by such
Securityholder on the date hereof or acquired hereafter that are
entitled to vote at such meeting or over which such
Securityholder has voting power (or the power to direct the
voting in respect of) and any and all other shares of Company
Common Stock or other securities issued on or after the date
hereof in respect of any such shares, including, without
limitation, the Securities listed opposite such Securityholders'
name on Schedule I hereto, to vote in the manner set forth in
items i) through iii) of Section 4.1 above.
ii) to execute and deliver one or more consents in writing (pursuant
to Section 75 of the NBBCA) in lieu of such meeting or
adjournment thereof;
7
<PAGE>
iii) if no meeting of shareholders is scheduled in accordance with the
Combination Agreement, or any such meeting is cancelled or
adjourned, and no action is taken by written consent in lieu
thereof, to take action to call a special shareholders meeting of
the Company or to act by written consent for the purpose of (i)
approving the transactions contemplated by the Combination
Agreement or any action with respect thereto or (ii) taking
action with respect to any Acquisition Proposal; and
iv) to waive for the term of this proxy any and all rights of such
Securityholder to exercise any dissent rights provided under
Section 131 of the NBBCA or otherwise in connection with the
Share Restructuring Plan.
5.2 PROXY TERMS. Each Securityholder affirms that this power of attorney
and proxy is issued in connection with the Combination Agreement to
facilitate the transactions contemplated thereby and in consideration
of Amdocs, Amdocs Parentco and Amdocs Holdco entering into the
Combination Agreement and as such power of attorney and proxy is
coupled with an interest and, to the fullest extent provided by law,
irrevocable. This power of attorney and proxy will terminate upon the
earliest to occur of (a) any material amendment to the terms and
conditions of the Share Restructuring Plan which has not been agreed
to in writing by the Company, (b) the closing of the transactions
described in the Combination Agreement and (c) the termination of the
Combination Agreement in accordance with its terms. For purposes of
this power of attorney and proxy, any notice of any shareholders'
meeting and any written consent shall be deemed delivered to such
Attorneys and proxies and their substitutes when delivered to Amdocs
in accordance with Section 8.9 below, and any written consent shall be
deemed delivered to the Company when delivered to it in accordance
with the Combination Agreement.
5.3 CONFIRMATION. By execution and delivery of this Agreement, each
Securityholder confirms that such Securityholder has received a copy
of the Combination Agreement and that all other information deemed
necessary by such Securityholder concerning the Share Restructuring
Plan, the Combination Agreement and the transactions contemplated
thereby or any other matters considered by such Securityholder to be
relevant to its decision to enter into this Agreement and grant this
power of attorney and proxy has been made available to such
Securityholder.
5.4 REVOCATION OF PRIOR OR SUBSEQUENT PROXIES. This Agreement revokes any
and all other powers of attorney and proxies heretofore granted by
each and any Securityholder to vote or otherwise to act with respect
to any of the Securities or Additional Shares to which the power of
attorney and proxy granted under this Section 5 relates. No
Securityholder shall give any subsequent power of attorney and/or
8
<PAGE>
proxy (and such power of attorney and/or proxy, if given, shall be
deemed not to be effective) with respect to such Securities or
Additional Shares that purports to grant authority within the scope of
the authority hereby conferred, except on the express condition that
such power of attorney and/or proxy shall not be effective unless and
until this power of attorney and proxy shall have terminated in
accordance with its terms.
5.5 SURVIVORSHIP. All authority herein conferred or agreed to be conferred
shall survive the death, dissolution, liquidation or incapacity of any
Securityholder and any obligation of any Securityholder hereunder
shall be binding upon the heirs, personal representatives, successors
and assigns of such Securityholder.
6. TERMINATION OF INVESTOR RIGHTS; ETC.
6.1 TERMINATION OF AGREEMENTS. To the extent a party thereto, each
Securityholder hereby agrees that, without any further action by any
party, each of the (i) the Second Amended and Restated Shareholders
Agreement dated as of December 17, 1999, as amended to the Effective
Time, between Solect and the Major Shareholders and the Purchasers
(and such terms are defined therein), (ii) the Second Amended and
Restated Investor's Rights Agreement dated as of December 17, 1999, as
amended to the Effective Time, between Solect and the investors listed
on Schedule A thereto and (iii) the Management Rights Agreement dated
July 27, 1998 between Solect and TCV II Strategic Partners, L.P., (iv)
the Convertible Debenture Purchase Agreement dated as of December 17,
1999, as amended to the Effective Time, between Solect and the
Investors listed on Schedule A thereto, (v) the Convertible Debenture
and Warrant Purchase Agreement dated as of January 11, 1999, as
amended to the Effective Time, between Strauss and the Investors
listed on Schedule A thereto and (vi) the Convertible Debenture and
Warrant Purchase Agreement dated as of July 27, 1998, as amended to
the Effective Time, between Strauss and the Investors listed on
Schedule A thereto (collectively, the "Terminated Agreements") shall
terminate as of the Effective Time.
6.2 WAIVER OF CERTAIN RIGHTS. Each Securityholder hereby waives any notice
requirements, consents, approval rights or other rights provided for
in any of the Terminated Agreements or in any other agreement that
have or will become effective prior to the termination thereof,
including, without limitation, any rights of first refusal, any
co-sale right, any right arising from or in reliance upon any
representation and warranty or from any affirmative or negative
covenant, or any right to receive notice from the Company or any other
person prior to the consummation of the Share Restructuring Plan, the
9
<PAGE>
holding of the shareholders meeting to be held to consider the Share
Restructuring Plan, the execution of the Combination Agreement or any
other transaction contemplated thereby or hereby or to consent to any
such transaction. Each Securityholder also hereby waives (effective as
of the Effective Time) any and all rights for indemnification
available to such Securityholder pursuant to any agreement between the
Company and such Securityholder regarding the issuance, sale or other
transfer to such Securityholder of any Company Common Shares,
warrants, debentures, options or any other equity, debt or other
Securities of the Company.
6.3 APPROVAL OF INVESTMENT. Each Securityholder hereby approves and
confirms the terms of the proposed issuance by the Company to British
Telecommunications plc of 437,500 Company Common Shares for an
aggregate purchase price of $4,659,375, as contemplated by the Summary
of Offering Terms dated January 2000, hereby authorizes the Company's
officers and directors to complete such transaction and hereby
ratifies and confirms the actions of such officers and directors
pursuant to such authorization and agrees to vote in favor of any
shareholder resolution approving or ratifying the same.
7. LOCK-UP PROVISIONS.
In consideration of the execution and delivery of the Combination Agreement
by Amdocs, Amdocs Parentco and Amdocs Holdco, and in order to induce each
of them to consummate the transactions contemplated thereby and in the
Share Restructuring Plan, each Securityholder hereby agrees as follows:
7.1 LOCK-UP PERIOD. Except to the extent provided in separate agreements
between Amdocs and employees of Solect or companies controlled by them
or as otherwise agreed to by Amdocs in advance in writing, during the
period commencing at the Effective Time and continuing until the first
anniversary thereof, not to, directly or indirectly, offer, sell,
contract to sell or otherwise dispose of, any Exchangeable Shares
received by the Shareholder upon the Effective Date in exchange for
the Company Common Shares and any Amdocs Ordinary Shares issued upon
the exchange of such Exchangeable Shares (other than exchanges of
Exchangeable Shares for Amdocs Ordinary Shares pursuant to the Share
Restructuring Plan) except as follows:
Percentage of Amdocs
Number of Months Ordinary Shares
After Effective Date Available for Sale
Up to 90 days after the Effective 0
Date
11
<PAGE>
From 90 days to 6 months 33%
From 6 to 12 months 66%
After 12 Months 100%
7.2 PERMITTED TRANSFERS. Notwithstanding the foregoing, the restrictions
specified herein shall not apply to any transfer to a trust for the
benefit of any Securityholder or members of such Securityholder's
family or any transfer by way of gift or donation, or any transfer to
an affiliate of any Securityholder; PROVIDED, in each case, that the
transferee thereof shall have undertaken to comply with the
restrictions and obligations contained in this Agreement with respect
to the transferred shares in a written instrument satisfactory to
Amdocs and countersigned by Amdocs prior to the transfer thereof.
8. MISCELLANEOUS.
8.1 CONSUMMATION OF SHARE RESTRUCTURING. Amdocs, Amdocs Parentco and
Amdocs Holdco hereby agree, in order to induce the other parties
hereto to enter into this Agreement, that they will consummate the
Share Restructuring Plan upon the terms and subject to the conditions
set forth therein and in the Combination Agreement.
8.2 ADDITIONAL SHARES. Each Securityholder hereby agrees, while this
Agreement is in effect, to promptly notify Amdocs of the number of
Additional Shares acquired by such Securityholder, if any, after the
date hereof.
8.3 EFFORTS. Each Securityholder agrees not to take any action that would
make any representation or warranty of such Securityholder herein
untrue or incorrect in any material respect or take any action that
would have the effect of preventing or disabling such Securityholder
from performing its obligations under this Agreement.
8.4 TERMINATION. It is understood that, if the Combination Agreement
(other than the provisions thereof that survive termination) shall
terminate or be terminated prior to issuance of the Exchangeable
Shares, each Securityholder will be immediately released without any
further action on its part from its obligations under this Agreement.
8.5 SPECIFIC ENFORCEMENT. The parties hereto acknowledge that damages
would be an inadequate remedy for a breach of this Agreement and that
the obligations of the parties hereto shall be specifically
enforceable, in addition to any other remedy that may be available at
law or in equity.
12
<PAGE>
8.6 COMMISSIONS. Each Securityholder and Amdocs, in connection with the
transactions contemplated hereby, and except as provided in the
Combination Agreement, agree to indemnify severally and not jointly
and hold the other harmless from and against any and all claims,
liabilities or obligations with respect to any brokerage fees,
commissions or finders' fees asserted by any person on the basis of
any act or statement alleged to have been made by such party or its
affiliate.
8.7 EXPENSES. All costs and expenses incurred in connection with this
Agreement and the transactions contemplated hereby shall be paid by
the party incurring such expenses.
8.8 AMENDMENT. This Agreement may not be modified, amended, altered or
supplemented except upon the execution and delivery of a written
agreement executed by all of the parties hereto.
8.9 NOTICES. All notices and other communications pursuant to this
Agreement shall be in writing and deemed to be sufficient if contained
in a written instrument and shall be deemed given if delivered
personally, by facsimile, sent by nationally-recognized overnight
courier or mailed by registered or certified mail (return receipt
requested), postage prepaid, to the parties at the following address
(or at such other address for a party as shall be specified by like
notice):
i) If to Amdocs, Amdocs Parentco or Amdocs Holdco, to:
c/o Amdocs Management Limited
Grand Buildings
1-3 Strand
London WC2N 5EJ
United Kingdom
Facsimile No.: 44-171-930-2321
with a copy to:
Reboul, MacMurray, Hewitt, Maynard & Kristol
45 Rockefeller Plaza, 11th Floor
New York, New York 10111
U.S.A.
Attention: Robert A. Schwed
13
<PAGE>
Facsimile No.: (212) 841-5725
ii) If to any Securityholder, to such Securityholder at the address
or facsimile number set forth on Schedule I hereto.
8.10 ENTIRE AGREEMENT. This Agreement (including the documents and
instruments referred to herein), together with the Registration Rights
Agreement and the Escrow Agreement, constitutes the entire agreement
and supersedes all other prior agreements and understandings, both
written and oral, among the parties, or any of them, with respect to
the subject matter hereto.
8.11 SUCCESSORS AND ASSIGNS. This Agreement shall not be assigned by
operation of law or otherwise without the prior written consent of the
other parties hereto, except that this Agreement may be assigned in
whole or in part to any affiliate of Amdocs. This Agreement will be
binding upon, inure to the benefit of and be enforceable by each party
and such party's respective heirs, beneficiaries, executors,
representatives and permitted assigns.
8.12 COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be deemed to be an original, but all
of which together shall constitute one and the same instrument.
8.13 GOVERNING LAW. This Agreement shall be governed in all respects,
including validity, interpretation and effect, by the laws of the
State of New York (without giving effect to the provisions thereof
relating to conflicts of law).
8.14 SEVERABILITY. Any term or provision of this Agreement that is invalid
or unenforceable in any jurisdiction shall, as to that jurisdiction,
be ineffective to the extent of such invalidity or unenforceability
without rendering invalid or unenforceable the remaining terms and
provisions of this Agreement or affecting the validity or
enforceability of any of the terms or provisions of this Agreement in
any other jurisdiction. If any provision of this Agreement is so broad
as to be unenforceable, the provision shall be interpreted to be only
so broad as is enforceable.
8.15 INDEPENDENT LEGAL ADVICE. Each Securityholder has received independent
legal advice with respect to the matters covered by this Agreement
prior to executing this Agreement or has been offered the opportunity
to seek such advice and has declined to do so.
14
<PAGE>
IN WITNESS WHEREOF, this Agreement has been duly executed and
delivered by each Securityholder and a duly authorized officer of Amdocs, Amdocs
Parentco, Amdocs Holdco and the Securityholders on the day and year first
written above.
AMDOCS LIMITED
By: /s/ THOMAS G. O'BRIEN
Name: Mr. Thomas G. O'Brien
Title: Treasurer and Secretary
AMDOCS(DENMARK) APS.
By: /s/ THOMAS G. O'BRIEN
Name: Mr. Thomas G. O'Brien
Title: Director
AMDOCS HOLDINGS ULC
By: /s/ THOMAS G. O'BRIEN
Name: Mr. Thomas G. O'Brien
Title: Director
SOUTHWEST SUN, INC.
By: /s/ PAUL ATKINSON
Name: Mr. Paul Atkinson
Title:
KL GROUP, INC.
By: /s/ GREG KIESSLING
Name: Mr. Greg Kiessling
Title: Chairman
15
<PAGE>
By: /s/ KEVIN KIMSA
Mr. Kevin Kimsa
TCV SOLECT (A) SRL
By: /s/ ROBERT C. BENSKY
Name: Mr. Robert C. Bensky
Title: Manager
TCV SOLECT (B) SRL
By: /s/ ROBERT C. BENSKY
Name: Mr. Robert C. Bensky
Title: Manager
TCV SOLECT (C) SRL
By: /s/ ROBERT C. BENSKY
Name: Mr. Robert C. Bensky
Title: Manager
16
<PAGE>
SCIENCE APPLICATIONS
INTERNATIONAL CORPORATION
By: /s/ DOUGLAS SCHRIER
Name: Mr. Douglas Schrier
Title: Senior Vice President
BCS INVESTMENT SRL
By: /s/ ED BRAKEMAN
Name: Mr. Ed Brakeman
Title: President
WPG NETWORKING-SOFTWARE SRL
By: /s/ MICHAEL SINGER
Name: Mr. Michael Singer
Title: General Counsel/Manager
MORGAN STANLEY DEAN
WITTER EQUITY FUNDING, INC.
By: /s/ DAVID POWERS
Name: Mr. David Powers
Title: Vice President
17
<PAGE>
SCHEDULE I
<TABLE>
<CAPTION>
(3)
(1) (2) Number of Common (4)
Number Amount and Shares that Convertible Aggregate
of Company Form of Convertible Securities Conversion
Securityholder and Address Common Shares Securities Are Convertible Into or Exercise Price
- -------------------------- ------------- ---------- -------------------- -----------------
<S> <C> <C> <C> <C>
Southwest Sun Inc. 5,700,000 N/A N/A N/A
148 Fullarton, London, Ont. N6A 5P3
Attn: Paul Atkinson
Kevin Kimsa 1,425,000 N/A N/A N/A
318 Glen Manor Dr.,
Toronto, Ont. M4E 2X7
KL Group Inc. 937,500 N/A N/A N/A
260 King St. E., Toronto, Ont. M5A 4L5
Attn: Greg Kiessling
TCV Solect (A) SRL N/A $2,131,183 554,274 N/A
c/o Ernst &Young, PO Box 261, Bay St., Convertible
Debenture
Bridgetown, Barbados
Attn: Carla Newell
TCV Solect (B) SRL N/A $2,185,574 568,420 N/A
c/o Ernst & Young, Convertible
" Debenture
"
18
<PAGE>
TCV Solect (C) SRL N/A $2,683,243 697,853 N/A
" Convertible
Debenture
TCV Solect (A) SRL N/A $1,069,216 92,975 N/A
" Convertible
Debenture
TCV Solect (B) SRL N/A $1,096,504 95,348 N/A
" Convertible
Debenture
TCV Solect (C) SRL N/A $1,346,184 117,059 N/A
" Convertible
Debenture
TCV Solect (A) SRL N/A N/A 197,596 N/A
" Warrants
TCV Solect (B) SRL N/A N/A 203,009 N/A
" Warrants
TCV Solect (C) SRL N/A N/A 249,235 N/A
" Warrants
TCV Solect (A) SRL N/A $2,131,183 41,285 51.62
" Liquidity
Preference
on Conv.
Debentures
TCV Solect (B) SRL N/A $2,185,574 42,339 51.62
" Liq. Pref.
on Conv.
Debentures
19
<PAGE>
TCV Solect (C) SRL N/A $2,683,243 51,980 51.62
" Liq. Pref.
on Conv.
Debentures
Science Applications International Corporation N/A $19,230,769 5,001,500 3.845
10260 Campus Point Drive, MS L5-A Convertible
San Diego, CA, USA, 92121 Debentures
Attn: Doug Schrier
Science Applications Intl. Corp. $4,000,000 347,826 11.500
" Convertible
Debentures
Science Applications Intl. Corp. N/A 2,500,750 N/A
" Warrants
Science Applications Intl. Corp. N/A 200,000 N/A
" Warrants
BCS Investment SRL $12,500,000 1,086,957 11.500
c/o Ernest and Young, PO Box 261, Bay St. Convertible
Bridgetown, Barbados Debentures
Attn: Ed Brakeman
Morgan Stanley Dean Witter Equity Funding, Inc. $1,000,000 86,957 11.500
1585 Broadway, New York, NY, USA, 10036 Convertible
Attn: James Head Debentures
WPG Networking-Software SRL $12,465,000 1,083,913 11.500
c/o Ernst and Young, PO Box 261, Bay St.
Bridgetown, Barbados
Attn: Raj Mehra
</TABLE>
20
EXHIBIT 99.1
NEWS RELEASE
AMDOCS LIMITED TO ACQUIRE SOLECT, LEADER IN CUSTOMER CARE AND BILLING
SOFTWARE FOR IP SERVICE PROVIDERS
CREATES UNMATCHED BUSINESS SYSTEMS SOLUTION FOR
COMMUNICATIONS AND INTERNET SERVICES
ST. LOUIS--(BUSINESS WIRE)--Feb. 29, 2000-- Amdocs Limited (NYSE: DOX - NEWS),
the leader in customer care, billing and order management solutions for the
communications industry, today announced that it has reached agreement to
acquire Solect Technology Group Inc., a leading provider of IP billing and
customer care software, for approximately $1 billion in Amdocs shares or 6.9% of
Amdocs' enlarged, fully diluted share capital. The acquisition of Solect will
create an unparalleled business systems solution for all kinds of communications
service providers, encompassing the full range of wireline, wireless, voice, IP
and convergent services. Amdocs expects the transaction to be accretive to cash
earnings per share in fiscal 2000 and thereafter, excluding goodwill and other
non-cash deal-related items.
"The Solect acquisition will immediately enrich Amdocs' existing IP software
offerings, instantly expand our market presence, and position Amdocs to further
leverage the strong growth of the IP sector," said Avi Naor, President and Chief
Executive Officer of Amdocs Management Limited. "The merger establishes
best-in-class, fully scalable product coverage across all wireline, wireless and
IP services. With the industry's richest functionality through all lines of
business, Amdocs offers the most complete business systems solution in the
communications and Internet industry."
Naor added, "The combination of leading products together with our comprehensive
support and project delivery capabilities is a key benefit for our target
customers. We are the only solutions provider for the IP market that offers
complete implementation, systems integration, and outsourcing services for its
own software platform. Only Amdocs combines the product versatility, scalability
and depth of services needed to deliver and support the complex, multi-service
solutions now being demanded by leading IP and convergent service providers."
Naor continued, "We are particularly excited by the addition of Solect's
founders, Paul Atkinson and Kevin Kimsa, and their team of over 250 IP experts
to the Amdocs organization. Their spirit of innovation and commitment to
excellence fit in well with the Amdocs culture, and we are very confident that
Solect's people will make a great contribution to the merged company. Solect's
strong group of talented Internet professionals complements and reinforces our
previously announced initiative to meet the requirements of the IP market
place."
Naor concluded, "The acquisition strengthens Amdocs' ability to effectively
address all segments of the IP market. With blue-chip customers like the IP
units at AT&T Canada, BT, GTE, SNET and Swiss Online, and over 60 installations
for ISP, ASP and broadband players, Solect is the vendor of choice for IP
leaders and emerging new entrants. For convergent voice-IP and high-end
multi-service providers, we will be offering Ensemble, empowered with enhanced
functionality from Solect's Horizon product. By bolstering Amdocs' position in
all IP sectors, the acquisition will reinforce our sustained growth as the IP
market unfolds."
"By joining forces with Amdocs, we are creating the most powerful business
systems solution in the communications industry," said Paul Atkinson, CEO of
Solect. "We are delighted to be partnering with Amdocs. We have great respect
for their technological expertise, unrivalled track record in project delivery,
and total commitment to the customer. Backed by Amdocs' vision, power and
resources, we are assured a pivotal role in facilitating the accelerated
transition to Next Generation communications services."
<PAGE>
British Telecommunications is a valued customer of both Amdocs and Solect.
Commenting on the deal, Ben Andradi, Managing Director BT eBusiness, said, "This
announcement is an indication of the emerging maturity of the Internet market.
Amdocs' move comes as IP service providers enter the next stage of their
development, encountering issues of scalability, product differentiation,
convergence, growing demands for profitability, and the fundamental but very
challenging task of managing an extremely complex and competitive business. In
order to manage this transition, service providers need powerful, sophisticated
business system solutions, a challenge that Amdocs has proven it can meet for
the world's most demanding communications companies."
Under the terms of the acquisition, which has been approved by the Boards of
Directors of both companies, Amdocs will issue an aggregate 15.5 million Amdocs
shares and options in exchange for the outstanding common stock of Solect and
the assumption of outstanding Solect employee stock options. To effect the
transaction under Canadian law, the holders of Solect's common shares will
receive a new class of exchangeable shares of Solect that would be exchangeable
at any time, share for share, for ordinary common shares of Amdocs. Based on the
closing price for Amdocs on the New York Stock Exchange on Monday, February 28,
2000, the transaction would be valued at approximately $1 billion. The
transaction will be accounted for under the purchase accounting method and will
be structured as a tax-free exchange for Solect's Canadian and U.S.
shareholders. The acquisition, which is expected to close by the end of April
2000, is subject to customary regulatory approvals and the approval of Solect
shareholders. Shareholders representing over 70% of Solect's outstanding share
capital have agreed to vote in favor of the transaction and have agreed not to
sell portions of their shares in Amdocs for periods ranging from three months to
one year after closing.
Amdocs expects to incur a one-time acquisition-related charge in its third
fiscal quarter ending June 30, 2000 to account for certain costs relating to the
acquisition, primarily the write-off of purchased in-process research and
development.
Upon completion of the transaction, Solect will operate as a division of Amdocs,
headquartered in Toronto, Canada. The division will continue to serve its
customers, and will focus on continued product development and business
expansion in the IP services arena. Solect's successful relations with its
worldwide partners will be further developed and cultivated. The new division
will be leveraged to facilitate expansion of Amdocs' presence in the Canadian
communications and Internet market. Paul Atkinson will become president of the
new division. Goldman, Sachs & Co. advised Amdocs Limited and Morgan Stanley
advised Solect in this transaction.
Solect is shaping the new public network with IAF Horizon, the world's leading
carrier grade billing, customer care and service management software for next
generation service providers including wireless and ASPs. Headquartered in
Toronto, Canada, with offices in the United States, United Kingdom, Australia
and Hong Kong, Solect has over 60 Service Provider installations globally.
Solect has relationships with leading technology companies such as: Alcatel,
Cisco Systems (NASDAQ:CSCO - NEWS), Ericsson, Netscape, Nokia (NYSE:NOK.A -
NEWS), Microsoft (NASDAQ:MSFT - NEWS), Hewlett Packard, Oracle Corporation
(NASDAQ:ORCL - NEWS), PricewaterhouseCoopers, Science Applications International
Corporation (SAIC), Sun Microsystems (NASDAQ:SUNW - NEWS), and Telcordia
Technologies (formerly Bellcore).
Solect's IAF Horizon enables service providers to introduce innovative new
business models, such as VISPs (Virtual ISPs) and packaged applications,
allowing them to increase their subscriber base by expanding into new market
segments, while maintaining the integrity of the individual brands. Solect is
continuously working with leading partners and customers such as AT&T Canada,
BT, GTE, Sun Microsystems and Cisco Systems, to ensure IAF Horizon provides the
adaptability required to meet the growing competitive market pressures service
providers are facing today. Visit Solect at HTTP://WWW.SOLECT.COM
<PAGE>
Amdocs is a leading provider of customer care, billing and order management
solutions for communications and Internet services. Amdocs has an unparalleled
success record in project delivery of its mission-critical products. Human
resources of more than 5,600 information systems professionals are exclusively
dedicated to the communications industry. Amdocs has an installed base of more
than 300 successful projects in more than 75 major communications companies
throughout the world.
Ensemble(TM) is Amdocs' platform for customer care, billing and order
management. Ensemble supports convergent multi-service operations, including
voice, data and IP services in wireline and wireless environments. The system
utilizes a scaleable, multi-tier, client-server UNIX platform and has been
proven to support the high-volume performance requirements of leading carriers.
For further information please call Amdocs Investor Relations at 314-212-8328 or
visit our web site at WWW.AMDOCS.COM.
Ensemble is a trademark of Amdocs Limited. This news release may contain certain
forward-looking statements relating to the future performance of Amdocs Limited
and Solect. The forward-looking information is within the meaning of Section 27A
of the Securities Act of 1933 and Section 21E of the Securities Act of 1934, and
subject to certain risks and uncertainties, and actual results may differ
materially. These risks and uncertainties are described in greater detail in
Amdocs' filings with the Securities and Exchange Commission.
CONTACT:
Amdocs
Thomas G. O'Brien, 314/212-8328
[email protected]
or
Porter Novelli
Dan Ginsburg, 212/601-8020
[email protected]
